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ABSTRACT 
   
This dissertation investigates the condition of skeletal muscle insulin resistance 
using bioinformatics and computational biology approaches. Drawing from several 
studies and numerous data sources, I have attempted to uncover molecular mechanisms at 
multiple levels. From the detailed atomistic simulations of a single protein, to datamining 
approaches applied at the systems biology level, I provide new targets to explore for the 
research community. Furthermore I present a new online web resource that unifies 





   
I would have never earned a PhD if it weren't for the support of my Advisor, 
Larry Mandarino. The first year of graduate school was challenging, and despite 5 
different rotations in various labs in the Biodesign Institute, none of the available projects 
felt like a proper fit to my interests. I had just 2 weeks left to find a lab, and happened to 
run into Larry at a talk. I was not aware that any labs on campus were studying a disease 
that had such a profound personal connection to me and my family. Larry and I clicked 
because we both had entirely different backgrounds than biology, and despite having zero 
requisite skills needed for the task at hand, Larry gave me the opportunity to completely 
transform. This document is proof that I have. Thanks Larry, for putting up with me. 
My co-chair, Josh LaBaer, similarly gave me a home within Biodesign to keep 
close ties to my program. I had rotated under Josh in his fantastic lab and learned a great 
deal of modern techniques. Although ultimately my PhD studies took me elsewhere, Josh 
allowed me to continue working in his lab and attend meetings to learn everything I know 
about cancer biology. The LaBaer lab, and its many friendly people, will always be 
family to me. 
The heart of the LaBaer lab is indisputably Mitch Magee, who has been a warm 
friend throughout graduate school. He has always been there through the bad times, kept 
me sane, calmed me down, and been like a father. He is well known throughout the 
building of being the man with the biggest heart. He is a shining example of how 
effective academia and science could be if everyone was as friendly and professional. 
Valentin Dinu has proven to be among the most loyal people I have ever had the 
privilege of serving under. When my first PhD project went south, Valentin gave me a 
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new lab home to play in with some of the kindest and most professional students I have 
ever corresponded with. Collaborating with Larry, Valentin provided me with the server 
infrastructure and support necessary to completely turn my PhD around in just a year. He 
has also been the strongest advocate of my abilities and has wished me success in my 
future career countless times. It is when conversing with Valentin that my dreams are 
kept alive, and he encourages me that I can go to better places and find my happiness. 
Wayne Willis, you continue to put all to shame with your commanding godlike 
knowledge of metabolic pathways and mitochondrial physiology! You are the true notion 
of the genius professor, yet you are among the most kind and approachable faculty I've 
met. Never before have I met someone at your level that I could still routinely eat lunch 
or grab a beer with. I will always miss our conversations, where I learned all of my 
bioenergetics theory in grad school. You have been a core teacher, and if I ever do great 
things, you can thank yourself for my knowledge. Party on Wayne! 
From the lab, I want to thank several fellow soldiers that trained me in the mission 
of fighting obesity: specifically Paul, Leon, April, and Jean for their incredibly patient 
mentorship. I needed a lot of help in the lab, and they taught me much. Without their 
guidance over the years, I could not be called a molecular biologist. 
I thank my family for their love and support over the years. I also want to thank 
the Biological Design Graduate Program for the opportunity and its support. I thank all of 
my peers still finishing up, and I wish them luck in defending and finding bright futures. 
Many of my closest friends here and abroad have supported me through all of the rough 
times: Marc, Roeland, Brad, Joe, Brian, Karl, Andrew, Brianne, Rene, Kurt, Jack, and 
countless others. I adore you all! I also thank the programs administrative support staff 
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(Maria, JoAnn, and Jim) for keeping us all sane during the most stressful times. Lastly, to 
Tom Goodman, you have been like a father to me, and I will always cherish your wisdom 
of what the future of humanity holds. 
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DEDICATION 
 This dissertation is dedicated to people who have been punished entirely too much 
for their weight. I love them all. 
 Obesity is a serious disease with profound health consequences, but it also comes 
with it a great social stigma. It is the nature of our culture to ridicule these people, subject 
them to judgment and bias, ignore them in friendship or relational circumstances, alienate 
or otherwise abandon them, and torture them with accusations of laziness or stupidity. We 
cast blame entirely on their lifestyle whilst ignoring their genetic circumstances or 
previous medical history. Having been obese for much of my life, I can personally attest 
to the immense pain and sadness that obesity causes. It truly is a condition which 
dramatically reduces the quality of one’s life, particularly in social or career 
circumstances. Obesity is the last remaining acceptable form of prejudice in our world, 
yet mounting molecular evidence indicates that it is a disease like any other. 
 I have been severely obese for my entire life, and I can personally attest to the 
immense pain this condition causes. I also have a complicated medical history of several 
endocrine problems, namely testosterone insufficiency and two bouts of thyroid cancer 
when I was very young. Nothing I tried got the weight off, even with intense dietary or 
exercise interventions, so I switched careers in grad school. As of the conclusion of this 
dissertation I've lost 120 lbs. The weight did not come off with traditionally defined diet 
and exercise, but with many episodes of forced starvation lasting several days. My story 
proves that lifestyle interventions can overcome genetic predispositions and prior medical 
conditions, but obese people have to try much harder! I believe the obese are stronger 
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people. They must deal with their own weight and the weight the world places upon 
them. There are few people in this world who lose so much weight, and even fewer who 
maintain the weight loss. These are the individuals who will stop at nothing to be healthy 
and be accepted by society, but their efforts require unreasonable sacrifice. 
 These victims are all my comrades, and I will continue to fight the enemy 
alongside them. The enemy is the hundreds of invisible molecular factors that make us ill, 
from genetic variability, to dietary toxins that are incompletely understood, to chemical 
compounds in our industrial environment that we are exposed to, and to pathogenic 
organisms that invade our gut and lead to inflammation. The enemy is not laziness or lack 
of will power. It never has been. It is the world fighting against our biology, at the 
molecular scale, in ways we have yet to comprehend. 
 Very recently, I have been genotyped by the consumer genetics testing company 
23andMe. I have discovered that I have some of the worst genetic variants associated 
with metabolic syndrome, and many of these genes are discussed in this dissertation. This 
self-discovery has put into perspective an entire life of suffering. With this knowledge I 
have learned, I will carry forward my mission to heal. I will strive for a cure, so that the 
many people who suffer these medical problems can be saved, and can be happy. 
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Metabolic syndrome is a growing health problem that places enormous weight on 
our society. It impacts the quality of life and longevity of the millions of victims suffering 
its effects, and the burden to our healthcare system is difficult to overestimate. Metabolic 
syndrome is a combination of several metabolic abnormalities that may have distinct 
causes but are commonly found together, including obesity, lipid abnormalities, and 
conditions of abnormal glucose homeostasis including insulin resistance and type 2 
diabetes. Metabolic syndrome is also associated with cardiovascular disease, which 
remains the leading cause of death worldwide. It is a complex systemic condition that is 
influenced by a variety of factors, which include genetic heritability, environmental 
exposures, the burden of other illnesses, and lifestyle choices including diet and exercise. 
Evidence is accumulating that these pathologies arise from many distinct underlying 
causes. Elucidating the fundamental mechanisms of these abnormalities is crucial to save 
millions. 
Metabolic syndrome is a complicated set of associated diseases in which the 
storage, transport, or utilization of energy is defective. These biological functions are 
precisely regulated at the cellular level by complex internal signaling mechanisms and 
metabolic pathways. Cells are deciding what to do based on their genetic makeup and the 
environment they are exposed to. Only by reverse engineering how cells think, we can 
come to an understanding of why they behave in specific ways and interact to form a 
complex system. This dissertation explores the molecular mechanisms underlying 
metabolic syndrome with a systems biology focus that promotes the viewpoint that the 
2 
entire system must be considered at all levels to understand the phenotype. New 
technologies are permitting us to scrutinize the inner workings of the cell at the genomic, 
transcriptomic, proteomic, and metabolomic levels. Unexpected connections can be 
found by “connecting the dots” between these various datasets. This underlying 
philosophy has resulted in several interesting discoveries that are discussed amongst 
these chapters. The stories explored in this dissertation range from the atomic details of 
single proteins, to entire signaling networks in cells, and indeed interactions between 
multiple organs. New strategies and tools are required to sort through the massive 
datasets and find the true points of control and failure within cellular information 
processing. 
In this dissertation, I characterize the biophysical properties of a single protein 
critical for mitochondrial functioning, and provide a compelling argument as to how it 
can direct the energy status of the entire cell from the bottom up. Additionally, I develop 
a simple approach to find direct connections between genetic variation, expression 
profiles, and metabolic phenotypes of experimental subjects. Finally, I have developed a 
web-accessible database that unifies genomics and proteomics sequence data with protein 
structures, thereby enabling the visualization and discovery of novel regulators of protein 
function. These projects focus around the study of metabolic syndrome, and its associated 
disorder of glucose homeostasis known as diabetes. 
 Diabetes is a disease defined by elevated blood glucose, and additionally the 
inability to respond to an increase in blood glucose following a meal. In a healthy 
individual, blood glucose concentrations are held within a specific range to maintain 
homeostasis. To regulate this range, the pancreas contains specialized cells in the 
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pancreatic Islets of Langerhans to detect blood glucose concentrations and respond by 
secreting hormones. The hormone insulin is the best known, as it is a hormone secreted 
from beta cells in the islets when blood glucose levels rise. Insulin informs peripheral 
tissues in the body that glucose supply is in excess, and peripheral tissues such as muscle 
and fat respond to this signal by absorbing the excess glucose for storage and eventual 
utilization. The mechanisms of this process are complex. Insulin binds to insulin 
receptors on cells, which leads to signal propagation through hundreds of downstream 
associated proteins. At this stage, information processing takes place within the cell to 
decide if glucose is needed. If it is, the end result is insertion of the insulin-responsive 
glucose transporter protein (GLUT4) into the cell membrane. This final insertion permits 
glucose uptake into the cell. 
 Diabetes is a chronic state of elevated blood glucose, and is broadly classed in 
two types. In type 1 diabetes, autoimmune destruction of the pancreas leads to 
insufficient insulin secretion. The lack of the hormone insulin leads to increased blood 
glucose levels. The disease typically develops at an early age, and is treated by careful 
glucose monitoring and injection of insulin. 
 In type 2 diabetes, peripheral tissues ignore the insulin secreted by the pancreas. 
This state of the peripheral tissues is known as “insulin resistance”, which is thought to 
lead eventually to type 2 diabetes after prolonged stress leading to pancreatic burnout. 
The molecular mechanisms of insulin resistance, particularly in human muscle, have been 
a core focus of research. Despite binding of insulin to its receptor in target tissues, the 
glucose transporter is not translocated to and inserted properly in the plasma membrane. 
Somewhere between the insulin receptor and the glucose transporter, the pathway 
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becomes switched off for reasons that are not entirely clear. Over the last decade, 
numerous molecular sites of several off switches have been found, and they appear to 
correspond to different environmental conditions that the cell finds itself experiencing. 
Exposure to free fatty acids (FFAs) appears to be one instigator of this deactivation, 
leading many to conclude that high fat American diets are to blame.[1] The signaling 
pathways are complicated however, and more work needs to be undertaken to study 
where the true control points are located. Such work will provide insights into therapeutic 
targets. 
 Chapter 2 discusses my effort to uncover core signaling nodes within muscle that 
ultimately determine its insulin sensitivity. A study previously conducted by our lab 
recruited 14 human subjects to partake in an exercise bout. A hyperinsulinemic 
euglycemic clamp experiment was performed to measure insulin sensitivity. In this 
technique, insulin is injected into subjects to stimulate glucose uptake in peripheral 
tissues, and glucose is then infused at a rate that maintains blood glucose concentrations 
at a steady level. The glucose uptake rate in peripheral tissues can then be estimated 
based upon the rate of infusion. In this study, a muscle biopsy was taken from one leg 
prior to the clamp experiment. On a separate day, subjects underwent an exercise bout, 
followed by a second muscle biopsy 30 minutes after exercise. Gene expression 
microarrays were then used to determine the expression levels in both biopsies. 
 This dataset presented an excellent opportunity to attempt data mining into the 
gene expression profiles of muscle that correspond to disease. Typical gene expression 
microarray studies focus entirely on the comparison between two measured states. For 
example, two groups of people are compared, or comparisons are made before and after 
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some intervention such as exercise. It is thus the fold change that is commonly 
considered, and rarely the steady state expression values. In exercise studies, these types 
of analysis have taught us much about the exercise-induced adaptations to metabolic 
systems within muscle, and how these adaptations are less pronounced [2] in some 
subjects, which suggests a state of exercise resistance. Gene expression studies of this 
sort typically identify genes that change significantly (up or down) amongst the entire 
group of participants. This however misses genes that respond in opposite directions 
amongst a group. 
 In our exercise study, several metabolic parameters were collected from test 
participants, including their height and weight, insulin stimulated glucose uptake rate, 
parameters from a full lipid panel, as well as exercise performance characteristics such as 
VO2max and watts produced on the stationary cycle. These metabolic parameters are 
continuous values, which presented a unique opportunity to mine the gene expression 
data for direct associations in both single biopsies as well as gene expression fold 
changes. To this end, a simple technique was devised whereby every gene expression 
probe on the microarrays was correlated with these various metabolic phenotypes. 
Correlation coefficients were sorted, and the top and bottom most positive/negative 
correlated were investigated with deep literature review. 
 Remarkably, the findings were profound. We present a model whereby top 
correlates to glucose uptake are directly tied to the wnt signaling pathway which is deeply 
associated to type 2 diabetes susceptibility in genome wide association studies (GWAS). 
Furthermore, two top-correlating genes are found in GWAS studies for diabetes and BMI, 
and these connections validate our systems biology approach to unifying domain 
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knowledge from multiple sources. Many negative correlating genes correspond to a well-
studied pathway of muscle atrophy, which is a phenomenon associated with metabolic 
syndrome [3]. Interestingly, muscle atrophy is initiated during times of fasting to provide 
amino acids to the liver to produce glucose in a process known as hepatic 
gluconeogenesis. When dietary glucose is scarce, the muscle must stop taking up glucose 
and start exporting amino acids, which keeps blood glucose available to the brain. These 
gene expression findings lead to a hypothesis that diabetic muscle thinks that the 
organism is starving, and leads us to propose a direct mechanistic connection between the 
muscle atrophy pathway and insulin resistance. This off switch is potentially mediated 
directly by proteolysis of proteins critical for glucose uptake, and I present evidence of 
this hypothesis. 
 The transcriptomics analysis leads to interesting findings which may unveil novel 
core regulatory pathways that regulate the phenotype of a cell, and indeed the phenotype 
of the whole organism. It also provided startling context to the nature of the disease. Gene 
expression values however only partially predict the abundance of proteins.[4] 
Furthermore, proteins undergo post-translational modification (PTMs), which can 
selectively change the biophysical properties of key residues. These modifications are not 
indicated in the genomic sequence but can rapidly and dynamically change the behavior 
of proteins. These processes are key to changing the reaction characteristics of metabolic 
enzymes and are also the primary mechanism by which signaling pathways in the cell 
process information. Thus the changing gene expression patterns in the cell only form 
half of the internal cellular computer. The remainder of the information processing is 
conducted within the proteome, and this layer must be additionally monitored to uncover 
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regulatory mechanisms that associate with disease. 
 It is biological mass spectrometry that has revolutionized the proteomics field in 
recent years. This amazing technology enables the routine detection and sequencing of 
intact proteins from biological samples, as well as the detection of post-translational 
modifications at specific sites in the protein sequence. This “protein sequencing” is now 
growing as a complement to the genome sequencing revolution that took biology in the 
previous decade. Briefly, proteins isolated from human samples are enzymatically 
digested into short peptides, separated with liquid chromatography, and then ionized into 
particle accelerators where their mass-to-charge ratios are measured. To sequence the 
peptides, they are literally blown apart at the peptide bonds via various fragmentation 
methods, and the sequence is determined from the pattern of peaks that emerges. This 
whole process is done routinely in the lab, and a typical tissue biopsy will unveil 
thousands of proteins and many associated modifications. 
By scrutinizing these proteomes, many advances have been made in studying 
insulin resistance. The insulin signaling pathway has been mapped by looking for 
interacting partners of key signaling molecules. Furthermore, the signaling “state” of the 
pathway can be elucidated by detecting the characteristic phosphorylation patterns on 
central signaling proteins.[5] In mapping out these pathways, we gain insight into the 
signal propagation paths, from receptors to effectors, and we are slowly detangling the 
inputs and processing that determines metabolic phenotypes. These advancements are 
allowing us to directly read out the signal pathways from tissues and deduce what the 
cells were “thinking” prior to isolation.  
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There are several proteins in the insulin signaling pathway that have received 
considerable attention with mass spectrometric analysis. One such protein is known as 
the Insulin Receptor Substrate-1 (IRS-1) because it directly binds to the insulin receptor 
upon activation. IRS-1 is considered the primary signaling hub of the pathway, as it 
contains many [5-7] sites which become phosphorylated. These sites serve as switches 
that regulate binding of many downstream signaling proteins that connect with other 
signaling pathways. Some of these sites are activating, and some are deactivating of the 
signaling pathway, and many of these sites are modulated by feedback mechanisms 
within the cell that keep the signaling properly regulated. Understanding how these sites 
become activated due to various environmental conditions is a focus of current research. 
Beyond signaling pathways, we are beginning to focus on metabolic enzymes in 
the cell. In characterizing them, we hope to find differences in abundance or 
modifications which regulate their activity and thus affect the metabolic properties of the 
cell. Chapter 3 discusses one such proteomic investigation that focuses on mitochondrial 
proteins and their associated modifications. Mitochondrial dysfunction has long been 
considered [2] to be physiologically associated with skeletal muscle insulin resistance. 
Recent proteomics analysis has revealed that post-translational modifications are 
abundant in mitochondria, specifically acetylation of lysines. Lysine acetylation is found 
in bacteria and considered [8] evolutionarily ancient, possibly developing before 
eukaryotic phosphorylation. Lysine acetylation has also been shown [9] to regulate the 
activities of many mitochondrial enzymes. This observation compels us to determine if 
mitochondrial acetylation is abundant in humans and whether it corresponds to metabolic 
abnormalities such as insulin resistance or mitochondrial dysfunction. 
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To this end, skeletal muscle biopsies were isolated from the vastus lateralis 
muscle in human subjects before and after an acute exercise bout. The mitochondria from 
these muscle biopsies were isolated, and HPLC-MS/MS analysis was performed to 
sequence the mitochondrial proteome. The MASCOT search engine was used to analyze 
the data and discover post-translational modifications to proteins. We searched for mass 
shifts that would correspond to lysine acetylation. Overall, we found the mitochondrial 
proteome to be abundantly acetylated before exercise, and we observed a dramatic 
reduction in protein acetylation one day after an exercise bout. This reduction of 
acetylation was more pronounced in insulin sensitive subjects. 
 Acetylation was discovered on a key mitochondrial protein: the Adenine 
Nucleotide Translocase-1 (ANT1). It is readily observed in human mitochondrial 
isolations as it is the most abundant protein found in the inner mitochondrial membrane. 
A member of the mitochondrial carrier family, ANT1 is the primary channel by which 
ADP and ATP exchange between the mitochondria and the cytosol. This protein is thus a 
key requirement for mitochondrial oxidative phosphorylation and delivery of ATP to be 
used by the cell. Several lysine residues were found to be acetylated, but the acetylation 
of a single lysine residue (K23) was found to change with exercise in a manner that 
correlated strongly with insulin sensitivity. 
We next found crystal structures of the bovine ANT1 protein in the protein 
databank (PDB) and found that the homologous lysine (K23) was located at core of the 
protein. Next, we found prior molecular dynamics studies which simulated the 
mechanisms of ADP transport and binding into the channel. K23 was shown by several 
studies to be a key binding site which directly bound to the negatively charged 
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phosphates of ADP. We reasoned that since lysine acetylation resulted in a loss of positive 
charge, that this modification detected in humans would reduce binding affinity for ADP, 
and thus attenuate transport and overall oxidative phosphorylation “flux”. 
We constructed an acetyl-lysine residue in silico, and then conducted molecular 
dynamics simulations to characterize the effects that acetylation would have on protein 
structure and dynamics. We additionally simulated binding of ADP ligands and estimated 
the reduction of binding energies associated with acetylation. Overall, the modeling 
demonstrated that acetylation of this critical binding residue would have a pronounced 
impact on ADP binding, and would therefore affect transport. With transport 
compromised, we predict that there will be physiological consequences to mitochondrial 
function in the muscle in vivo. 
 Our modeling results are further strengthened by prior mutagenesis work in yeast, 
which systematically determined the key residues necessary for ADP/ATP transport.[10] 
The yeast protein was highly homologous, and we discovered that K23 in humans 
corresponded to a conserved lysine in yeast (K38) that was required for transport activity. 
With this critical lysine mutated, the yeast could not survive on a non-fermentable carbon 
source, which indicated a complete failure in mitochondrial oxidative phosphorylation. 
This gives us full confidence that this acetylation event in humans will have 
physiological consequences, but what remains to be determined is the fraction of 
damaged ANT1 proteins within the mitochondria of insulin resistant humans. 
 The ANT1 story, although incomplete at this stage, has provided a compelling 
insight into the profound effects that can be caused by a change in a single residue on a 
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protein within the cell. A loss of a single positive charge in ANT1 caused a dramatic 
reduction in binding. Indeed, at the molecular scale, as the basis of all cellular function, 
binding is everything. The ANT1 story emerged from a long and careful analysis of the 
protein structure, reading of numerous simulation studies, careful study of the protein 
sequences, and luckily finding the right mutagenesis study in another organism to base 
our central hypothesis. Connecting these “dots” took substantial manual effort to 
determine how a single modified residue on a single protein can modulate metabolic 
activity. Modern proteomics experiments however are finding thousands of modified 
residues on proteins. It was clear from this study that new systems were needed to find 
these connections faster. 
New sequencing and genotyping techniques are rapidly contributing to our 
knowledge of genomic variants and their effects on protein function. With this, the field 
of biological mass spectrometry is growing quickly, and new databases are emerging 
which comprehensively map countless post-translational modifications. Additionally, 
databases such as Uniprot [11] offer detailed knowledge of manually and computationally 
discovered protein functional sites, such as catalytic active sites and binding motifs. 
Finding functional connections between these positions can be automated, potentially 
discovering new regulatory protein modifications or pathogenic gene mutations. To 
accomplish this, a system is needed which simply aggregates these multiple data sources 
together and finds co-localized residues of interest. 
Chapter 4 discusses our solution to this problem. We have developed AMASS, 
which “amasses” together these databases into a unified platform for exploration and 
visualization. The AMASS web server is publically available (amass-db.org) and free to 
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use. The search interface pulls from Uniprot, and displays the protein residue-level 
annotations from that resource. Additionally, cancer mutation count data is pulled from 
the Catalogue of Somatic Mutations in Cancer (COSMIC)[12, 13] database, and 
phosphorylation sites from mass spectrometry datasets are displayed from the 
PhosphoSite [14] database. The core feature of our service however is direct integration 
with protein structures: when structures are found in the Protein Databank (PDB) that 
have at least 50% sequence identity, they are displayed alongside the annotations with an 
interactive Jmol [15] applet. Clicking anywhere in the protein sequence, or on interactive 
histogram plots, or on entries in the residue annotations table will show the user the exact 
location of that residue mapped to the 3D structure. This functionality allows 
investigators a quick and direct way of discovering novel biophysical interactions 
between mutations, modifications, and functional sites. 
In summary, metabolic syndrome is an enormously complex condition. At the 
cellular level, metabolic networks regulate the net flux of countless metabolites, and the 
cell precisely controls the expression of these networks with intricate signaling pathways 
that process information and make decisions. System wide, it is ultimately the collection 
of countless cells in a cacophony of hormonal and neurological signaling that regulates 
the health of the organism. To understand complex diseases such as metabolic syndrome, 
we must monitor and decrypt this biological chatter. Doing this requires data from all 
levels, from disease associated variants in the genome, to transcriptional activity in the 
cell, and to proteomic alterations such as post-translational modifications that precisely 
regulate the biophysical interactions of signaling molecules and metabolic enzymes. 
Once we piece together all of this data, the true switches which regulate metabolism can 
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be found, giving us true targets for therapeutic intervention. 
As the era of personalized medicine approaches, we will finally be able to 
understand metabolic syndrome for what it may be: a collection of numerous completely 
independent diseases that lead to the same phenotypes: obesity, diabetes, insulin 
resistance, dyslipidemia, and heart disease. New technologies are permitting personalized 
diagnostics by enabling individual profiling of genotypic variants. Soon this will be 
supplanted by inexpensive full genome sequencing. Perhaps someday, transcriptomics or 
proteomic profiling within target metabolic tissues will allow the scanning of cellular 
thought processes within patients to determine the bottom-up causality for each 
individual. For this dream to be realized however, we need to understand the whole 
system works. We need to map the signaling pathways where cellular decisions are made. 
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Chapter 2 
TRANSCRIPTOMICS ANALYSIS REVEALS GENE EXPRESSIONS ASSOCIATED 
WITH METABOLIC PHENOTYPES 
Introduction 
 Insulin resistance is a complicated phenomenon whereby a cell makes a 
“decision” to ignore an insulin signal and pass up on available glucose. When insulin 
resistance develops at a systemic level, blood glucose levels remain elevated, leading 
eventually to type 2 diabetes. The elucidation of the molecular mechanisms of this 
cellular thought process is crucial for the health of millions. In recent decades, the 
complexities of the insulin signaling pathway have been slowly unraveled to reveal 
hundreds of potentially involved signaling proteins. 
 Due to this seemingly unfathomable complexity, much research attention has 
been spent at the proximal and distal steps of the pathway. At the proximal end lies the 
insulin receptor and the associated proteins that are recruited upon stimulation, such as 
the insulin receptor substrate-1 (IRS-1). At this nodal site, substantial progress has been 
made in finding molecular alternations associated with insulin resistance, with many 
identified post translational modifications which correlate to disease in human 
populations.[5] At the distal end of the pathway, the insulin responsive glucose 
transporter (GLUT4) lies dormant in GLUT4 storage vesicles (GSVs), waiting to be 
transported and inserted into the cellular membrane. The molecular mechanisms of this 
process have been equally scrutinized by many labs.[16] Yet everything between these 
nodal points the pathway diverges along many confusing paths. Several other signaling 
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pathways in the cell exchange information via crosstalk and feedback, and it is simply too 
challenging to determine the true points of control without running in circles. 
 Mass spectrometry has leaded the field due to its capacity of finding interacting 
partners and mapping protein modifications. Information on both of these aspects of the 
pathway is needed to understand how the signal propagates from the receptor to GLUT4. 
Mass spectrometry is limited however in that it only sees the most abundant proteins in 
the cell, with a typical skeletal muscle dataset finding just several thousand proteins on 
modern instruments. Signaling molecules such as kinases and receptors are extremely 
low in abundance and rarely show up in whole proteomes. This limitation can be 
sidestepped with the use of immunoprecipitation, but this requires specific affinity 
reagents and insights from the investigator of where to look. Until new proteomics 
technologies arise that will “flatten” the proteome we will not have an unbiased view of 
the global proteome. 
 Although dated by today’s standards, gene expression microarrays do give a 
global view of the entire transcriptome. On whole genome arrays, each gene is measured 
on independent spots, and the signal is more directly attributable to transcript 
concentration then is true of mass spectrometric measurement of protein abundance. 
Although gene expressions do not always predict true protein abundances and fail to 
account for post translational modifications, there is likely still information to be found 
that may fill in the gaps of our knowledge of the pathway. Gene expression 
measurements also give us profound insight into the activation of transcription factor 
circuits within a cell, and thus can reveal behavioral programs that are initiated during 
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different stimuli. Transcriptional activation of whole pathways can elucidate what the cell 
is thinking in pathological states. 
 Most studies using gene expression microarrays compare expression profiles 
between two discreet states. Subjects are either grouped into diseased/healthy 
dichotomies or compared pre/post some intervention such as exercise. Gene expressions 
are then assessed amongst the entire group, and transcripts that change significantly are 
filtered. This technique favors highly abundant transcripts that more easily pass statistical 
significance. Signaling pathways however can have changes that are far more subtle, with 
small changes in transcript or protein concentration yielding large modulations in signal. 
It is plausible that such small changes will never show statistical significance. Changes in 
gene expression are also typically considered as a group, and this can confound analysis 
in instances where a gene will increase in some subjects and decrease in others. 
Furthermore, grouping subjects into discreet categories of healthy/diseased or focusing 
just on pre/post comparisons removes much of the information content in the gene 
expression values. Subjects within any group will have a continuum of gene expression 
values. Furthermore, many of the phenotypes that we measure are also measured on a 
continuum. This information is lost when either gene expressions or subject phenotypes 
are divided into discreet categories. 
 In many of these studies continuous-valued phenotypes such as glucose disposal, 
BMI, and exercise performance measurements are experimentally determined alongside 
the microarray data, and these values can and should be directly compared with gene 
expressions. In this work, we present a simple technique whereby externally measured 
metabolic phenotypes are directly correlated with steady-state gene expression values in 
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the pre and post exercise conditions, as well as gene expression fold changes induced by 
exercise. Despite the simplicity of this technique, we find many gene targets that have 
striking connections with biological function. 
 Using correlation analysis against glucose uptake, we identify several genes that 
appear to connect with the wnt signaling pathway, well known to be associated with type 
2 diabetes in genome wide association studies (GWAS). Two gene expressions are also 
found highly correlated with glucose uptake and body mass index (BMI) which have 
been previously identified as genome wide susceptibility loci for these phenotypes. These 
findings validate the GWAS data, and additionally unveil the target tissues where these 
genes exert pathological phenotypes. Furthermore, we demonstrate that many co-
correlating genes have known associations with one another, either by forming direct 
complexes or partaking in the same signaling pathways. Overall, the results provide a 
birds-eye view of mostly-uncharted areas of insulin action and new mechanisms for 
insulin resistance and its modulation by exercise. This technique, if adopted in similar 
studies, may unveil new therapeutic targets to combat insulin resistance, diabetes, and 
obesity. 
Exercise Study 
Subjects. Fourteen normoglycemic volunteers took part in this study, which was 
approved by the Institutional Review Board of Arizona State University. All studies were 
conducted at the Clinical Research Unit at ASU. Informed, written consent was obtained 
from all subjects. All of the volunteers were sedentary, with none engaged in regular 
exercise, and no one reported having a change in body weight for at least 6 months before 
participating in this study. Subjects were instructed not to exercise for 48 hours before 
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study and to maintain their usual diet.  A medical history, physical examination, 12-lead 
electrocardiogram, and a complete chemistry panel were obtained, and a 75-g oral 
glucose tolerance test was performed using American Diabetes Association criteria to 
exclude nondiabetic subjects with impaired glucose tolerance. No one was taking any 
medication known to affect glucose metabolism. 
Peak aerobic capacity. Peak aerobic capacity (VO2peak) was determined as 
previously described, with continuous heart rate monitoring . Briefly, exercise was started 
at a workload of 40 W and increased by 10 W/min until perceived exhaustion or a 
respiratory quotient of 1.10 was reached. 
Muscle biopsy and hyperinsulinemic euglycemic clamp.  Euglycemic clamps 
and muscle biopsies were performed as described .  After a 10-h overnight fast, a 
percutaneous biopsy of the vastus lateralis muscle was obtained with a Bergstrom 
cannula under local anesthesia one hour before the start of insulin infusion.  This biopsy 
served as the resting, non-exercised control.  A stable isotope ([6,6-
2
H] glucose) was used 




 was used. 
Exercise bout with muscle biopsies. All subjects also underwent an exercise test 
consisting of a single bout of aerobic exercise. The exercise bout was conducted on a 
separate day after determination of VO2peak, as described previously  and at least 1 week 
either before or after the euglycemic hyperinsulinemic clamp. Design of the exercise bout 
is given in Figure 1.  Subjects reported to the Clinical Research Unit at about 7 AM after 
fasting overnight and exercised on a stationary bicycle, alternating between 70% (8 
minutes) and 90% (2 minutes) of heart rate corresponding to that at VO2max, for a total of 
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4 sets of exercise, with two minutes rest between sets . Immediately after completing 
exercise, the subject was moved to a bed where a biopsy of the vastus lateralis muscle 
was performed within 30 min of the end of exercise. 
mRNA expression assays:  Muscle RNA was isolated as described. Total RNA 
(500 ng) was amplified and labeled using the Amino Allyl MessageAmp™ II aRNA 
Amplification Kit, as per manufacturer’s instructions (Life Technologies, Carlsbad, CA).  
After labeling, antisense RNA (aRNA) was quantified using a NanoVue 
Spectrophotometer for cyanine 3 (Cy3) dye labeled aRNA concentration, RNA 
absorbance ratio (260 nm/280 nm), A260 values, ADye values, and dye/probe values.  
The Cy3-labeled aRNA was then fragmented using Agilent Gene Expression 
Hybridization Kit (Agilent Technologies, Palo Alto, CA), as per the instructions.  The 
fragmented aRNA was hybridized to the 4x44K Whole Human Genome Microarray 
(Agilent Technologies, Palo Alto, CA) using a SureHyb DNA Microarray Hybridization 
Chamber at 65°C, for 17 hours in a rotating incubator. After hybridization, slides were 
washed in Gene Expression wash buffers 1 and 2 as per manufacturer’s instructions, and 
then scanned with an Agilent DNA microarray scanner (Agilent Technologies, Palo Alto, 
CA).  Feature Extraction Software version 10.5.1.1 (Agilent Technologies, Palo Alto, 



































 Raw expression values for each individual probe were log2 transformed and 
quantile normalized. To determine fold change of gene expression between the post-
exercise biopsy and the resting biopsy, the log2-transformed resting expression values 
were subtracted from the post-exercise values. 
 Correlations were computed using Pearson’s product-moment method between 
gene expression values and externally measured metabolic phenotypes. Correlations were 
independently performed with the expression values in both the resting and post-exercise 
biopsies, as well as the gene expression fold changes induced by exercise. These three 
tests independently determine gene expressions that may influence glucose uptake 
(resting biopsy) and exercise performance (post-exercise biopsy), as well as exercise 
adaptations (fold changes) that are dependent on metabolic parameters. Correlations were 
calculated utilizing the Scientific Python (scipy) library[17] in a custom script which 
reads gene expression values from a comma-separated-values (csv) spreadsheet and 
corresponding subject metabolic phenotypes from a second csv file. The correlations are 
output into separate results spreadsheets sorted by correlation coefficient. We then 
performed literature searches on the top 20 most positively correlating probes and the 
bottom 20 most negatively correlating probes. We focused most of our attention on 
resting gene expression correlations with glucose uptake (M); however, additional 
scrutiny was given to all correlations with BMI and post-exercise gene expression 
correlations with exercise performance. 
 We observed several spurious correlations with non-biological control spots on 
the array. These so called “dark corners” are composed of sequences designed to form 
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hairpins, and otherwise not hybridize to sequences found within the human genome. 
These control spots are amongst the darkest spots on the array, and have signal levels 
considered to be background. It is possible that these dark control probes may be located 
near bright biological spots that have high correlations, and that cross-talk on the array is 
leading to the spurious correlations. Another possibility is that the spurious correlations 
are entirely random. Given that these spots have the lowest signal to noise on the array, 
and that the photon counting error follows Poisson statistics, it follows that the 
background-level probes will have the highest propensity toward spurious correlations. 
To compensate for this, we only considered correlating probes that had log-transformed 
intensities of 9 or higher. (Figure 2) These spot intensities are considered to be outside of 
the background signal range as determined by the distribution of dark corner intensities. 
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Figure 2 : Microarray signal intensities 
 
Histograms showing distribution of signal intensities on microarray. Dark corner spots 
show the background level of signal intensities. For resting-state correlations, only the 












 We performed independent correlations of both the resting and post-exercise 
biopsy gene expressions, as well as the exercise-induced fold-changes of the gene 
expressions. Correlations were performed against insulin stimulated glucose uptake and 
body mass index (BMI) to look for interesting associations. Of the approximately 40,000 
probes on the array, most showed little to no correlation, but a small handful of probes 
displayed significant positive or negative correlation. The distribution of correlations 
shows the rapid decline of probes with increasing correlation strength. (Figure 3) These 
top positive-correlating and bottom negative-correlating probes are scrutinized. For each 
of the genes represented by these probes, we conducted systematic literature review to 
find potential explanations. This analysis unveils both previously known and novel 
protein targets which may act as high-control nodes in affecting these various metabolic 
characteristics. 
Resting state expressed genes that correlate with glucose uptake 
 In our study, the resting “pre exercise” muscle biopsy was obtained just one hour 
prior to a hyperinsulinemic euglycemic clamp. Given the close time proximity, we 
hypothesize that gene expression values in this resting state may be most-directly 
associated with the glucose disposal rate (M mg/kg/min) as measured in this experiment. 
Thus we focused most of our attention and developed the most comprehensive story 
based on correlations with this metabolic parameter. Excitingly, genes were uncovered 
that are genetically associated with diabetes and have direct connections to translocation 
of the glucose transporter. Furthermore, the results unveil a well-characterized muscle 
atrophy pathway that may provide a clue to the physiological purpose of insulin 
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resistance. Top correlating genes are presented for correlations with glucose disposal rate 
(Table 1) as well as the glucose disposal rate adjusted for fat-free mass. (Table 2) In both 
of these tables, genes with interesting connections are bold faced and discussed. 
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Correlation ID Description 
0.86 GOPC Homo sapiens golgi associated PDZ and coiled-coil motif containing 
0.83 ZBED3 Homo sapiens zinc finger 
0.83 MEA1 Homo sapiens male-enhanced antigen 1 (MEA1) 
0.83 BC014384 Homo sapiens 
0.83 GLUD1 Homo sapiens glutamate dehydrogenase 1 (GLUD1) 
0.82 PDE4A Homo sapiens phosphodiesterase 4A 
0.81 EIF4ENIF1 Eukaryotic translation initiation factor 4E nuclear import factor 1 
0.8 PPP2R3A Homo sapiens protein phosphatase 2 (formerly 2A) 
0.79 LOC401708 PREDICTED: Homo sapiens similar to Glutamine synthetase  
0.79 PPP2CB Homo sapiens protein phosphatase 2 (formerly 2A) 
0.79 PUS7 Pseudouridylate synthase 7 homolog (S. cerevisiae) (PUS7) 
0.79 MIER1 Homo sapiens mesoderm induction early response 1 homolog 
0.78 BC037535 Homo sapiens cDNA clone IMAGE:5274219. [BC037535] 
0.77 GIT2 Homo sapiens G protein-coupled receptor kinase interactor 2 (GIT2) 
0.77 RAD23B Homo sapiens RAD23 homolog B (S. cerevisiae) (RAD23B) 
0.77 RBMX2 Homo sapiens RNA binding motif protein 
0.77 TCEB2 Homo sapiens transcription elongation factor B (SIII) 
0.77 FDPSL4 PREDICTED: Homo sapiens similar to farnesyl diphosphate synthase 
Correlation ID Description 
-0.78 RPLP0 Homo sapiens ribosomal protein 
-0.78 RPLP0 Homo sapiens ribosomal protein 
-0.78 ADRM1 Homo sapiens adhesion regulating molecule 1 (ADRM1) 
-0.78 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
-0.78 UBE2E3 Homo sapiens ubiquitin-conjugating enzyme E2E 3 
-0.78 PDXDC2 Homo sapiens mRNA; cDNA DKFZp686B0962 
-0.78 RPLP0 Homo sapiens ribosomal protein 
-0.79 DYSF Homo sapiens dysferlin 
-0.8 EIF3S5 Homo sapiens eukaryotic translation initiation factor 3 
-0.8 EEF1B2 Homo sapiens eukaryotic translation elongation factor 1 beta 2 
-0.8 RPS3A Homo sapiens ribosomal protein S3A (RPS3A) 
-0.8 RPLP0 Homo sapiens ribosomal protein 
-0.81 A_24_P50489 Unknown 
-0.83 FBXO32 Homo sapiens F-box protein 32 (FBXO32) 
-0.85 LOC440350 Homo sapiens similar to nuclear pore complex interacting protein 
-0.85 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
-0.87 FBXO9 Homo sapiens F-box protein 9 (FBXO9) 
 
Table 1 : Top positive and bottom negative correlating gene expression probes with glucose uptake. 
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Correlation ID Description 
0.87 EIF4ENIF1 Eukaryotic translation initiation factor 4E nuclear import factor 1 
0.86 GOPC golgi associated PDZ and coiled-coil motif containing 
0.85 RAD23B Homo sapiens RAD23 homolog B (S. cerevisiae) (RAD23B) 
0.84 PPP2CA Homo sapiens protein phosphatase 2 (formerly 2A) 
0.84 LOC401708 Homo sapiens similar to Glutamine synthetase  
0.83 MEA1 Homo sapiens male-enhanced antigen 1 (MEA1) 
0.83 PPP2R3A Homo sapiens protein phosphatase 2 (formerly 2A) 
0.83 PDE4A Homo sapiens phosphodiesterase 4A 
0.83 THC2674354 Q36LB5_MARHY  Nucleoside-diphosphate-sugar epimerases 
0.82 ITGB1 Homo sapiens integrin 
0.82 PSCD1 Homo sapiens pleckstrin homology 
0.82 PUS7 Homo sapiens pseudouridylate synthase 7 homolog (S. cerevisiae)  
0.82 ARS2 Homo sapiens ARS2 protein (ARS2) 
0.82 SERBP1 Homo sapiens SERPINE1 mRNA binding protein 1 (SERBP1) 
0.81 RMI1 Homo sapiens RMI1 
0.81 MAPK14 Homo sapiens mitogen-activated protein kinase 14 (MAPK14) 
0.81 ZBED3 Homo sapiens zinc finger 
Correlation ID Description 
-0.78 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
-0.78 RPLP0 Homo sapiens ribosomal protein 
-0.79 SFRS8 Homo sapiens splicing factor 
-0.79 A_24_P136011 Unknown 
-0.79 PHKG1 Homo sapiens phosphorylase kinase 
-0.80 FBXO9 Homo sapiens F-box protein 9 (FBXO9) 
-0.81 CEP63 Homo sapiens centrosomal protein 63kDa (CEP63) 
-0.82 RYR1 Homo sapiens ryanodine receptor 1 (skeletal) (RYR1) 
-0.82 EIF3S5 Homo sapiens eukaryotic translation initiation factor 3 
-0.82 RPL6 Homo sapiens ribosomal protein L6 (RPL6) 
-0.82 LOC440350 Homo sapiens similar to nuclear pore complex interacting protein 
-0.83 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
-0.83 RPLP0 Homo sapiens ribosomal protein 
-0.83 LSM3 Homo sapiens LSM3 homolog 
-0.83 A_24_P50489 Unknown 
-0.84 FBXO32 Homo sapiens F-box protein 32 (FBXO32) 
-0.84 RPS3A Homo sapiens ribosomal protein S3A (RPS3A) 
-0.85 UCP3 Homo sapiens uncoupling protein 3 (mitochondrial 
 
Table 2 : Top correlates of glucose uptake adjusted for fat free mass (mg/kg_ffm/min) 
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Positive Correlates : Diabetes Genetic Associations + Wnt Signaling 
 Beginning with investigation of positive correlating probes with glucose uptake, 
we find several genes that participate in the wnt/β-catenin signaling pathway. We will 
briefly summarize what is known about this pathway and its connections to type 2 
diabetes. We direct the reader to an excellent reviews on the canonical wnt pathway[18] 
and its known role in regulating insulin sensitivity.[19, 20] 
 The downstream effector of the wnt pathway is the β-catenin protein. In the 
unstimulated cell, β-catenin concentrations are kept very low due to constant attack by a 
“destruction complex” consisting of the proteins Axin, Adenomatous Polyposis Coli 
(APC) , Glycogen Synthase Kinase-3 (GSK-3), and casein kinase 1α (CK-1α). When 
bound to this complex, β-catenin is phosphorylated, ubiquitinated, and degraded by the 
proteosome. When the wnt pathway is activated however, this destruction complex is 
inhibited. A variety of endogenous wnt protein ligands bind to cell-surface receptor 
complexes composed of Frizzled proteins and LDL receptor-related proteins (LPR). 
When activated, these receptor complexes recruit a variety of intracellular proteins. 
Dishevelled (Dsh) is recruited and activated, which inhibits GSK-3. Furthermore the 
destruction complex members Axin, APC, and GSK-3 are recruited and sequestered at 
the receptor, thereby rescuing β-catenin from degradation. This leads to an increase in 
cytosolic β-catenin concentration which then translocates into the nucleus and 
heterodimerizes with transcription factors of the T-Cell Factor (TCF) and Lymphoid 
Enhancer-binding Factor (LEF) family. These activated complexes bind to DNA and 
transcribe target genes. 
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 There is profound genetic evidence that wnt/β-catenin signaling is central to 
diabetes pathogenesis and regulation of glucose homeostasis in a variety of tissues.[19] 
For many years, genome wide association studies (GWAS) have clearly shown that the 
TCF transcription factor TCF7L2 is the single most significant type 2 diabetes 
susceptibility locus with many pathogenic single nucleotide polymorphisms (SNPs).[20, 
21] Despite this clear statistical evidence, the signaling mechanisms by which defects in 
TCF7L2 promote the development of type 2 diabetes are largely a mystery. Until recent 
years, most research on pathogenic TCF7L2 polymorphisms have focused on pancreatic 
development and function, however canonical wnt signaling is not active in adult β-cells 
after development.[22] This observation is directing research to other tissues of the body 
involved in glucose metabolism. TCF7L2 is additionally expressed in the brain, liver, 
muscle, and adipocytes. 
 A recent study by Abiola et. al. [23] has focused on wnt signaling in muscle, and 
promotes the hypothesis that wnt signaling modulates the balance between myogenic vs. 
adipogenic behavior. They established an inverse expression pattern of the endogenous 
wnt ligand wnt10b with the lipogenic transcription factor Sterol Response Element 
Binding Protein-1 (SREBP-1). During the development or post-injury regeneration of rat 
muscles, they observed that wnt10b is dominantly expressed alongside the transcription 
factor myogenin, whereas SREBP-1 expression was suppressed. After development, they 
observe that wnt10b becomes undetectable and that SREBP-1 expression is induced. This 
observational data in animals suggested an inverse relationship between these genes. To 
test this hypothesis, they performed numerous experiments with myoblasts and myotubes 
in culture. 
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 They demonstrated that wnt10b knockdown in myoblasts led to a dramatic 
increase in the expression of SREBP-1, and wnt10b overexpression in myotubes lead to a 
suppression of SREBP-1. They additionally observed that PPARG was affected, 
mirroring the expression of SREBP-1. They next demonstrated that SREBP-1 
knockdown was sufficient to induce the expression of wnt10b in contracting myotubes. 
From these combined results, they concluded that wnt10b and SREBP-1 show an inverse 
expression pattern, even after differentiation. To assess the effects of wnt signaling on 
insulin sensitivity, they performed 2-Deoxyglucose (2-DG) uptake experiments. They 
showed that culturing myotubes in high glucose conditions for 48 hours induced marked 
insulin resistance in which insulin would not stimulate any glucose uptake, but wnt10b 
overexpression completely restored insulin sensitivity in these cells. 
 They concluded that the primary signaling node which mediated this balance was 
Glycogen Synthase Kinase-3 (GSK-3), which they inhibited with the inhibitor BIO. They 
demonstrated with oil-red-o staining that BIO completely inhibited the formation of lipid 
droplets in myotubes cultured under high glucose conditions, and furthermore induced 
the formation of sarcomeres. From all of this evidence, they concluded that wnt signaling 
promotes a myogenic phenotype in muscle cells and that SREBP-1 inhibits the wnt 
signaling pathway and promotes an adipogenic phenotype in which intracellular lipids 
accumulate and insulin sensitivity is reduced. This exciting study suggests that the 
inhibition of adipogenic behavior by wnt signaling is as true in myocytes as it is in 
adipocytes. 
 In another recent study by Yoon et. al. [24] a high-throughput RNAi screen was 
used to determine genes that affect mitochondrial function. The wnt signaling pathway 
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was determined to be a direct activator of mitochondrial biogenesis. Furthermore, the 
study identified that Insulin Receptor Substrate-1 (IRS-1), the critical hub in the insulin 
signal transduction pathway, was a direct transcriptional target of wnt signaling. They 
concluded that wnt signaling directly potentiates insulin sensitivity in these cells. 
 Combined, these two recent studies give enthusiastic evidence that wnt signaling 
in muscle is directly related to insulin sensitivity. It may soon become evident that the 
ultimate downstream effector of this signaling is TCF7L2, which would provide 
validation of the GWAS results and evidence that muscle is a target tissue of its 
pathogenic effects. Even despite validation of this particular downstream wnt effector 
molecule, it is clear from these two studies that enhancement of wnt signaling in muscle 
will increase insulin-stimulated glucose uptake. Interestingly, several positive correlating 
genes have connections to wnt signaling, which may further hint at the importance of this 
pathway. 
 ZBED3: The second-ranking transcript showing high positive correlation (Figure 
4) with glucose uptake is ZBED3. Little work has been done characterizing the function 
of this gene, however recent genomic evidence hints at a connection to type 2 diabetes. In 
a recent large scale genome wide association study (GWAS), a combined 42542 
individuals with type 2 diabetes (T2D) and 60912 controls were studied to determine the 
genetic loci contributing to the disease.[21] 12 new susceptibility loci were identified that 
have not yet been reported in prior GWAS literature. One of these SNPs is located 
upstream of the ZBED3 gene on chromosome 5. Given that type 2 diabetes is a disease 
associated with insulin resistance, it is exciting that this gene expression correlate is now 
known to have associated polymorphisms with the disease. Aside from this GWAS study 
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however, there is little knowledge of the function of ZBED3 with only a single study 
characterizing its cellular function.[zbed3] It was determined to directly modulate the 
wnt/ β-catenin signaling pathway. 
 Chen et al.[25] were seeking novel interacting partners of Axin, which is the core 
scaffold protein of the β-catenin destruction complex. By using a yeast-two-hybrid assay, 
they identified zinc-finger BED domain-containing protein 3 (ZBED3). The authors 
directly confirmed interaction with in-vitro pulldown experiments. Their study also 
focused on a characteristic PPPPSPT motif found within ZBED3. This characteristic 
motif was shown to be the binding site for Axin, and that Glycogen Synthase Kinase 3 
Beta (GSK3B) phosphorylates this motif at the serine and threonine residues. 
Furthermore, they demonstrate via pull-down experiments that interaction between Axin 
and ZBED3 is enhanced with the overexpression of wild-type GSK3B, but not with the 
overexpression of a kinase-dead version. 
 The authors went on to determine if ZBED3 overexpression modulated Wnt/ β-
catenin signaling. Using a reporter gene in NIHT3T cells, they verified that expression of 
ZBED3 alone promoted transcription at LEF-1 binding sites. In a complementary 
experiment, they demonstrate that Wnt/ β-catenin signaling is decreased under conditions 
of a ZBED3 RNAi knockdown. This evidence illustrates that the concentration of 
ZBED3 alone may directly modulate wnt signaling and transcription of β-catenin target 
genes. The function of ZBED3 appears to be that of binding Axin and sequestering it in 
the same mechanism that Frizzled/LRP receptor complexes sequester it upon pathway 
activation, making ZBED3 an internal activator of the pathway. Given the prior in vitro 
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studies in muscle, it is reasonable that this gene would directly promote insulin 
sensitivity. 
 GOPC: The most positively correlating transcript to whole body glucose uptake 
in our exercise experiment (Figure 5) was GOPC, and this transcript is additionally the 
second most positively correlating gene for clamp glucose uptake adjusted for fat free 
mass. (Table 2) GOPC, also known as CAL and FIG, was originally described as Protein 
Interacting Specifically with TC10 (PIST).[26] Very recently Bogan et. al. provided 
compelling evidence that GOPC/PIST is a direct activator of glucose transport in the 
cell.[27] 
 In the insulin unstimulated state, the insulin responsive glucose transporter 
(GLUT4) is stored within GLUT4 storage vesicles (GSVs) that are retained 
intracellularly until an insulin stimulus promotes mobilization, translocation, and 
ultimately docking and insertion of GLUT4 into the plasma membrane. Once inserted, 
GLUT4 permits glucose uptake into the cell. This concerted effort requires many proteins 
and several discreet biochemical stages, however the molecular mechanisms behind this 
process are incompletely understood.[28] 
 It has been elucidated that in the unstimulated state, GSVs are physically 
anchored to the Golgi apparatus by a tether protein known as TUG. It was proposed that 
insulin stimulation releases this tether and thus permits GSV translocation to the cellular 
membrane.[29] This hypothesis was confirmed recently by demonstrating that TUG 
proteins undergo endoprotylitic cleavage into separate N-terminal and C-terminal 
fragments.[27] The authors demonstrated that the C-terminal half of TUG anchors GSVs 
to the intracellular golgi apparatus, and that overexpression of a C-terminal fragment 
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resulted in translocation of GFP-tagged GLUT4 to the plasma membrane in the insulin 
unstimulated state. Additionally, glucose uptake assays were performed with 2-
deoxyglucose, and it was demonstrated that glucose uptake is dramatically increased in 
both the resting and insulin-stimulated conditions when TUG was knocked down with 
shRNAs. While the fluorescence experiments confirmed that GLUT4 translocation can 
be directly activated via TUG knockdown, the direct glucose uptake assay confirms that 
releasing the TUG tether additionally mediates insertion of GLUT4 into the cell 
membrane. 
 Excitingly, GOPC/PIST was shown by Bogan et. al. [27] to be an interacting 
partner of TUG, and also shown to interact with the Golgi protein Golgin-160. The pull-
down experiments imply a model in which GLUT4, TUG, GOPC/PIST, and Golgin-160 
are bound in a linear arrangement. They propose a model whereby this complex of four 
proteins form the putative anchor which immobilizes stored GSVs to the golgi in the 
insulin unstimulated state. Given that GOPC/PIST is an effector of TC10a, and that 
TC10a has been shown to be required for insulin stimulated GLUT4 translocation in 
adipocytes,[30] Bogan et. al. hypothesized that GOPC/PIST may be the effector molecule 
that facilitates cleavage of TUG. Knockdown of TC10a with siRNAs inhibited TUG 
proteolytic processing, indicating that TC10a is required for cleavage of TUG and 
untethering of GLUT4 from the Golgi apparatus. This combined evidence hints that 
GOPC/PIST may be the final “on switch” for GLUT4 trafficking/insertion, and that the 
expression levels of this protein may indeed directly predict insulin sensitivity in muscle 
measured during a glucose clamp. 
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 Intriguingly, beyond its role in regulating the glucose transporter, GOPC has been 
documented to facilitate the transport of several other proteins to the cell membrane. 
GOPC has been shown to be an interacting partner of frizzled receptors, which partake in 
wnt signaling. In a yeast-two-hybrid experiment, GOPC was demonstrated to bind to the 
c-terminal domain of Frizzled 8. GOPC has a PDZ domain, and was proven to interact 
with frizzled via a c-terminal PDZ binding motif (Ser/Thr–X–Val).[31] Upon co-
transfection of GOPC and frizzled 5 into COS7 cells, the authors observed with 
immunofluorescent staining that GOPC and frizzled co-localized at the Golgi apparatus. 
At 20 hours after transfection, GOPC and frizzled were observed co-localized at the cell 
membrane. Thus GOPC is involved in a secretory pathway that translocates frizzled 
receptors to the cell membrane. From this evidence, we hypothesize that GOPC may have 
a secondary effect on insulin sensitivity by increasing wnt signaling, thereby increasing 









Figure 5 : GOPC correlation with glucose uptake 
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 PP2: Protein Phosphatase 2, also known as PP2A, is a heterotrimeric 
serine/threonine protein phosphatase. It is composed of structural protein component, a 
catalytic protein component, and an optional regulatory subunit. The structural subunits 
are encoded by two isoforms (PPP2R1A and PPP2R1B) as are the catalytic subunits 
(PPP2CA and PPP2CB). There are many regulatory subunit genes encoding a variety of 
sizes with diverse functions. Interestingly, amongst the top positive correlates we find a 
catalytic gene (PPP2CB) and a regulatory subunit gene (PPP2R3A). The co-occurrence 
of these two probes in the top correlates list hints that PP2A activity may increase insulin 
sensitivity. Interestingly, PP2A [32] is a positive regulator of wnt signaling by 
specifically targeting β-catenin for dephosphorylation, although this was mediated with 
the pr55 regulatory subunit (PPP2R2). The regulatory subunit correlated in our study 
(PPP2R3A) however has conflicting effects on wnt signaling. The PPP2R3A gene 
encodes multiple transcript variants that encode both a 72kD (pr72) and a 130kD (pr130) 
isoform. A study has shown that the pr72 isoform down regulates[33] wnt signaling. A 
later study by the same lab discovered that the pr130 isoform up regulates[34] wnt 
signaling. It is the possible that alternative splicing of this gene may precisely fine-tune 
wnt signaling, but the microarray platform does not allow us to distinguish which variant 
is being transcribed. 
 
Negative Correlates – The Muscle Atrophy/Wasting Pathway 
 We next turned our attention to the bottom most-negatively correlating genes. We 
have provided evidence that the top positive correlates may potentiate insulin signaling 
through wnt signaling, or even directly activate the GLUT4 translocation/insertion 
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machinery. These may be putative “on switches” of glucose metabolism. Likewise, gene 
expressions with strong negative correlation may provide evidence of the mechanisms of 
pathological insulin resistance. Indeed, if a glucose uptake “off switch” can be found, 
then novel therapeutic targets can be realized. 
 Interestingly, many of the strongest negative correlates appear to participate in the 
well-studied skeletal muscle atrophy pathway. Muscle atrophy and wasting is associated 
with many causes, including: starvation, disuse, inflammation, diabetes, cancer, and 
aging.[35] Despite several completely distinct causes for muscle atrophy, the 
phenomenon is mediated via a common cellular process: the ubiquitin proteosome system 
(UPS). The small protein tag known as ubiquitin is selectively ligated onto targeted 
proteins which are then recognized by the proteosome and subsequently degraded. 
 The ubiquitination of target proteins is accomplished by a cascade of reactions 
regulated by three classes of enzymes. The ubiquitin protein is first activated by a small 
set of activation enzymes (E1), and then transferred to one of about 40[36] mammalian 
ubiquitin conjugating enzymes (E2), and finally attached to a specific target protein by 
one of many hundreds of ubiquitin ligases (E3). Amongst the negative correlates to 
glucose uptake, we find a skeletal muscle specific E2 and two E3s, alongside a protein 
already demonstrated as a ubiquitin target in muscle atrophy. Alongside these genes, we 
find two probes for NFKB1, which is a transcription factor demonstrated as required for 
skeletal muscle atrophy via the UPS. This profound enrichment of genes in the most 
negative correlates suggests that skeletal muscle atrophy, mediated via the ubiquitin 
proteosome system, may be a direct “off switch” to glucose uptake in vivo. 
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 UBE2E3 is classified as an E2 ubiquitin conjugating enzyme. The E2 proteins in 
the human genome show a marked tissue[36] specificity, and northern hybridization 
analysis[37] has demonstrated a strong and specific expression of UBE2E3 in skeletal 
muscle. Interestingly, in a recent microarray study of insulin sensitive and insulin 
resistant human subjects, UBE2E3 was the third highest ranked probe that was found 
significantly elevated in insulin resistant muscle.[38] This substantiates the strong 
negative correlation with glucose uptake in our analysis and suggests that this gene may 
be equally linked with both increased ubiquitin proteosome activity and insulin 
resistance. 
 E2 ubiquitin conjugating proteins are sometimes colloquially referred to as 
“ubiquitin carriers”, as they carry ubiquitin tags until they eventually form complexes 
with the hundreds of E3 ubiquitin ligases that ultimately target downstream substrate 
proteins. A particularly large class of E3 ligases are the SCF (Skp1-Cullin-Fbox) 
complexes. Cullin forms a central scaffold which binds Skp1 and Roc1. Roc1 binds E2 
conjugating enzymes that carry ubiquitin tags. Skp1 binds a large class of Fbox adaptor 
proteins that target specific downstream protein targets for ubiquitination. The full 
complex brings together E2 ubiquitin conjugates with target proteins and facilitates the 
transfer of the ubiquitin. With this modular system, the cell can regulate proteolysis by up 
regulating various Fbox proteins to handle degradation of different subsets of the 
proteome. Amongst the highest negative correlates of glucose uptake, we find two Fbox 
proteins associated with muscle proteolysis: FBXO32/Atrogin and FBXO9. Thus 
amongst the negative correlates, we see a strong association of both the E2 and E3 steps 
in the ubiquitination pathway with reduced glucose uptake. 
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 FBXO32 is the fourth most-negatively correlating transcript with glucose uptake, 
and second when glucose uptake is adjusted for fat-free mass. Muscle atrophy can be 
readily induced with fasting, since the protein stores in muscle serve as a source of amino 
acids for hepatic gluconeogenesis in times when dietary glucose is restricted. To identify 
the specific molecular mechanisms behind this process, Gomes et. al.[3] used cDNA 
microarrays to identify genes up regulated during fasting. By comparing skeletal muscle 
samples of fed and fasted mice, they identified FBXO32 as a gene induced seven to nine 
fold after as little as 16 hours of fasting. Due to its clear role in inducing the atrophy 
process, the authors named this gene Atrogin-1. 
 Given that loss of muscle mass is a common characteristic[35] of metabolic 
disorder, it is compelling that this gene is amongst the most negative correlating genes 
with glucose uptake. It is furthermore compelling that this gene was originally identified 
in the skeletal muscle of fasted animals. Indeed the subjects in our study were instructed 
to fast for 10 hours overnight prior to the hyperinsulinemic euglycemic clamp. The 
measured M-values, adjusted for fat-free-mass, ranged from about 5 to 13 mg/kg/min. 
This molecular connection suggests that this range of insulin sensitivity in the human 
population may relate to an individuals propensity to muscle atrophy during times of 
fasting. Some individuals may be more prone to waste muscle on shorter time scales then 
others. This suggests that to understand insulin resistance, as measured by these glucose 
clamp experiments, we must understand short term muscle atrophy in these subjects and 
ascertain if it is higher in some subjects than in others. 
 FBXO9: Interestingly, another Fbox protein occupies the list of strong negative 




 most negative ranking correlate when glucose uptake is adjusted for fat free 
mass. FBXO9 is not as well-characterized in the literature as FBXO32/Atrogin-1, 
however in recent years a handful of studies have identified preliminary molecular targets 
of this protein. 
 FBXO9 was recently demonstrated to modulate mTOR signaling by mediating the 
ubiquitination and degradation of specific proteins within the mTOR complexes.[39] 
Telomere maintenance 2 (Tel2) and Tel2 interacting protein 1 (Tti1) are proteins that 
regulate the abundance of PI3K-related kinase (PIKK) family members such as mTOR. 
These proteins are integral complex members that are found in both the mTORC1 and 
mTORC2 complexes. The authors found that in certain cancers, FBXO9 overexpression 
selectively targets Tel2 and Tti1 in mTORC1 for ubiquitination and degradation. This 
causes reduction in signaling through mTORC1. It has long been accepted [40] that 
mTOR signaling is a central regulatory node for insulin sensitivity. 
 In a separate study, FBXO9 was demonstrated to be a required signaling molecule 
for adipogenesis.[41] The authors found that in the white fat tissue of mice, FBXO9 
expression was elevated fivefold in mice fed a high fat diet as compared to a control diet. 
Furthermore, FBXO9 expression was shown to correlate highly with obesity. Expression 
was also significantly elevated when 3T3-L1 cells were stimulated with various inducers 
of differentiation, including dexamethasone and insulin. Lastly, the authors demonstrated 
that FBXO9 knockdown inhibited this adipogenesis. Blots were performed with this 
knockdown and with a scrambled siRNA control to assess the effects on various 
signaling molecules. Remarkably they show a marked reduction in β-catenin when 
FBXO9 is expressed. When knocked down, β-catenin stays elevated and adipogenesis is 
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inhibited. They also found that FBXO9 expression promoted PPARG expression, and 
FBXO9 knockdown lead to suppression of PPARG. They determined that this regulation 
was indirect and mediated via CEBPb.[41] 
 Altogether, the evidence provided by this study suggests that FBXO9 is a potent 
stimulator of adipogenic phenotypes in adipocytes. The question now becomes whether 
or not similar effects would impose an adipogenic phenotype in muscle. The degradation 
of β-catenin when FBXO9 is expressed is an interesting phenomenon worth 
investigating. It is unknown whether this is a direct target of FBXO9 ubiquitination or if 
another mechanism is leading to this suppression. This evidence does suggest however 
that the wnt signaling pathway may be directly suppressed by this gene. This is evidence 
of direct crosstalk between this negative-correlating atrophy pathway and the positive-
correlating wnt pathway. Wnt signaling is anti-adipogenic, and FBXO9 is now 
established as pro-adipogenic. 
 EIF3S5 (eIF3-f) encodes the f subunit of the eukaryotic initiation translation 
factor 3, which is a major regulator of protein translation within the cell. Intriguingly, 
eIF3-f was recently shown [42] to be a direct interacting partner of FBXO32/Atrogin in a 
yeast-two-hybrid screen, and that atrogin ubiquitinates eIF3-f which results in 
proteosomal degradation. Atrogin knockdown in atrophying myotubes was sufficient to 
inhibit eIF3-f degradation. They also showed that eIF3-f may be a direct regulator of 
atrophy by showing that repression of eIF3-f alone induces atrophy and eIF3-f 
overexpression blocks atrophy in serum starved conditions. In the same study, eIF3-f was 
electroporated directly into the right leg tibialis anterior muscle of a live mouse, and an 
empty vector control into the left leg. They measured fiber diameters 14 days later, and 
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noted an 11% increase in fiber diameter with eIF3-f expression. They concluded that 
eIF3-f is a critical regulator of muscle hypertrophy by regulating the balance between 
protein translation and teardown. 
 Increased protein proteolysis is an essential aspect of muscle atrophy, and it is 
reasonable that decreased protein synthesis is an additional facet of this condition. This 
would especially be relevant in conditions of fasting or starvation in which amino acids 
must be conserved. Alongside its role in the proteolysis of sarcomeric proteins, the 
targeting of eIF3-f by Atrogin facilitates this dual strategy and fine tunes this balance 
between anabolism and catabolism. 
 It is however paradoxical that eIF3-f expression is negatively correlated with 
glucose uptake. One might expect that greater expression of the eIF3-f gene would result 
in higher quantities of the eIF3-f protein and a concomitant increase in protein translation 
in the cell. One possible explanation of this observation is that the cell may be 
upregulating the eIF3-f transcript to compensate for a dramatic reduction of the eIF3-f 
protein. Many proteins inhibit their own expression by binding to the promoter regions of 
their own genes. The concentration of the eIF3-f protein may be precisely regulated in the 
cell due to this process or some other indirect mechanism. To test this hypothesis, the 
eIF3-f protein itself must be assayed in muscle. Regardless of the seeming opposite 
direction of this correlation, the fact that eIF3-f interacts with Atrogin and appears as a 
strong negative correlate provides even more evidence that Atrogin is a core instigator of 
insulin resistance.  
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 NFKB1: Intriguingly, two separate probes for NFKB1 appear in our list of strong 
negative correlates. NFKB1 encodes the p50 subunit of the nuclear factor kappa-light-
chain-enhancer of activated b cells (NF-KB) transcription factor, which is a core activator 
of the inflammatory response in cells. There are 10 probes for this gene on the 
microarray, and they all show highly negative correlation coefficients ranging from -0.64 
to -0.84. This is encouraging because several studies have indicated that NF-KB activity 
is a critical mediator of skeletal muscle atrophy. NFKB1 encodes the p50 subunit of the 
NF-KB transcription factor. 
Very early work has demonstrated that KFKB activity directly activates 
FBXO32/Atrogin. Hunter et. al. [43] demonstrated that NFKB1 and BCL3 knockout 
mice are resistant to disuse atrophy. BCL3 heterodimerizes with p50, and activates 
transcription of target genes such as Atrogin, and thus both genes were shown to be 
required for muscle atrophy. A later study indicated that inhibition of the upstream 
IkappaB Kinase Alpha (IKKa) and Beta (IKKb) has a similar effect, along with inhibition 
of FOXO.[44] 
 A very recent publication provides far more detail into the transcriptional 
regulation of atrophy by performing chromatin immunoprecipitation (ChIP) assays to 
determine the subsets of transcribed genes targeted by NF-KB and Bcl3.[45] The results 
verify that p50, the protein encoded by NFKB1, does indeed bind to the promoter regions 
of many genes involved in skeletal muscle atrophy, including FBXO32/Atrogin, FBXO9, 
and FOXO3. Despite the fact that p50 does not increase in binding during muscle 
unloading, BCL-3 does increase in binding for several genes, including 
FBXO32/Atrogin. In the same study, quantitative real time PCR (qPCR) was used to 
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measure the expression of various atrophy related genes in both BCL3 and NFKB1 
knockout mice. During hindlimb unloading, induction of FBXO32/atrogin expression 
was reduced to half with either gene knocked out. 
 These results suggest that despite the controversy concerning changes in p50 
binding to the FBXO32/Atrogin promoter, binding of p50 to the promoter does stimulate 
atrophy due to heterodimerization with BCL3. Therefore it is reasonable to assume that 
increased NFKB1 gene expression and p50 protein content will promote muscle atrophy, 
possibly in part due to increased expression of FBXO32/Atrogin. The question remaining 
is why NFKB1 expression is increased in our insulin-resistant subjects as suggested by 
our correlation analysis. It has been shown[1] that expression of NF-KB proteins such at 
p65 and p50 (NFKB1) can be increased in L6 muscle cells with exposure to palmitate, 
and that this was associated with insulin resistance. From this we hypothesize that the 
accumulation of intracellular lipids may be a driving factor. 
 Another possibility is that NFKB1 expression is enhanced by extracellular 
inflammatory stimuli. The expression of NFKB1 can be induced[46] via exposure to 
tumor necrosis factor (TNF) and by NF-KB activation itself.[47] TNF-a has a 
longstanding reputation in obesity, diabetes, and insulin resistance. It is found elevated in 
the adipose tissue in obese human subjects.[48] Furthermore, administration of 
exogenous TNF-a can induce insulin resistance.[49] This plausible connection suggests 
that the inflammatory environment defined by elevated TNF-a levels could signal to the 
NF-KB pathway, and thereby upregulate muscle atrophy pathways. 
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 ADRM1: Further connections to the ubiquitin proteosome system are found with 
ADRM1, a protein which binds to and activates [50] Uch37, a deubiquitinating enzyme 
located at the mouth of mammalian proteosomes. It has been shown [51] that knockdown 
of ADRM1 decreases the degradation of short-lived proteins in the cell. This evidence 
suggests that the expression levels of ADRM1 may directly accelerate the overall activity 
of the ubiquitin proteosome system, and thus accelerate skeletal muscle proteolysis. 
UCP3: Remarkably, UCP3 shows as a strong negative correlate to glucose uptake 
rate, but only when normalized to fat free mass. (Table 2) UCP3 is an uncoupling protein 
found in the mitochondrial of skeletal muscle, and has long been a focus of research into 
metabolic syndrome. [52] Genetic variants of the UCP3 gene have been associated with 
insulin sensitivity, type 2 diabetes, and obesity, however the reports are highly 
controversial. [53] It has been shown that both the mRNA expression and protein content 
of UCP3 are reduced in diabetic muscle. [54] Recently, Senese et. al. [55] assessed the 
effects of UCP3 expression on insulin sensitivity by progressively reducing its expression 
in heterozygous and homozygous knockout mice, and concluded that greater UCP3 
expression levels correlated with increased insulin sensitivity. These results are opposite 
to the correlations we find in this study, which indicate that increased expression 
correlates with reduced insulin stimulated glucose uptake. Despite the controversy, UCP3 
has been a strong focus of research into skeletal muscle insulin sensitivity, and it is the 
most negative correlating gene for fat-free mass in this analysis. This suggests that it may 
have a central and complicated role in modulating insulin sensitivity in skeletal muscle 
that can only be resolved with further attention. It is possible that in our test subjects the 
UCP3 protein content is substantially reduced and that the gene expression is increased to 
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compensate for metabolic abnormalities such as increased ROS production. This 
relationship may behave in an opposing direction to less natural manipulations such as 
genetic knockout mice or overexpression. 
 DYSF: Dysferlin is a protein with strong genetic associations to muscular 
dystrophy, particularly Miyoshi myopathy and limb girdle muscular dystrophy.[56]The 
defining characteristic of these diseases is muscle weakness brought about by wasting. It 
is unclear how increased expression of this gene would contribute to this process, as it is 
typically the loss of function that is associated with disease. Dysferlin is responsible for 
repairing damaged cell membranes [57] in states of muscle inflammation, so it is possible 
that upregulation of the transcript is occurring in these conditions during insulin 
resistance. 
Exercise-mediated gene expression changes correlating with glucose uptake 
 Given that the resting biopsy was performed immediately prior to the 
hyperinsulinemic euglycemic clamp, those expression values are the most relevant in 
deducing transcriptional control of glucose uptake. We did not consider correlations with 
the post-exercise gene expressions since no post-exercise glucose clamp was performed. 
We did however consider the hypothesis that the insulin sensitivity of a subject may 
relate to the changes in gene expression with exercise. Thus we performed correlations 
against the exercise-induced expression fold changes. (Table 3) Unlike correlations with 
the resting gene expression values, we did not observe any spurious correlations with 
dark corner control spots. We speculate that this is due to the fact that differencing the 
log-transformed values will negate any spurious correlations due to random noise. To this 
end, we considered all highly-correlating probes regardless of dim signal intensity.
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Correlation ID Description 
0.86 KCNMB2 potassium large conductance calcium-activated channel 
0.86 ACP5 acid phosphatase 5 
0.85 LIN28B lin-28 homolog B (C. elegans) (LIN28B) 
0.84 HAO2 hydroxyacid oxidase 2 (long chain) (HAO2) 
0.83 AL157439 [AL157439] 
0.81 PRKAG2 cDNA FLJ90194 fis 
0.81 GPX4 glutathione peroxidase 4 (phospholipid hydroperoxidase) 
0.80 AF349445 maxi-K channel HSLO mRNA 
0.80 TJAP1 tight junction associated protein 1 (peripheral) (TJAP1) 
0.79 TRIM43 tripartite motif-containing 43 (TRIM43) 
0.79 AF116673 PRO1925 mRNA 
0.79 DGKZ diacylglycerol kinase 
0.79 KIAA1772 KIAA1772 (KIAA1772) 
0.79 SART3 squamous cell carcinoma antigen recognized by T cells 3 
0.78 CBFA2T2 core-binding factor 
0.78 PFKFB3 6-phosphofructo-2-kinase/fructose-2 
0.78 PFKFB3 6-phosphofructo-2-kinase/fructose-2 
 
 
Correlation ID Description 
-0.76 BG115911 BG115911 
-0.76 THUMPD1 THUMP domain containing 1 
-0.77 RAB1A RAB1A 
-0.77 P2RY1 purinergic receptor P2Y 
-0.77 AK026659 cDNA: FLJ23006 fis 
-0.77 MAP3K7IP3 MAPKK  7 interacting protein 3  
-0.77 BRCA1 breast cancer 1 
-0.78 AA235942 cDNA clone IMAGE:687981 5' 
-0.78 HAPLN1 hyaluronan and proteoglycan link protein 1 
-0.79 C13orf27 chromosome 13 open reading frame 27 
-0.79 THC2618142 Unknown 
-0.79 ESR1 estrogen receptor 1 (ESR1) 
-0.80 DDX52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 
-0.81 FLJ14959 cDNA FLJ14959 fis 
-0.82 UEVLD UEV and lactate/malate dehydrogenase domains 
-0.83 ESR1 estrogen receptor 1 
-0.87 A_24_P916453 Unknown 
 
Table 3 : Top positive and negative gene expression fold change correlates with glucose uptake 
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 BK Channels: Large conductance potassium channels, also known as Maxi-K, 
Big-K (BK), or slo1 channels, are calcium/voltage activated conductors of potassium 
ions. They function in smooth muscles to regulate vasodilation. Genetic polymorphisms 
of these channels are highly associated with hypertension in humans.[58-61] BK channels 
are composed of tetrameric alpha subunits which form the pore. Regulatory beta subunits 
encoded by four different genes can bind with the alpha tetramer to precisely regulate 
channel opening. Interestingly, amongst our top correlates we observe a probe encoding a 
beta subunit (KCNMB2) and a probe representing the alpha subunit (AF349445).  
 Interestingly, the probe detecting the alpha subunit does not sense the putative 
alpha subunit gene (KCNMA1), but instead it probes for a single 132bp exon which has 
been documented to differentially splice with the alpha subunits and modulate their 
activity.[62] It is well known that alpha subunits of BK channels are heavily spliced to 
precisely fine tune their calcium and voltage sensitivity in various tissues. This is 
evidence that exercise is possibly mediating this change, however the probe intensities 
for both of these genes are incredibly weak. This may be because the transcripts are likely 
only present in the blood vessels in the muscle biopsy samples. Confounding this issue 
further, there are two probes on the array detecting KCNMB2 expression. Alongside the 
high positive correlation probe we observe, the other probe has a strong negative 
correlation (-0.6) with glucose disposal rate. Both probes target the 3' UTR of the gene. 
 Given the low signal intensity and correlative ambiguity of this signal, we would 
not focus on this gene had we not uncovered evidence that it is relevant in diabetic 
vasculopathy. It has been demonstrated that the beta subunits of BK channels are 
downregulated substantially in diabetic blood vessels, and that this compromises BK 
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conductance, leading to reduced vasodilation.[63, 64] Remarkably, Zhang et al.[65] 
showed that the reduction of beta subunits was caused by targeted proteolysis mediated 
by FBXO32/atrogin and FBXO9. These E3 ligases are upregulated in the smooth muscle 
of diabetic blood vessels, and ultimately activated by FOXO3A under high glucose 
conditions. They recognized that FBXO32/Atrogin in particular recognized the beta 
subunits with a PDZ-binding motif (T/S-X-V) located in most BK-beta proteins. 
Mutation of the PDZ binding motif eliminated the proteolysis induced by 
FBXO32/Atrogin overexpression and rescued the BK channel conductance in cell culture 
models. 
 This surprising connection to diabetic vasculopathy and to the atrophy pathway 
hints that the regulation of vascular tone may underlie the insulin sensitivity gains in 
response to exercise. Unfortunately, the ambiguity of the two counter-correlating probes 
for KCNMB2 confounds this finding. 
 ACP5/TRAP: A strongly-correlating expression change is observed with the 
gene ACP5, known more commonly as tartrate resistant acid phosphatase (TRAP). 
Functionally TRAP is known to specifically dephosphorylate the protein osteopontin 
(OPN), which has roles in bone remodeling [66, 67] and in immune system function. 
 A recent study shed light on the potential metabolic relevance of TRAP by 
creating mice which overexpressed it in adipose tissue. The mice developed[68] severe 
hyperplastic obesity, but remarkably the mice remained completely insulin sensitive, in 
contrast to typical models of obesity. Elevated TRAP levels in the adipose tissue were 
shown to be secreted from resident macrophages. Since macrophage residence has long 
been thought [69] to directly mediate the connections between obesity and localized 
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insulin resistance, this hints that TRAP may partake in signaling pathways which regulate 
inflammatory response. Despite the increased fat mass of these animals, the investigators 
saw no evidence of global activation of inflammatory macrophages or the associated 
cytokines. Perplexingly, TNFa mRNA was elevated in adipose tissue, but the level of 
TNFa protein was not elevated in serum. Overall, these mice lacked the global 
inflammatory response typically observed in obesity. 
 Further evidence of this inflammatory connection comes from human genetics 
studies. Genetic deficiency of human TRAP causes [70] a disorder of chronic muscle 
inflammation known as inflammatory myositis, a condition which itself is characterized 
by marked insulin resistance of muscle and metabolic disorder.[71] In individuals with 
TRAP deficiency, phosphorylated osteopontin accumulates in the serum and is associated 
with autoimmunity.[72] This evidence suggests that the lack of TRAP results in chronic 
levels of inflammation, as opposed to an overexpression of TRAP in mice which 
abrogated inflammation. 
 The putative TRAP dephosphorylation substrate, osteopontin, has much stronger 
connections with metabolic disorder. Aside from its role in bone remodeling, osteopontin 
acutely attracts macrophages by binding to surface integrin receptors. Osteopontin is 
expressed and secreted by regenerating muscle and is thought to facilitate the invasion of 
inflammatory macrophages during repair.[73] It is also thought to mediate the 
inflammatory component of muscular dystrophy.[74] Given that macrophage infiltration 
into tissues is commonly associated with metabolic disorder, this protein may be a viable 
therapeutic target. 
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 Osteopontin knockout mice are completely protected from diet induced insulin 
resistance.[75] Furthermore, injecting obese mice with antibodies which bind and 
neutralize osteopontin inhibits inflammation and its associated insulin resistance.[76] 
This effect was associated with attenuated infiltration of macrophages into the liver and 
adipose tissues in these animals. This evidence suggests that osteopontin is a dominant 
factor regulating the residence of inflammatory macrophages, and that it is these 
macrophages which impart the systemic insulin resistance associated with diet induced 
obesity. 
 The interactions between osteopontin and macrophages are mediated via binding 
to both b3-integrin receptors and CD44 receptors. Chemotaxis is enabled via the CD44 
receptor, and macrophage activation is mediated through the b3-integrin receptor. 
Binding to the b3-integrin however requires phosphorylation of osteopontin.[77] Given 
that TRAP dephosphorylates osteopontin to mediate detachment from the avb3 integrin 
receptors of osteoclasts during bone resorption, it is possible that TRAP mediates a 
similar detachment in the context of macrophage infiltration. 
 This combined evidence leads us to hypothesize that TRAP expression at the site 
of regenerating muscle may deactivate the migration of macrophages into the muscle 
tissue. If this process reduces the level of resident inflammatory macrophages or reduces 
their level of activation, then the lower burden of inflammatory cytokines may lead to an 
improvement in insulin sensitivity. This model may explain the complete lack of 
inflammation in the TRAP overexpressing mouse study. In adipocytes, TRAP may 
downregulate the local inflammatory response, ultimately lowering cytokines which 
induce localized insulin resistance in the fat pads. In our system, we are unaware of 
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whether the TRAP is expressed by the muscle or resident leukocytes, or if the expression 
is localized to the muscle. These questions warrant further attention. 
 PRKAG2: AMP-activated protein kinase (AMP) is a critical energy-sensing 
protein in the cell which detects intracellular ratios of adenosine monophosphate and 
adenosine triphosphate. AMPK has long been thought to be a critical regulator of insulin 
sensitivity in the cell. The diabetic drug metformin is thought to target its activation.[78] 
Furthermore, there has been much focus studying the modulation of AMPK activity 
induced by exercise interventions.[79-83] 
 AMPK is composed of catalytic α, and regulatory β and γ subunits. The γ subunits 
contain multiple domains which bind AMP. Two isoforms for each of the α and β 
subunits, and three isoforms of the γ subunit are present in the human genome. The gene 
found correlated with glucose uptake in our dataset, PRKAG2, specifically encodes the γ-
2 subunit. 
 A comprehensive study[84] has characterized the molecular functions of each of 
these γ subunits in humans. The three γ subunits of AMPK have markedly different tissue 
expression profiles, with the γ-1 subunit as the dominant isoform in nearly all tissues, 
except for the brain which has near equal partitioning of all three. In muscle the γ-1 
subunit shows ~90% expression, with ~10% of γ-2 and negligible γ-3. The authors also 
characterized the enzymatic fold activation of AMPK with these various subunits. By 
measuring kinase activity without exposure to AMP, and with exposure to 200uM AMP, 
they denoted that the fold activation of various γ 
 subunits was markedly different. Regardless of the catalytic subunit used, the AMP-
binding γ-2 subunit showed nearly twofold activity levels over the γ-1 or γ-3 subunits. 
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These results demonstrate that even though the γ-2 subunit has low expression in skeletal 
muscle, it is more sensitive to AMP levels and can activate the catalytic subunit more 
strongly. Thus small changes in the fractional expression of this particular subunit of 
AMPK during exercise may result in a marked increase in AMPK signaling, and thus 
mediate marked improvements in insulin sensitivity. 
 Lin28B: Micrornas (miRs) have a profound influence regulating the cellular 
transcriptome by hybridizing to select mRNA transcripts and promoting their 
degradation. In particular, the let-7 family of miRs have long been understood to inhibit 
cellular growth and proliferation, particularly in cancer models. Lin28 proteins suppress 
let-7 miRs by binding their precursors and targeting them for degradation. This process 
downregulates the pool of let-7 miRs, and thereby serves as a counterbalance against 
their inhibition of cellular growth. Most focus on the Lin28/let-7 axis has been in cancer 
research. 
 A recent paper connected the entire Lin28/let-7 axis to insulin metabolism and 
diabetes.[85] Transgenic mice were created overexpressing either Lin28a or LIN28B, and 
showed enhanced glucose tolerance and resistance to high-fat induced obesity. 
Opposingly, knocking out Lin28a in muscle or inducing the expression of let-7 produced 
mice with glucose intolerance. This data demonstrated that the Lin28/let-7 axis is a 
central regulator of glucose metabolism. 
 To determine the molecular mechanisms behind this adaptation, in vitro work was 
conducted in C2C12 myoblasts as a model of muscle. By overexpressing Lin28a they 
noted an increase in the mRNA levels of several genes in the insulin signaling pathway, 
including the insulin receptor, insulin receptor subtrate-1 (IRS-1), multiple PI3-Kinase 
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isoforms, and constituents of mTOR complexes such as Raptor and Rictor. They then 
used the TargetScan algorithm to find cononical let-7 miR binding sites in the 3' 
untranslated regions (UTRs) of several of these genes. Using a luciferase reporting 
system, they verified that overexpression of let-7f suppressed the insulin receptor, IRS2, 
AKT2, Rictor, and several other proteins relevant to insulin signal transduction. This 
overall evidence suggests that expression of Lin28 proteins may be a core regulatory 
node by which a cell can fine-tune insulin sensitivity. Our correlations analysis 
demonstrates that Lin28B may have high control strength on insulin sensitivity. 
Interestingly, the expression change of this transcript was zero amongst the group of 
subjects. Roughly half of the participants downregulated Lin28B, and the other half 
upregulated it, with  a maximal expression change of just %15. 
 PFKFB3: 6-phosphofructo-2-kinase / fructose-2,6-bisphosphatase 3 is an enzyme 
that catalyzes the formation or degradation of fructose 2,6-bisphosphate. This molecule is 
a potent allosteric activator of 6-phosphofructo-1 kinase, which is the rate limiting 
enzyme in glycolysis. PFKFB3 is an inducible form of this enzyme, and its 
overexpression has been shown to markedly increase glucose uptake in adipocytes.[86] In 
a recent study, Guo et. al. [87]demonstrated that PFKFB3 is a transcriptional target of 
peroxisome proliferator-activated receptor gamma (PPARG) and is the enzyme 
responsible for improved insulin sensitivity obtained by treatment with 
thiazolidinediones, commonly used to treat diabetics. Disruption of PFKFB3 in knockout 
mice eliminated the effectiveness of these drugs in improving insulin sensitivity. 
Intriguingly, they also demonstrated that adipose tissue cytokine expression and 
inflammation was markedly increased in these animals. This combined evidence suggests 
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that this enzyme may similarly regulate glucose uptake and inflammation in skeletal 
muscle. Upregulation of this enzyme after exercise may be a critical regulatory node for 
increasing glucose uptake. 
 DGKZ: Diacylglycerol (DAG) is a cell membrane lipid that serves as an 
important second messenger in a variety of signaling pathways. It is formed by the 
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme phospholipase 
C. After cleavage, the resulting DAG remains in the membrane and allosterically 
activates protein kinase C. It is widely accepted that DAG concentrations in the cell cause 
insulin resistance [88] by activating protein kinase C, which then inhibits insulin 
signaling via phosphorylation of insulin receptor substrate 1 (IRS-1). 
Diacylglycerol kinases are enzymes which convert diacylglycerol (DAG) to 
phosphatidic acid. DGKZ is the zeta isoform of this class of enzymes. By reducing the 
concentration of DAGs, these enzymes attenuate protein kinase C signaling, and thus 
should improve insulin signaling. It has already been shown that downregulation of 
diacylglycerol kinases delta in skeletal muscle leads to insulin resistance. [89]Given that 
these enzymes catalyze the same reaction, it is likely that the increase in DGKZ 
expression after exercise would mediate similar effects.
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Correlations with BMI: 
 In addition to correlations with glucose uptake measured in the hyperinsulinemic 
euglycemic clamp, we also performed correlations between the subjects’ body mass 
index (BMI) against steady-state gene expression values and exercise-induced fold 
changes. (Table 4) Amongst the fold change correlations, the top correlating gene 
(LRP1B) has a genetic connection with BMI as determined by a recent large scale 
GWAS screen. 
 The Genetic Investigation of ANthropomorphic Traits (GIANT) consortium 
performed an association analysis against a sizeable population of 249,796 subjects. 18 
new BMI susceptibility loci were uncovered [90] in this study. Among them was a BMI-
associated polymorphic allele was found upstream the LRP1B gene with a minor allele 
frequency (MAF) of 18% in the population. Most of the previously-discovered BMI 
associated loci are associated with genes expressed predominantly in the central nervous 
system, particularly in the hypothalamus where energy expenditure and feeding behavior 
is regulated.[90] We have demonstrated however that the change in LRP1B expression 
due to exercise intervention is the most correlated fold change with the measured BMI. 
This evidence suggests that LRP1B may act in skeletal muscle or other peripheral tissues 
and affect systemic obesity. This connection clearly warrants further investigation. 
 The expression of this gene decreased with exercise intervention, and the decrease 
was greater in subjects with a lower BMI. (Figure 6) The immediate question that arises 
is whether or not the relationship is causal. Certainly pathogenic variants in LRP1B, if 
present in our subjects, would be causal as the BMI could have no effect on the genotype. 
These gene expression changes however could be influenced by BMI due to some 
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internal feedback mechanism. If the expression changes are causative of BMI however, 
then these results could suggest that test subjects respond to exercise in profoundly 
different ways. Exercise, as an intervention, may be less effective in subjects that do not 
appropriately downregulate the LRP1B gene. Future work must determine if these gene 
expression changes are associated with genotype at this pathogenic allele, and how these 
expression values are regulated due to the environmental circumstances of the cell. The 
polymorphism upstream the gene could affect resting expression levels or response to key 
transcription factors that are activated during exercise. 
 A recent study [91] describes what little is known on the function of LRP1B. It is 
primarily found expressed in the brain, thyroid gland, and skeletal muscle, and at low 
levels in other tissues. Interacting ligands have been identified with immunoprecipitation 
and mass spectrometric identification. LRP1B binds to many signaling ligands including 
fibrinogen, clusterin, and vitronectin. The study also demonstrated binding and uptake of 
ApoE containing very low densitiy lipoproteins (VLDLs). 
 We can infer additional function based on homology with other receptors in the 
LRP family. LRP1B is so named because it shares ~60% sequence homology [91] with 
LRP1, which is far more characterized in the literature. Interestingly, a proteomics 
analysis[92] of GLUT4 storage vesicles (GSVs) has shown that LRP1 is present 
abundantly and similarly trafficked to the cell membrane by insulin. The authors showed 
that LRP1 directly interacts with the luminal domains of the GLUT4 protein and the 
cytoplasmic tail of AS160, an important signaling node in the GLUT4 activation 
pathway. They showed that knockdown of LRP1 also reduced the expression levels of 
GLUT4, indicating that it is integral to the regulation of glucose uptake. If LRP1B has 
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similar or possibly competing functions of its close homologue LRP1, then it may affect 
dynamics of these GSVs.
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 Interestingly, LRP1 also modulates wnt signaling. Two related proteins from the 
same family, LRP5 and LRP6 bind to frizzled receptors to form functional receptor 
complexes at the cell membrane. These co-receptor proteins are required for frizzled 
receptor activation. LRP1 has been shown [93] to form similar dimers with frizzled-1 
receptors in the membrane, however instead of activating the complex it sequesters the 
receptor and prevents activation by endogenous wnt3a ligands. Paradoxically, another 
study [94] explored the role of LRP1 knockout in mouse fibroblasts, and concluded that 
LRP1 is required for canonical wnt5a signaling. Without the wnt signaling pathway 
active, fibroblasts that are stimulated for adipocyte differentiation accumulate cholesterol 
and hypertrophy. These studies, although conflicting, point to a complicated role for 
LPR1 in regulating lipid transport and wnt pathway signaling. 
If LPR1B behaves in a similar or opposing manner, then its exercise-mediated 
differential expression will likely have large impact on cellular metabolism by regulating 
wnt signaling, which as we have discussed appears to have a large influence on the lipid 
storage/utilization phenotype of muscle and fat cells.[23] The connection to cholesterol 
transport is also relevant as it possibly explains the wnt-surpressive effects of SREBP-1, a 
transcription factor which is activated when cellular cholesterol levels are low. Indeed, an 
inverse relationship is observed between the expression levels of LRP1 and various 




Correlation ID Description 
0.89 LRP1B low density lipoprotein-related protein 1B (deleted in tumors) 
0.88 AK024372 cDNA FLJ14310 fis 
0.87 TPM3 tropomyosin 3 (TPM3) 
0.86 TMEM126A transmembrane protein 126A (TMEM126A) 
0.85 LGI1 leucine-rich 
0.84 C12orf60 chromosome 12 open reading frame 60 (C12orf60) 
0.84 ZNF415 zinc finger protein 415 (ZNF415) 
0.83 IKBKAP inhibitor of kappa light polypeptide gene enhancer in B-cells 
0.82 CRNKL1 crooked neck pre-mRNA splicing factor-like 1 (Drosophila)  
0.82 GPAM glycerol-3-phosphate acyltransferase 
0.81 A_24_P341489 Unknown 
0.81 THC2574008 Q475C5_RALEJ (Q475C5) Phosphate butyryltransferase   
0.81 MYL2 myosin 
0.81 HINT1 histidine triad nucleotide binding protein 1 (HINT1) 
0.81 ALDH3A2 aldehyde dehydrogenase 3 family 
0.81 SPIN1 spindlin 1 (SPIN1) 
0.80 A_24_P49800 Unknown 
 
Correlation ID Description 
-0.80 POLD1 polymerase (DNA directed) 
-0.80 BQ072652 AGENCOURT_6763016 NIH_MGC_118 cDNA clone 
-0.80 TMEM48 transmembrane protein 48 (TMEM48) 
-0.80 AA464246 Soares ovary tumor NbHOT cDNA clone 
-0.81 BC017937 Homo sapiens 
-0.82 THBS1 thrombospondin 1 (THBS1) 
-0.82 GUSB Glucuronidase 
-0.83 GUSB Glucuronidase 
-0.83 HOXA11S homeo box A11 
-0.83 HEXIM2 hexamthylene bis-acetamide inducible 2 (HEXIM2) 
-0.84 GUSB Glucuronidase 
-0.85 A_32_P80295 Unknown 
-0.86 CR610211 full-length cDNA clone of Neuroblastoma 
-0.86 BC089451 cDNA clone IMAGE:30554612. [BC089451] 
-0.88 C12orf54 chromosome 12 open reading frame 54 (C12orf54) 
 




 We have performed a simple correlation analysis to determine which genes may 
activate or deactivate insulin-stimulated glucose uptake in the cell. Positive correlating 
genes appear to have connections to wnt signaling, of which the terminal effectors are 
transcription factor complexes of the protein β-catenin and proteins of the TCF or LEF 
families. The TCF family protein TCF7L2 is the single most associated gene with type 2 
diabetes in GWAS studies. This gene has been shown to directly regulate transcription of 
the insulin receptor. Furthermore, signaling through this pathway increases insulin-
stimulated glucose uptake and decreases the accumulation of intracellular lipids in 
muscle cells. Overall, these results suggest that wnt signaling is a primary determinant of 
the cells insulin sensitivity. Our top correlating gene, GOPC, has been established to 
directly traffic GLUT4 storage vesicles to the cell membrane, as well as Frizzled 
receptors which are the putative inputs to the wnt signaling pathway. Our second top 
correlate ZBED3 has been demonstrated to increase wnt signaling in the cell by binding 
and sequestering Axin. Overall, these results give new gene targets which regulate insulin 
sensitivity at the level of transcriptional regulation. 
 The most negatively correlating genes are associated with low insulin-stimulated 
glucose uptake, and are thus possibly the genes which bring about the state of insulin 
resistance. These genes have clear connections to the ubiquitin proteosome system, and 
thus the skeletal muscle atrophy pathway. Muscle atrophy and wasting is induced 
predominantly in states of fasting and starvation. With the reduction of dietary 
carbohydrates, the body must preserve blood glucose concentrations for proper 
functioning of the central nervous system. Hepatic gluconeogenesis can produce glucose 
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from free amino acids, and muscle provides the primary reserve of amino acids in the 
body. Thus, during starvation, putative atrophy activating genes such as Atrogin are 
dramatically upregulated to target muscle proteins for degradation by the proteosome. To 
further preserve blood glucose concentrations during starvation, peripheral tissues 
become insulin resistant, thereby decreasing their uptake and utilization of glucose. [96, 
97] This connection between muscle atrophy and insulin resistance makes physiological 
sense. During starvation, muscles must cease the import of glucose and excrete free 
amino acids to support gluconeogenesis. 
 Muscle glucose uptake can be stimulated by both insulin signaling and exercise 
induced contraction. [98] This reflects the fact that glucose is needed for both anabolism 
at rest and as an energy source during exercise. These signaling pathways are disjoint 
with different sensory inputs, but nonetheless result in the common output of GLUT4 
translocation and membrane insertion. We thus postulate that if glucose uptake must be 
blunted, that there are evolutionary advantages of inhibiting the signal at either the 
sensory inputs or at the terminal GLUT4 control points. If glucose uptake must be 
inhibited only for anabolic purposes, then it follows that inhibition of the insulin 
signaling pathway at the location of the insulin receptor or IRS1 is the most sensible 
point of control. If however, due to starvation, perceived starvation, or internal cellular 
stress, glucose uptake must be inhibited for any reasons, then it follows that inhibition at 
the level of GLUT4 translocation is the most advantageous. 
 Given this physiological connection, we hypothesize that proteolysis of a key 
unidentified protein may be the central off switch for insulin sensitivity. Intriguingly, our 
top positive correlating gene for insulin sensitivity selectively targets proteins for 
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membrane trafficking with a Ser/Thr-X-Val PDZ motif. GOPC transports the frizzled 
receptor [31] to the membrane, which activates the wnt signaling pathway. GOPC 
additionally inhibits the surface expression of the beta-adrenergic receptor by binding to a 
characteristic EKSV motif.[99] Curiously, in smooth muscle cells, Atrogin targets BK 
channels for degradation [65] by binding to the same PDZ binding motif (Ser/Thr-X-V). 
We thus hypothesize that Atrogin and GOPC share a common binding partner protein, 
and that this unknown protein may directly modulate insulin sensitivity. This protein 
could be a frizzled receptor, which are the activators of wnt signaling. Aside from 
Atrogin, FBXO9 was another strong negative correlate we scrutinized, and is also an 
Fbox ubiquitin ligase like Atrogin. It was demonstrated to be required for adipogenesis in 
adipocytes, and its expression was associated with the reduction of β-catenin. [41] It is 
unknown what molecular targets of FBXO9 induce the adipogenic program, but this 
program appears counter to the anti-adipogenic effects of wnt signaling. These 
connections could form a direct bridge between the insulin sensitivity on switch and the 
insulin resistance off switch in the cell. 
 If the skeletal muscle wasting pathway is indeed the cause of insulin resistance, 
we must now understand why it is activated in diabetic muscle. Much work has shown 
that muscle wasting is directly tied to fasting and starvation, and this connection between 
proteolysis and insulin resistance makes physiological sense. Other conditions however 
can induce muscle wasting, including disuse, sepsis, and inflammation. [35] NFKB 
signaling has been shown to be a direct upstream activator of muscle wasting [43, 45] due 
to either inflammation or disuse. Chronic inflammation is however already associated 
with insulin resistance in adipose tissue and muscle, and this chronic inflammation is 
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directly associated with resident activated pro-inflammatory macrophages [69] which 
secrete inflammatory cytokines and stimulate NFKB signaling. These macrophages are 
attracted and polarized by phosphorylated osteopontin [77] which can be 
dephosphorylated [66] via TRAP. Our correlations with exercise-induced expression fold 
changes demonstrate that insulin sensitive subjects overexpress TRAP to a larger degree 
with exercise intervention. This single protein may thus be a dominant upstream regulator 
of skeletal muscle insulin sensitivity. By dephosphorylating osteopontin, macrophage 
recruitment and activation is blunted, which reduces proinflammatory cytokine secretion, 
NFKB activation, and thus induction of skeletal muscle wasting. Under this model, it is 
systemic inflammation that may ultimately cause insulin resistance in non-fasting 
pathological states; however it is mediated through pathways that evolved to handle 
fasting conditions. 
 The polarization of proinflammatory macrophages in skeletal muscle may thus be 
the key upstream aspect of the disease manifestation. Understanding why these 
macrophages are activated is of paramount importance. In a recent work [100] it was 
demonstrated macrophages are resident in human skeletal muscle and correlate with 
insulin resistance. Furthermore, the study performed co-culture experiments with 
myotubes and macrophages, and showed that the presence of macrophages caused 
dramatic upregulation of proinflammatory cytokines such as TNFa and IL-1, as well as 
the gene Atrogin. This evidence provides a clear connection between macrophages and 
muscle wasting, likely due to TNFa-mediated NFKB signaling and induction of Atrogin. 
This evidence provides a plausible bridge between the immune system and the 
intracellular pathways we previously scrutinized. 
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Conclusion: 
 We have presented a technique whereby gene expression values are directly 
compared to externally-measured metabolic phenotypes. Despite the seemingly naïve 
simplicity of this technique, our analysis has elucidated several interesting findings that 
may be worth pursuing as novel therapeutic targets.  
Future work using this technique could involve the simultaneous expression 
profiling of several distinct tissues, such as the brain, adipose tissue, and liver. This 
would permit a more cohesive understanding of how organs are communicating and 
coordinating global physiological responses such as starvation or inflammation. 
Additionally, a wide expansion of the characterized metabolic phenotypes may reveal 
more interesting patterns. Such phenotypes can include characterizations of fat 
metabolism and fuel selection, as well as the signaling of other metabolic hormones of 
interest. With these strategies, the adoption of new technologies such as RNAseq may 
enable more direct and reliable quantification of gene expressions values. 
 Two highly-correlating genes have been found that are associated with pathology 
at the level of genomic variance. A gene correlating with peripheral glucose disposal has 
pathogenic alleles associated with type 2 diabetes. Another gene, whose exercise-induced 
gene expression fold change correlates with BMI, has polymorphisms associated with 
BMI. These findings indicate that gene expression differences in skeletal muscle can 
correlate with disease status, and suggest that these expression differences may depend 
on the genotype of promoter-resident polymorphisms for these genes. Further validation 
of this hypothesis is needed. Genome wide association studies (GWAS) can survey 
hundreds of thousands of people for the underlying genetic contributors to phenotype, 
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however these studies fail to provide an organ-specific context for where molecular 
defect may manifest. This technique however suggests that these two susceptibility loci 
may exert influence in peripheral tissues such as skeletal muscle. Furthermore, these 
observations may point to differences in exercise tolerance and benefits to health, and can 
therefore guide lifestyle interventions for people with differing genotypes. 
 Alongside these two surprising hits, an additional glucose-uptake associated gene 
(GOPC) has been found which has a clearly documented connection with glucose 
transporter trafficking to the cell surface. This prior in vitro work investigating the 
molecular function of this gene gives enthusiastic validation that our correlation-based 
technique is a sensible approach to finding new targets to investigate. Overall, the targets 
found with this technique provide enthusiastic evidence that such gene expression 
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Proteomics techniques reveal that lysine-acetylation is abundant in mitochondria. This 
study was undertaken 1) to determine how mitochondrial protein acetylation is regulated 
in human skeletal muscle, and 2) to use molecular modeling techniques to understand the 
consequences of acetylation of ANT1, the key protein required for ADP/ATP exchange 
across the inner mitochondrial membrane. Healthy subjects had euglycemic clamps and 
an exercise bout with muscle biopsies. A number of acetylated mitochondrial proteins 
were identified. Acetylation decreased after exercise (P < 0.01), and the acetylation at rest 
correlated with insulin sensitivity (r = 0.603, P < 0.01). One acetylation site in ANT1 that 
was deacetylated after exercise, K23, is in the ADP binding pocket. Its extent of 
deacetylation correlated with insulin sensitivity (r = 0.90, P < 0.05). Molecular dynamics 
methods were used to characterize changes in ANT1 structure/dynamics induced by 
acetylation. Ensemble docking predicted the ADP binding site at a pocket of critical 
positively-charged residues. We calculated binding affinities that appear physiologically 
relevant, and predicted substantial reductions in affinity upon acetylation. Given these 
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estimates, acetylation of ANT1 could have dramatic physiological effects on ADP/ATP 
exchange; the greater deacetylation of K23 in insulin sensitive individuals could enhance 
mitochondrial ADP/ATP exchange. 
INTRODUCTION 
Post-translational modifications of proteins provide a multidimensional 
mechanism for regulation of protein structure and function.  For example, protein 
phosphorylation is an important means of regulating proteins, but other post-translational 
modifications also affect protein function. Protein lysine acetylation is a widespread, but 
poorly understood phenomenon.  Once thought only to be important in regulation of 
chromatin structure, recent evidence shows lysine acetylation regulates function in other 
proteins.  Lysine acetylation is an ancient, evolutionarily conserved regulatory 
mechanism, widespread across phyla, and more conserved across prokaryotes and 
eukaryotes than is the rest of the proteome [101]. In prokaryotes, acetylation coordinates 
metabolic flux [8, 102], so it is no surprise that mitochondrial proteins are over-
represented in the acetylome of human cells [9, 101]. A published acetylome of human 
liver shows many metabolic enzymes to be acetylated [9].  
Other more targeted studies show that reversible acetylation regulates 
mitochondrial function in mammals. Acetylation of enoyl-CoA hydratase, malate 
dehydrogenase, and long chain acyl CoA dehydrogenase regulates their activities [103].  
Fasting alters acetylation of mitochondrial proteins, suggesting reversible acetylation may 
regulate function [104]. Sirtuins are evolutionarily conserved protein deacetylases, with a 
requirement for NAD+ linking them to metabolism [105].  Sirt3, 4, and 5 are present in 
mitochondria (42-44), but Sirt3 regulates mitochondrial fatty acid oxidation and appears 
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to be the primary mitochondrial sirtuin [103]. Fasting induces Sirt3 expression in mouse 
liver, and deletion of Sirt3 gene results in higher concentrations of acylcarnitines and 
triglycerides, due to defective fatty acid oxidation [103].  Sirt3 null mice also have 
reduced ATP production in liver and are cold-intolerant [106], and exhibit increased 
acetylation of mitochondrial proteins critical for energy homeostasis.  
Little is known regarding regulation of the human mitochondrial acetylome or the 
effects of acetylation on function of specific human mitochondrial proteins.  The unclear 
relationship between mitochondrial dysfunction and insulin resistance in humans 
provides a compelling rationale for understanding regulation of lysine acetylation in 
human tissues, particularly in mitochondria. In this study we combine clinical research, 
mass spectrometry, and molecular modeling approaches to show that the mitochondrial 
acetylome is related to insulin action in human muscle. We identify adenine nucleotide 
translocase (ANT)1 as a mitochondrial protein that is extensively acetylated.  As the 
primary mitochondrial carrier for transport of ADP/ATP across the inner mitochondrial 
membrane, ANT1 is vital for oxidative metabolism. We show that, in humans, 
acetylation of mitochondrial proteins is related to insulin sensitivity, and that 
deacetylation of ANT1 is regulated by muscle contraction in a manner dependent on 
insulin sensitivity.  Finally, we provide the results of molecular modeling simulations that 
indicate that acetylation of a key regulated lysine residue on human ANT1 may affect its 
ability to translocate adenine nucleotides across the inner mitochondrial membrane. 
EXPERIMENTAL PROCEDURES 
Subjects. A total of 21 normoglycemic volunteers took part in this study, which 
was approved by the Institutional Review Board of Arizona State University. All studies 
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were conducted at the Clinical Research Unit at ASU. Informed, written consent was 
obtained from all subjects. None of the volunteers engaged in regular exercise, nor did 
they report a change in body weight for at least 6 months before participating in this 
study. Subjects were instructed to not exercise for 48 hours before study and to maintain 
their usual diet.  A medical history, physical examination, 12-lead electrocardiogram, and 
a complete chemistry panel were obtained, and a 75-g oral glucose tolerance test was 
performed using American Diabetes Association criteria to exclude nondiabetic subjects 
with impaired glucose tolerance. No one was taking any medication known to affect 
glucose metabolism.  Other in vivo and mitochondrial function data and data for the 
subjects who had only a euglycemic clamp and not an exercise study has been reported 
elsewhere [107]. 
Muscle biopsy and hyperinsulinemic, euglycemic clamp.  Euglycemic clamps 
and muscle biopsies were performed in all participants, as described [7].  After a 10-h 
overnight fast, a percutaneous biopsy of the vastus lateralis muscle was obtained with a 
Bergstrom cannula under local anesthesia one hour before the start of insulin infusion. A 
stable isotope ([6,6-
2
H] glucose) was used to trace glucose metabolism, and an insulin 




 was used. 
Exercise bout with muscle biopsies. Five of the 21 subjects, besides having a 
euglycemic clamp, also underwent an exercise test consisting of a single bout of aerobic 
exercise. The exercise bout was conducted on a separate day after determination of 
VO2peak and at least 1 week either before or after the euglycemic hyperinsulinemic 
clamp. Design of the exercise bout is identical to that previously described [2].  Subjects 
reported to the Clinical Research Unit at about 7 AM after fasting overnight. Subjects 
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exercised on a stationary bicycle, alternating between 70% (8 minutes) and 90% (2 
minutes) of heart rate corresponding to that at VO2max, for a total of 4 sets of exercise, 
with two minutes rest between sets [2]. After completing exercise, the subject was 
discharged.  They returned the following morning, again after an overnight fast, for a 
final biopsy of the vastus lateralis muscle, 24 hours after the end of exercise. 
Peak aerobic capacity. Peak aerobic capacity (VO2peak) was determined on a 
separate day in these five subjects as previously described, with continuous heart rate 
monitoring [108]. Exercise was started at a workload of 40 W and increased by 10 W/min 
until perceived exhaustion or a respiratory quotient of 1.10 was reached. 
Mass spectrometry. Whole muscle lysates were processed as previously 
described [4]. Mitochondria were isolated from freshly obtained muscle biopsies as 
described [109]. Muscle lysate or mitochondrial proteins were resolved by one-
dimensional SDS-PAGE.  The band corresponding to the molecular weight of ANT1 was 
excised, and samples were prepared and analyzed using a Thermo HPLC-nanospray 
LTQ-FTICR hybrid mass spectrometer, as described [4].  A data-dependent tandem mass 
spectrometry approach was utilized to identify peptides in which a full scan spectrum was 
acquired followed by collision-induced dissociation (CID) mass spectra of the 10 most 
abundant ions in the survey scan that was acquired using the FTICR mass analyzer in 
order to obtain high resolution, high mass accuracy data. 
Data analysis and bioinformatics. Extracted tandem mass spectra were assigned 
charge states and searched against the IPI_HUMAN_v3.59 database 
(http://www.ebi.ac.uk/IPI/) as described [4]. Search parameters used were as described 
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[4], with the addition of acetylation as a modification and allowing for three 
miscleavages. The normalized spectral abundance factor (NSAF) method was used for 
label-free quantification [4, 109]. 
Creation of a Homo sapiens Homology Model. The crystal structure of bovine 
ANT1 is known (Protein Data Bank (PDB) entry: 1OKC) [110]. Protein sequence 
alignment showed that the bovine transporter is nearly identical to the human transporter 
with a sequence similarity of ~96%. We performed homology modeling using Modeller 
[111] to obtain a predicted human model. The protein was missing two residues at the N-
terminus and four residues from the C-terminus. To add them, we used the molfacture 
plugin from VMD [112] to construct peptides of the first three (MGD) and last eight 
(YDEIKKYV) amino acids of the human sequence. Using the multiseq plugin [113] of 
VMD, we then performed structural alignments with the STAMP algorithm [114] to fit 
the glycine residue of the N-terminal extension and the first four residues (YDEI) of the 
C-terminal extension to the protein model.  To visualize the final human homology 
model, we again used the VMD multiseq plugin to perform a whole-protein structural 
alignment with the original bovine crystal structure. Having aligned the structures, we 
then merged the original crystallographic water molecules from the bovine structure to 
ensure the protein would maintain proper hydration within tight pockets of the protein. 
The carboxyatractyloside (CATR) inhibitor, cardiolipins, and detergents in the original 
pdb were not included. 
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Preparation of Acetylysine Patch. To properly model the effects of acetylated 
lysine residues in MD simulations and docking experiments, we prepared an acetyllysine 
(KAC) patch. Following the same strategy described in Eichenbaum et. al. [115], we used 
the acetyl group from the existing CHARMM ACE patch. Linking the acetyl group to the 
lysine residue was accomplished by deleting the lysine amine-group hydrogens and 
forming an amide bond between the lysine NZ atom and the CY atom of the acetyl group. 
The atom type of NZ was changed to NH1, and the bond length was set to 1.345 Å, 
reflecting the equilibrium bond length defined in the CHARMM22 parameter file. Atom 
partial charges were assigned as performed in Eichenbaum et. al. [115]. 
Molecular Dynamics Simulations. All-atom simulations were performed with 
the NAMD [116] simulation package (Version 2.8). The VMD psfgen plugin was used to 
create an Xplor protein structure file (psf) of the human ANT1 structure using the 
CHARMM22 [117] topology for proteins and lipids with CMAP correction. Bulk water 
molecules were then added with the Solvate program using a minimum water shell 
thickness of 6 Å and 8 gaussians to define the solvent boundary. 
To insert the protein into a lipid bilayer, water molecules that were within a 30 Å 
slice centered on the transmembrane axis of the protein were trimmed away. A 90x90 Å 
palmitoyl-oleyl-phosphatidyl-choline (POPC) bilayer was constructed with the VMD 
membrane builder plugin. The protein was then centered into the membrane by 
translating its center of mass, and lipid molecules within 3 Å of the protein were 
removed. Finally, the prepared membrane+protein system was fully solvated in a 
90x90x90 Å water box with 18 chloride counterions to neutralize the net protein charge. 
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The solvated ANT1+Membrane system was equilibrated via a 4-stage process 1) 
The membrane was "melted" by performing a 0.5 ns simulation in which only the lipid 
tails were permitted to move. 2) With the protein constrained with a harmonic energy 
function, the entire system was subjected 1000 steps of minimization followed by 0.5 ns 
of equilibration at 310K. 3) An additional 0.5 ns of equilibration was performed without 
protein constraints to further equilibrate the entire system. 4) Finally, an additional 25 ns 
of equilibration was performed while holding the area of the lipid patch constant. 
Equilibration of the system over this lengthy trajectory was validated by plotting the 
RMSD of the system and observing a convergence. 
We refer to the endpoint of this wild-type equilibration as the "equilibrated 
reference system", as it served as a common input structure to all of our computational 
experiments. Using the acetyllysine patch on this system, (see below) we prepared a 
series of three acetylated systems at lysines 10, 23, and 92. In each of these acetylated 
systems, the furthest chloride ion from the channel was deleted to re-neutralize the net 
charge. The wild-type (WT) and three modified systems (K10, K23, K92) were then 
subjected to re-minimization, 10 ns of independent equilibration, and finally 30 ns of full 
MD simulation in the isothermal-isobaric (NPT) ensemble. These four systems lacked the 
presence of ADP, and are thus hereafter referred to as the "Apo-ANT1" simulations. 
Electrostatics Analysis. VMD PMEPOT [118] plugin was used to compute the 
electrostatic potentials of the assembled ANT1 systems and simulation results. To 
compare the functional effects of lysine acetylation, potentials were computed on the 
static protein after the application of an acetyllysine (KAC) patch to the K10, K23, and 
K92 residues. Isosurfaces of the potential were visualized in VMD. To produce 2D slices 
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and line-profile plots of the potential, we used the Python GridDataFormats library to 
import the OpenDX files exported from PMEPOT. Profiles were calculated by 
interpolating along a line drawn through the lumen of the channel. The origin of the 
system was taken as the geometric center of the alpha-carbon atoms belonging to the 
three proline-hinge residues (P28, P133, P230) which define the gate of the transporter. 
2D slices were rendered with the matplotlib Python library. 
Ensemble Docking. Autodock4 [119] was used to perform docking of ADP to an 
ensemble of protein conformations derived from 1500 equidistant snapshots from each of 
our four Apo-ANT1 systems of MD simulations. A custom TCL script was written to 
convert the NAMD dcd trajectory files. For each simulation snapshot, the protein was 
aligned to the equilibrated reference system and the protein structure was written to a 
separate file. 
Instead of assigning partial charges via the Gasteiger method implemented in 
Autodock tools, we preserved the partial charge assignments previously defined from the 
CHARMM22 topology files used for all-atom simulations. To export these partial 
charges explicitly, PQR files were exported from the NAMD trajectories. The 
prepare\_receptor4.py script from Autodock Tools (ADT) was then used to convert the 
PQR files to the native Autodock PDBQT format. We manually validated that protein 
snapshots from wild-type and acetylated systems each had +18 and +17 net charge 
respectively. 
Autogrid4 was invoked with a default grid spacing of 0.375 Å. The bounding box 
was created for the lower pocket of the channel, positioned at the center of mass of the 
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protein. An XYZ grid size of 40x40x40 points was used. Docking was then performed on 
each ANT1 MD snapshot conformation with a Lamarckian genetic algorithm. A 
population of 256 was used, with 2500000 maximum energy evaluations and 27000 
maximum generations. We adjusted these parameters extensively, but arrived at similar 
distributions for each experiment. The ADP ligand was exported from VMD into PQR 
format and prepared manually with Autodock Tools. Nonpolar hydrogens were merged, 
and 9 active torsions were defined by default. The net charge of ADP was reported at -3. 
After docking, binding energies and estimated binding constants were parsed from results 
files with the unix programs egrep, awk, and sort. 
In addition to ensemble docking, we also performed ADP docking to the static 
equilibrated wild-type system. The docked pose was similar to the best poses found in 
ensemble docking to the Apo-ANT1 ensembles. The docked ligand was subsequently 
incorporated into the ANT1 structure, and two additional MD simulations were 
performed on both the wild-type (WT) and acetylated K23 systems. These bound 
"ANT1+ADP" simulations were subsequently analyzed and subjected to independent 
rounds of ensemble docking. 
RESULTS 
Acetylated proteins are widespread and abundant in human skeletal muscle.  To 
assess the extent and sites of lysine acetylation in skeletal muscle proteins, muscle 
biopsies were lysed. Lysate proteins were resolved by one-dimensional SDS-PAGE. 
Samples were processed and mass spectrometry analysis performed as previously 
described [4, 109]. Acetylated proteins and specific sites of acetylation in whole muscle 
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are shown in (Table 5).  Data shown in (Table 5) are a compilation of acetylation sites 
observed in 3 separate biopsies from different healthy individuals.  Both mitochondrial 
and non-mitochondrial are represented, with myosin isoforms being heavily acetylated, as 
assessed by the large number of spectra for acetylated myosin proteins observed (not 
shown). 
Mitochondrial proteins are heavily acetylated.  To obtain better proteomic 
coverage of mitochondrial proteins, mitochondria were isolated from freshly obtained 
skeletal muscle biopsies (n=3) from healthy volunteers.  Mitochondrial protein lysates 
were prepared and analyzed in the same manner as whole muscle lysates.  Simplifying 
the complexity of whole muscle proteins revealed many more acetylation sites in a 
variety of mitochondrial proteins.  The abundance of myosin spectra in whole muscle 
lysates masks other ions of lower abundance.  Results of this analysis are shown in (Table 
6).  Some proteins, such as trifunctional enzyme, were found to be acetylated in whole 
muscle and mitochondrial lysates. Others were found mainly in the mitochondrial lysates.  
Proteins involved in several aspects of mitochondrial function were represented, 
including shuttle activity (aspartate aminotransferase), fatty acid metabolism 
(hydroxyacyl-coenzyme A dehydrogenase), citric acid cycle (malate dehydrogenase), 
NADP-dependent isocitrate dyhydrogenase, ATP synthesis (ATP synthase subunits b,d, 
and O), reactive oxygen species metabolism (Mn-superoxide dismutase), and adenine 





Protein Acetylated amino acid sequence 
Myosin-2 773AGLLGLLEEM(ox)RDDK(ac)786 
Myosin-7 146K(ac)RSEAPPHIFSISDNAYQYM(ox)LTDR169 
Myosin light chain 3 124NK(ac)DTGTYEDFVEGLR138 
Gamma-enolase 202DATNVGDEGGFAPNILENSEALELVK(ac)227 
Histone H3.2 19KQLATK(ac)AAR27 
Voltage-dependent 
anion-selective 







complex subunit 2, 
mitochondrial 
353AAYNQVK(ac)TIAQGNLSNTDVQAAK375 
Tubulin beta-2C chain 319GRMSMK(ac)EVDEQMLNVQNK336 
Myoglobin 65HGATVLTALGGILK(ac)K79 
 33LFK(ac)GHPETLEK43 
Isoform 1 of 
Myomesin-1 
372YK(ac)GEFDETRFHAGASTM(ac)PLSFGVTPYGYASR402 









Acetylation sites are indicated as K(ac); methionine oxidation M(ox) 
 










  8DFLAGGVAAAVSK(ac)TAVAPIER31 
  81YFPTQALNFAFK(ac)DK94 
Trifunctional enzyme 









  356TQLVSNLK(ac)K364 
  394LIK(ac)EFSIYM(ox)TK404 
  397EFSIYM(ox)TK(ac)DGR407 




Isoform 1  254GDASK(ac)EDIDTAM(ox)K266 
Malate dehydrogenase 53LTLYDIAHTPGVAADLSHIEK(ac)AAVK78 
  177ANTFVAELK(ac)GLDPAR191 
  298GIEK(ac)NLGIGK307 
    302NLGIGK(ac)VSSFEEK314 




  115GELLEAIK(ac)R123 









mitochondrial  70LILPHVDIQLK(ac)YFDLGLPNR89 
  81YFDLGLPNRDQTDDQVTIDSALATQK(ac)YSVAVK112 
  173HAHGDQYK(ac)ATDFVADR188 
  383GK(ac)LDGNQDLIR393 
ATP synthase subunit 
b 
155SQQALVQK(ac)R163 
ATP synthase subunit 
O 
58QNKLEQVEK(ac)ELLR64 
  159TVLK(ac)SFLSQGQVLK172 
  163SFLSQGQVLKLEAK(ac)176 
  189IGEK(ac)YVDMSVK199 
 












Adenine nucleotide translocase 1 (ANT1) contains multiple acetylation sites in 
human skeletal muscle mitochondria.  Among the proteins deacetylated after exercise 
was the adenine nucleotide translocase, ANT1. ANT1 has significant control of 
mitochondrial respiration under physiological conditions [120], so we then focused on 
this protein.  Using a combination of data-dependent and hypothesis-driven 
approaches[6], we identified a total of 5 acetylated lysine residues in ANT1. The primary 
amino acid sequence of ANT1, with verified acetylation sites highlighted, is shown in 
Figure 7.  The crystal structure of ANT1, in the “c” conformation (open to the inner-
mitochondrial space), complexed with the inhibitor carboxyatractyloside, is shown in 
Figure 8 and Figure 9. The human ANT1 homology model was prepared and inserted 
into a POPC membrane for simulation (Figure 10). Acetylation sites are highlighted.  
Amino acid sequences surrounding this acetylation site exhibit high evolutionary 
conservation (Figure 7). 
Acetylation of mitochondrial proteins is related to insulin sensitivity.  To 
determine the relationship between the mitochondrial acetylome and insulin resistance, 
total acetylation states of mitochondrial proteins (sum of all NSAF for acetylated spectra) 
were compared with insulin stimulation of glucose disposal during a euglycemic clamp.  





Yellow and green highlighting represents mass-spec coverage and observed 
lysine-acetylations respectively. For the yeast sequence, red highlights indicate residues 
required for ADP transport as demonstrated in a prior mutation study 
Figure 7 : Sequence alignment of human ANT1 and yeast AAC2 
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Figure 9 : Side view of bovine ANT1 complexed with the carboxyactractyloside inhibitor 
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  Mean / SEM Range 
Gender (F/M) 8/8  
Age years 39.9 / 3.0 24 – 60 
BMI Kg/m
2
 29.1 / 1.8 19.1 – 39.1 
Body Fat percent 31.3 / 1.9 25.6 – 48.4 













 7.03 / 0.80 3.5 – 14.5 
Hba1c Percent 5.51 / 0.07 4.8 – 5.8 
Total Cholesterol mg/dl
-1
 175 / 10 131 – 254 
Plasma Triglycerides mg/dl
-1
 88 / 16 39 – 286 
 
 
Table 7 : Characteristics of subjects receiving only euglycemic clamps 
 
 
  Mean / SEM Range 
Gender (F/M) 2/4  
Age years 33.5 / 4.3 23 – 48 
BMI Kg/m
2
 27.8 / 1.7 22.1 – 29.9 







 9.3 / 1.4 6.1 – 13.2 
Hba1c percent 5.31 / 0.14 5.0 – 5.7 
Total Cholesterol mg/dl
-1
 183 / 12 145 – 202 
Plasma Triglycerides mg/dl
-1





 33.0 / 3.7 25.5 – 47.1 
Maximum Heart Rate BPM 187 / 4 174 – 197  
Data are given as Means / SEM and ranges of values. 
 













Figure 11 : Acetylation is correlated with insulin sensitivity 
 
Acetylation is correlated with insulin-stimulated glucose disposal.  Sixteen healthy 
volunteers underwent a two hour euglycemic, hyperinsulinemic clamp as described in the 
Methods.  Muscle biopsies were taken at rest, after an overnight fast, approximately one 
hour before the insulin infusion was initiated.  Mitochondria were isolated from the 
muscle biopsies and acetylation of mitochondrial proteins was quantified using the NSAF 
method.  Data are given as rates of insulin stimulated glucose disposal in the last 30 
minutes of the glucose clamp, expressed in units of mg glucose per minute per Kg fat-


















r = 0.603 
 
Figure 12 : Acetylation of mitochondrial proteins decreases with exercise 
Acetylation of mitochondrial proteins decreases after exercise.  Five healthy volunteers 
underwent a single bout of exercise as described in the Methods.  Muscle biopsies were 
taken at rest, after an overnight fast, and 24 hours after the end of the exercise bout, again 
after an overnight fast.  Mitochondria were isolated from the muscle biopsies and 
acetylation of mitochondrial proteins was quantified using the NSAF method.  Data are 






















r = 0.90  
Figure 13 : Change of K23 acetylation with exercise 
 
Ant1 acetylation at lysine 23 decreases after exercise.  Five healthy volunteers 
underwent a single bout of exercise as described in the Methods.  Muscle biopsies were 
taken at rest, after an overnight fast, and 24 hours after the end of the exercise bout, again 
after an overnight fast.  Mitochondria were isolated from the muscle biopsies and 
acetylation of Ant1 was quantified using the NSAF method.  Insulin stimulated glucose 
disposal was quantified during a two hour euglycemic, hyperinsulinemic clamp as 
described in the Methods Data are given as rates of insulin stimulated glucose disposal in 
the last 30 minutes of the glucose clamp, expressed in units of mg glucose per minute per 




Acetylation of mitochondrial proteins is regulated by exercise.  To determine 
whether a vigorous bout of exercise can result in deacetylation of mitochondrial proteins, 
five separate normoglycemic subjects (Table 8) underwent euglycemic clamps and on a 
separate day, vigorous bout of exercise. Overall, exercise resulted in a significant 
decrease in acetylation of mitochondrial proteins (Figure 11).  Among the deacetylated 
proteins, ANT1 showed extensive deacetylation.  Moreover, the extent of acetylation of 
mitochondrial proteins was significantly correlated with insulin action (Figure 12). 
Regulation of deacetylation of specific ANT1 lysine residues after muscle 
contraction are related to insulin sensitivity. We reasoned that exercise/muscle 
contraction would increase the NAD
+
/NADH ratio, activate sirtuins, and deacetylate 
critical mitochondrial proteins.  Under resting conditions, there was no correlation 
between the sum of acetylation of ANT1 at all sites (total acetylation) and insulin 
sensitivity (r=0.42, NS).  After exercise, there was a significant decrease in total ANT1 
acetylation (Figure 13).  When examined on a site-by-site basis, this trend was due to a 
significant (P < 0.05) decrease in acetylation of lysine 23 of ANT1, and this decrease was 
negatively correlated with insulin sensitivity (Figure 13).  
Acetylation affects electrostatic properties of ANT1.  Lysine acetylation results 
in a loss of positive charge. To assess the functional significance of these modifications, 
we analyzed the electrostatic properties of the wild-type (WT) and acetylated (K10, K23, 
K92) protein structures. After application of our acetylysine (KAC) patch, we produced 
2D slices (Figure 14) and a 3D isosurface (Figure 15) of the electrostatic potential. ANT1 
exhibited a strong electrostatic potential at the bottom of the cavity, which indeed serves 
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to direct the binding of negatively-charged ADP molecules. Interestingly, the observed 
potential is highest near the side chain of lysine 23 (Figure 16), emphasizing its 
importance in binding ADP. Upon acetylation, we noted only slight changes to the 
positions and shapes of the isopotentials, but the magnitude of the potential was reduced. 
To visualize the potential in a more straightforward way, we also interpolated the 
potentials along a line drawn through the axis of the channel. (Figure 15) As observed 
from the iso-electric surfaces the electrostatic potential of these 1-D plots near the 
binding pocket and experiences a rapid falloff with distance through the channel opening 
(Figure 16). However the potential at the core binding pocket was dramatically reduced 
with acetylation of lysine 23, which also suggests that acetylation of lysine 23 could 







Figure 14 : 2D slices of the electrostatic potential 
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Figure 15 : Interpolation of electrostatic potential along channel 
 
To visualize the electrostatic profile along a hypothetical reaction coordinate in which 
ADP would translocate, we performed interpolation of the potential along a 30 Angstrom 
line (orange) drawn in the vertical axis. The origin was defined as the geometric center of 
the proline hinge alpha carbon atoms. The three mitochondrial carrier motif gate-helices 
are highlighted in purple. The electrostatic potential is maximum at a site near the 
sidechain of K23 (red sphere). 
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Figure 16 : Electric potential along reaction coordinate 
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Modeling of Apo ANT1.  We prepared a wild-type (WT) and three lysine 
acetylated (K10, K23, K92) ANT1 systems and performed all-atom molecular dynamics 
(MD) simulations for 30 ns. These simulations were performed without the presence of 
ADP, and are thus referred to as "Apo-ANT1" simulations. To test the hypothesis that 
lysine acetylation may affect the structure or dynamics of Apo-ANT1, we performed 
root-mean-square-fluctuation (RMSF) analysis on the four simulation trajectories. The 
fluctuation values are plotted with respect to sequence position in Figure 17. 
In each of the trajectories, there were small localized differences in fluctuations at 
single residues. More substantially however, a large and broad increase in fluctuations is 
seen in the vicinity of hydrophobic residues 76-87 localized to the midpoint of the second 
transmembrane helix of acetylated K23 simulation trajectory (Figure 18). Upon further 
investigation of the trajectory, we found that the sidechain of acetylated K23 drifts 
upwards away from the lower binding pocket. Rather than  strong  electrostatic 
interactions of K23  with E30  with the salt-bridge network observed  in wildtype 
simulations,   the hydrophobic  part of the sidechain of acetylated K23 interacts with  
residues Y81 and N77 (Figure 18). These hydrophobic interactions appear to pull the 
second transmembrane helix slightly inward into the lumen of the channel. In the other 
three simulations, wild-type K23 remains localized to the binding pocket due to 
electrostatic interactions with E30 in the salt-bridge network. 
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Figure 18 : Effect of K23 acetylation on ANT1 structure 
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Figure 19 : Binding energy distributions obtained from ensemble docking of the four simulated 
systems. 
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To investigate the consequences of lysine acetylation on ADP binding, we used 
an ensemble docking approach. For each of the four Apo-ANT1 simulations, we 
performed independent docking runs to 1500 snapshots from the simulation trajectories 
using Autodock.  Docking was focused to the core binding pocket of the channel, and 
thus docking experiments to the acetylated K10 and K92 systems served as replicates of 
the wild-type system. We found that ADP adopts highly similar docking poses among 
each of the four systems. The two phosphate groups were always arranged in a vertical 
orientation near the center of the pocket, preferentially interacting with four basic 
residues: Arginines 80, 280, 236, and Lysine 23. The adenine ring appears to not adopt 
any preferred orientations in the channel. 
Despite no apparent differences in conformation of bound ADP, this analysis 
revealed substantial differences in binding affinity. We produced histograms (Figure 19) 
of the estimated binding energies of our ensemble docking reported by Autodock. These 
distributions were similar between the WT, K10, and K92 systems. However, acetylating 
K23 resulted in a large shift in the total binding energy of ADP. The peak of the 
distribution for the acetylated K23 system is located at approximately -1 kcal/mol. The 
other three systems, with an unmodified pocket, show binding energy  peaks at 
approximately -3 kcal/mol. These binding energies are very weak, and would correspond 
to binding affinities in the millimolar range. Having arrived at these estimates, we 
hypothesized that docking experiments to static snapshots of Apo-ANT1 may yield weak 
binding affinities since the binding pocket is unable to rearrange to more favorably 
accommodate the ligand. To allow such rearrangements, we proceeded to conduct full 




Figure 20 : Overlayed WT+K23 ANT1 systems before simulation 
 
The overlayed binding pocket regions of both WT and Acetylated K23 systems 
before ADP is docked. The acetyl group atoms in the acetylated system are colored red 
for oxygen and teal for carbon 
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Figure 21 : Overlayed WT+K23 ANT1 systems after 30ns simulation 
 
The overlayed binding pockets for both systems after ADP is docked at the systems are 
simulated for 30ns. From the overlay, we see that all charged residues have similar 
ending conformations except acetylated K23, which drifts away from ADP. Only the 
phosphates of ADP are shown for clarity. Dark blue sidechains interact the strongest with 
ADP and are homologues of critical yeast mutants. Lightly-colored residues form the 
underlying salt bridge network. 
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Figure 23 : Induced fit of binding pocket 
 
 
We measured the radial distance of basic sidechains in the binding pocket in the 
Apo and Bound simulations. The dramatic stabilization after ADP insertion demonstrates 
an induced fit. 
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Figure 24 : Distribution of ADP binding energies 
 
Distribution of binding energies obtained from ensemble docking experiments for 
the WT+ADP and K23+ADP simulations. 
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Modeling of ANT1 with ADP bound - We postulated that all-atom MD 
simulations of the ANT1 in the ADP-bound state might yield more insight into the 
dynamical consequences of lysine acetylation. We thus performed docking of ADP to the 
static equilibrated WT structure and used this system as an input for two further MD 
simulations. A wild-type bound (WT+ADP) and acetylated  K23 bound  (acetylated 
K23+ADP) system were prepared and simulated as before for 30 ns. 
While visualizing the trajectories we observed a rapid reorganization of the charged 
residues within the binding pocket. Within the early stages of the wild-type simulation, 
R80, R280, R236, and K23 rearranged to form tight hydrogen bonds with the negatively-
charged ADP phosphate groups. This observed effect suggests the concept of an induced 
fit model with regards to ADP binding to the ANT1 transporter. We present 
superimposed structures of the WT and K23 simulations with ADP bound. Both systems 
start in the same initial configuration (Figure 20) in which the critical residues of the 
binding pocket interact with charged residues at the periphery. After 30 ns of simulation 
however, the sidechains of these residues rearrange to a more centralized conformation to 
bind the ADP phosphates (Figure 21). In both systems, the final side chain conformations 
are highly similar for each charged residue, with the distinct exception of acetylated 
Lysine 23, which drifts away from the binding pocket (Figure 21). The location of the 
docked ADP within the WT ANT1 after 30ns of simulation is illustrated in Figure 22. 
The terminal phosphates of ADP interact primarily with 4 basic residues, one of which is 
K23. 
To further characterize these structural rearrangements, we analyzed the radial 
positions of the conserved critical residues in the binding pocket (K23, R80, R280, K33, 
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R138, R235, R236) as a function of time. From the wild-type simulation, we computed 
the average position of the terminal phosphorus atom of ADP. Sidechain distances were 
then calculated from this position to the NZ atoms of K23 and K33, and the CZ atoms of 
R80, R138, R235, R236 and R 280 through the snapshots for both the 25 ns unbound 
(WT) equilibration and the 30 ns  bound simulation (WT+ADP). Time evolutions of 
these distances which indirectly measure the interaction with ADP and these highly 
conserved residues critical for binding (Figure 23), shows a substantial change of binding 
pocket stability at the transition of the equilibration and the bound simulations. It appears 
that these residues drift in and out of the center binding pocket during the apo 
equilibration, but rapidly stabilize to a central configuration during simulations with ADP 
bound. Consequently, this suggests that the presence of ADP results in an induced-fit 
binding with the channel. 
We hypothesized that this induced fit may strengthen ADP binding, and therefore 
we re-evaluate the binding affinities of ADP to wild type and acetylated K23 ANT in 
different ensemble docking results. We thus conducted an independent set of docking 
experiments on snapshots from the two bound ANT1+ADP simulations. We fit normal 
distributions to the binding energy histograms obtained from these ensemble docking 
experiments. (Figure 24) From the estimated mean binding energies, we observe a 
significant improvement of binding energies over the Apo-ANT1 docking experiments 
(Figure 19). ADP binding affinity of the wild-type ANT1 shows an increase from ~-3 
kcal/mol in the Apo-ANT1 ensemble to -7.7 kcal/mol for the bound wild-type structure 
(WT+ADP). For the acetylated K23 system, ADP binds with an  estimated binding 
energy of -5.8 kcal/mol to the bound (K23+ADP) ensemble. These stronger binding 
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energies further suggest that ADP binding to ANT1 is facilitated by an induced-fit of the 
binding pocket. These pocket rearrangements lead to a substantially stronger interaction 
with the ligand and may subsequently prepare the channel for opening and translocation.  
 From the histograms, it is clear that the ensemble docking technique has resulted 
in a large interval of estimated binding energies. To assess the physiological relevance of 
acetylation, we wish to associate these binding energies with equilibrium dissociation 
constants (Kd). Given the exponential dependence of Kd on binding energy, however, we 
must carefully consider the uncertainty in our estimates. To this end, we have compiled a 
table of Kd values (Table 9) calculated from the range of binding energies of 1 standard 
deviation to the left and right of the estimated means. From this table we see that small 
changes in binding energy can correspond to substantial ranges of Kd. Nonetheless, it is 
clear that acetylation of K23 may have significant physiological consequences on ADP 





 Wild Type K23 
Binding Energy 
(Mean) 
-7.7 kcal/mol -5.816 kcal/mol 
Kd (of mean energy) 3.66 uM 79.39 uM 
Binding Energy 
(Std Dev) 
0.78 kcal/mol 1.28 kcal/mol 
Binding Energy 
Range 
(+- 1 StdDev) 
-8.49 to -6.928 kcal/mol -7.09 to -4.53 kcal/mol 
Corresponding Kd 
Range 
1.02 to 13.042 uM 9.94 uM to 634 uM 
Table 9: Estimated binding energies of ADP docked with either WT and K23-acetylated ANT1. 
 
Means of binding energies were obtained through fitting the normal distribution to 
histograms of binding energies from ensemble docking experiments. The estimated 
standard deviations were used to consider a range of binding energies of 1 sigma to either 





Although a significant body of evidence exists in favor of the concept that 
mitochondrial dysfunction is associated with insulin resistant skeletal muscle [121], this 
finding is not universal [122]. Some investigators report subtle, but potentially important, 
changes in mitochondrial function [123]. Given the wide variety of methods and 
measurements used by many investigators, and because many measurements reflect 
overall pathway activity rather than individual steps, it may not be surprising that there 
are disparate results.  The present study was undertaken to understand how one potential 
regulator of mitochondrial proteins, acetylation, might affect the function of 
mitochondria, particularly with respect to insulin sensitivity. 
We used mass spectrometry-based proteomics to identify a number of lysine 
acetylation sites in skeletal muscle, including mitochondrial and other proteins.  Because 
we did not use any enrichment methods, these proteins are likely to represent the most 
abundantly acetylated proteins in human skeletal muscle and a minimum acetylation.  To 
our knowledge, this is the first reported acetylome of human skeletal muscle.  There 
undoubtedly are many more, lower abundance acetylation sites that can be revealed using 
enrichment methods.  Nevertheless, many of the proteins we observed to be acetylated 
are involved in metabolism, which is consistent with the idea that acetylation is a 
widespread regulator of metabolism[9]. 
Using a label-free mass spectrometry quantification method that we previously 
validated [4], we observed that the overall extent of acetylation of mitochondrial proteins 
was positively correlated with insulin-stimulated glucose disposal during a euglycemic 
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clamp, which quantifies insulin sensitivity in skeletal muscle [124]. We also showed that 
exercise is associated with an overall decrease in acetylation of mitochondrial proteins.  
In particular, acetylation of lysine 23 in the adenine nucleotide translocase (ANT1), gene 
name SLC25A4 decreased after exercise in a manner dependent on insulin sensitivity, 
that is, to a greater degree in insulin sensitive individuals.  Therefore, it appears that in 
general insulin sensitivity is associated with a greater range of protein acetylation, that is, 
higher values under basal conditions and greater physiological changes.  This 
phenomenon is reminiscent of the concept of “metabolic inflexibility” of insulin resistant 
skeletal muscle [125], and may provide a clue to understanding the underlying molecular 
mechanism. 
Under physiological conditions, ANT1 displays significant control strength over 
the rate of mitochondrial respiration [120]. Because abnormalities in mitochondrial 
function have been linked to insulin resistance in muscle [123], we sought to understand 
how acetylation of ANT1 might alter its function.  To address this, we chose a molecular 
modeling approach, since the crystal structure of the highly homologous bovine ANT1 is 
known [110].  Abnormalities in the structure of ADP/ATP carriers have long been 
investigated in metabolic defects and disease. In a recent work both biochemical assays 
and all-atom MD simulations were used to characterize six pathological mutants 
observed in humans [126]. Several of these mutations have been linked to fatigue, 
weakness, and exercise intolerance in individuals, as well as extreme ptosis [126]. These 
associations demonstrate a clear point of control at the ADP/ATP carrier for proper 
metabolism in muscle.  
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The functional importance of charged residues in ANT1 has already been 
demonstrated in mutation studies.  Nelson and colleagues performed a screen for site-
directed mutants of the yeast AAC2 transporter, a close homologue of human ANT1 [10]. 
By growing yeast on a non-fermentable carbon source such as glycerol, they were able to 
screen for mutants of AAC2 that affected ADP/ATP transport. They demonstrate that six 
arginines and one lysine residue are absolutely required for growth. Sequence alignment 
of the yeast AAC2 carrier with human ANT1 (Figure 7) demonstrates that the two 
proteins are highly homologous.  Of the six arginines identified as critical for transport, 
three are part of the RRRMMM motif, which is a characteristic feature of all ADP/ATP 
transporters [127]. The second arginine in this motif is R236, which interacts closely with 
the ADP phosphate groups in our simulations and docking. Another two mutant arginines 
in yeast correspond to R80 and R280 in the human transporter, which bind ADP and 
flank K23 on both sides. Finally, the single most critical lysine in yeast, K38, is 
homologous to K23 in human ANT1. As our mass spectrometry results indicate that K23 
is acetylated in humans, regulated physiologically, and related to insulin resistance, we 
feel there is strong evidence that channel transport and metabolic activity may be tightly 
controlled by this critical modification. 
Given the strong evidence in the literature that ANT1 is a central point of control 
for oxidative metabolism, and that defects of ANT1 at specific sites can cause profound 
dysfunction, we focused our efforts to characterize the biophysical mechanisms that 
ANT1 transport might be inhibited. Acetylation of critical residues could affect the 
electrostatic properties of ANT1 and thereby inhibit either the initial capture or tight 
binding of ADP. Acetylation could also perturb the structure or dynamics of ANT1, 
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possibly changing the shape of its binding pocket or altering molecular dynamics that 
may facilitate ligand recognition or channel opening. We thus explored all of these 
possibilities in our modeling efforts. 
 To capture and transport ADP, ANT1 relies upon a substantial +18 charge to 
attract negatively-charged ADP molecules into the mitochondrial matrix. In prior work, 
Wang et. al.[128] demonstrated using bioinformatics analysis that this large charge is 
extraordinary in comparison to most of the mitochondrial proteome.  It is thus critical to 
understand the effects that lysine acetylation has on the electrostatic properties of the 
channel. Of the three lysines addressed in our study, K23 is uniquely positioned at the 
binding pocket where the electrostatic potential is maximum (Figure 15). Furthermore, a 
dramatic loss of electrostatic potential is observed when this single lysine is acetylated. 
(Figure 16) We believe that this electrostatic loss will profoundly affect ADP capture in 
vivo. 
We additionally hypothesized that lysine acetylation may perturb either the 
structure or dynamics of ANT1 and thus affect its transporter activity. After the initial 
ADP capture and binding to the lower pocket, ANT1 is thought to undergo a 
conformational change that leads to channel opening and passage of ADP into the 
mitochondrial matrix. ANT1 is a member of the mitochondrial carrier family (MCF) of 
proteins, all of which are characterized by three "mitochondrial carrier motifs" 
PX(D/E)XX(K/R). The three motifs co-localize in the structure of bovine ANT1 (PDB: 
1OKC) and form a triple-helix “gate” at the matrix side of the channel. The proline 
residues form kinks in the alpha-helices, presumably allowing a hinge motion to occur 
during opening and closing of the channel. The two charged (D/E) and (K/R) residues of 
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each helix form salt-bridges that bind the neighboring helices together in a closed 
conformation. Channel opening has long been thought to require the coordinated 
disruption of this salt-bridge network, presumably by the binding of ADP to the three 
basic residues located on these helices. ANT1 has long been postulated to undergo a 
conformational switch between a cytosol-facing C state and a matrix-facing M state, in 
which either ADP or ATP is bound and translocated in alternating order. We therefore 
postulated that a perturbation of these dynamics via lysine acetylation may influence the 
function of the channel. 
We conducted fluctuation analysis to determine if the gate helices would be 
perturbed by acetylation but found no such changes in the Apo simulations. We instead, 
however, discovered a large structural difference in the channel brought on specifically 
by acetylation of lysine 23. The second transmembrane helix from residues 76-87 is 
dramatically perturbed due to specific interactions with acetylated K23.  With the charge 
of K23 completely neutralized by acetylation, hydrophobic interactions dominate and 
induce local packing with the hydrophobic residues on the sidewall of the channel. These 
results suggest that channel narrowing may be a structural consequence of K23 
acetylation that may conceivably effect ADP transport. 
Alongside our investigations into the Apo-ANT1 structure, we sought more direct 
computational evidence that capture or binding of ADP would be reduced.  Two 
prominent computational studies [128, 129] have simulated the early capture and 
translocation events of ADP using all-atom MD techniques with very long simulations. 
Both studies focused on the strong electrostatic properties of ANT1 acting as a "funnel" 
to capture ADP molecules from the inner-membrane space and transport them to the 
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lower binding pocket. These simulations required a diverse range of translocation times 
due to the stochastic nature of transport. In these simulations, ADP became trapped in 
various locations and orientations for extended durations. We felt that these stochastic 
and chaotic processes precluded the use of all-atom MD to simulate capture events for 
purposes of comparing the effects of lysine acetylation. 
We thus focused on the docking of ADP directly into the lower binding pocket 
where K23 is located. In a recent work [130], Autodock was successfully employed to 
perform a screen of possible ATP binding sites on the closed matrix-facing surface of the 
ANT1 protein, and so we adopted similar methodologies for ADP binding in the cytosol-
facing pocket. Our experiments resulted in highly-reproducible bound conformations of 
ADP that agrees with previous all-atom MD results [128]. Furthermore, the Autodock 
software provided us with estimates of binding energies that give us perspective of how a 
single acetylation event can have a significant effect at such a critical core residue in the 
pocket. 
Ensemble docking to our Apo-ANT1 molecular dynamics results was used to 
successfully assess the binding energies in four variants of the ANT1 channel. These 
results suggested there could be a dramatic inhibition of ADP binding that resulting from 
a single acetylation at K23. We then extended the docking technique to produce an 
ANT1+ADP complex for further all-atom simulations. These simulations and subsequent 
ensemble docking experiments further elucidated the structural rearrangements associated 
with ADP binding and provided even more compelling evidence that lysine 23 is critical 
for proper function. 
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In our docking experiments and our all-atom MD simulations, we specifically 
observed R80, R280, R236 and K23 to be the primary binding partners of the ADP 
ligand. These critical residues account for the majority of the critical mutation sites 
previously identified [10] in yeast (Figure 7). Over longer timeframes, we also observed 
R138 and R235 moving towards the ligand. It is apparent from our simulations that the 
strong negative electrostatic field of the ADP ligand is beginning to disrupt two of the 
salt-bridges that keep the channel closed. Without the presence of ADP, the basic side 
chains are highly mobile and have highly varying distances from the channel center. In 
the bound ANT1 simulations (ANT1+ADP) however, the basic residues quickly 
rearrange to a stable minimal distance from the average phosphate position. Intriguingly, 
two of the three basic salt-bridge residues show a strong rearrangement. This is direct 
evidence that the salt-bridge network holding the channel closed is indeed perturbed by 
the binding of ADP. 
Other studies have found acetylation of mitochondrial proteins to regulate 
function.  For example, fasting alters acetylation of mitochondrial proteins, suggesting 
reversible acetylation may regulate function [104]. Sirtuins are important protein 
deacetylases that depend on NAD
+
 for activity.  Sirt3, 4, and 5 are present in 
mitochondria and may regulate aspects of mitochondrial function [131-133]. For 
example, fasting induces Sirt3 expression in mouse liver, elevating fatty acid oxidation, 
and deletion of Sirt3 gene results in higher concentrations of acylcarnitines and 
triglycerides, due to defective fatty acid oxidation (29). Deacetylation of LCAD by Sirt3 
is critical for fatty acid oxidation [103]. Sirt3 null mice also have reduced ATP 
production in liver and are cold-intolerant [106], and exhibit increased acetylation of 
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mitochondrial proteins critical for energy homeostasis. Sirt3 expression is increased by 
exercise and fasting in mouse muscle, where it is highly expressed in oxidative muscle 
[80]. 
The results of this study provide important new information about the role of 
reversible acetylation in mitochondrial function. Our data provide strong evidence that 
acetylation of lysine 23, through its electrostatic effects, profoundly reduces the affinity 
of ADP binding to ANT1. ADP dissociation constants (Kd; the concentration of ADP 
ligand required for half-occupancy of the ANT1 channel) calculated from the mean 
binding energies from ensemble docking experiments give insight into the performance 
of WT and acetylated ANT1 in vivo. 
The estimated Kd values were 3.66 
with the acetylation of K23. These Kd values would correspond roughly to KMADP for 
respiration values if 1) ANT1 was the single locus of mitochondrial respiratory flux 
control and 2) ANT1 flux and cytosolic [ADP] conformed to a simple Michaelis-Menten 
(M-M) relationship. In fact, in mixed human skeletal muscle contracting in the mild-to-
moderate aerobic metabolic range, ANT1 is the major locus of aerobic flux control [120] 
and 
31
P-nmr non-invasive measurement of energy phosphate concentrations have shown 
that simple M-M kinetics can, under such conditions, provide a reasonable fit of the 
[ADP]:VO2 relationship [134], however higher order models have been demonstrated as 
well [135]. Thus, it is of interest to compare these Kd values to free [ADP] and apparent 
KMADP values measured in vivo. These studies demonstrate that in vivo, resting human 
skeletal muscle free [ADP] is in the 10- MADP has been 
reported to be roughly 30-
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estimates of the binding affinities of the WT and K23 acetylated systems. Rearrangement 
of the Michaelis-Menten equation yields an estimate of the fractional velocity of ANT1: 
v/Vmax = [ADP]/([ADP] + KMADP) 
 a 
KM
with KM 2 
roughly 1 or 2% of its aerobic capacity [125, 136, 137], it seems the former, wild type 
scenario greatly overestimates mitochondrial ATP output, while the acetylated condition 
yields a reasonable match. 
Important caveats obviously attend such hypothetical scenarios. For one example, 
the scenario assumes ANT1 Vmax equals the maximum rate of mitochondrial ATP 
production, when it may be threefold higher, based on isolated mitochondria in which 
maximal respiration is titrated out by carboxyatractyloside (CAT) titration, an ANT1 
inhibitor that binds with very high, nearly 1:1, affinity [138]. But the analysis 
nevertheless affords useful insight into the role of ANT1 in the control of mitochondrial 
respiration. The observation that the in vivo apparent KMADP for respiration is 
intermediate to the widely disparate Kd values of wild type vs. acetylated ANT1 modeled 
here may reflect a mechanism that adjusts mitochondrial sensitivity to the ADP 
respiratory signal in a manner geared to metabolic demand. In the context of basic 
biology, such a mechanism might partly explain the observation that the kinetics by 
which ADP controls respiration appear to be higher order, rather than simple Michaelis-
Menten [135]. 
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In summary, acetylation of mitochondrial proteins, and in particular the adenine 
nucleotide translocase ANT1, is abundant in human skeletal muscle mitochondria, is 
related to insulin sensitivity, and physiologically regulated by an acute exercise bout in an 
insulin sensitive manner, especially at lysine 23. The use of simulations and docking 
experiments revealed that lysine 23 is a critical residue for controlling the affinity of ADP 
binding to ANT1, with the acetylated system having a much lower binding affinity for 
ADP. Therefore, the brisk deacetylation of K23 by exercise in insulin sensitive 
individuals could have important implications in regulating mitochondrial function.  
 
Software Credits 
 Sequence alignment in Figure 7 was drawn with ESPript[139] 
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Chapter 4 
AMASS: A NEW DATABASE FOR INVESTIGATING PROTEIN MODIFICATIONS 
 
 




 Motivation: Bioinformatics is traditionally sequence-driven, however new 
technologies have created an explosion of protein structural data. Sequence annotations 
must be unified to these structures to enable visualization and understanding of protein 
function and molecular abnormalities potentially involved in disease. 
 Results: We have created the AMASS Database, which seeks to bridge the gap 
between 1D sequence annotation databases and 3D protein structures. We additionally 
provide a service whereby users can query arbitrary sites in protein sequences to find 
possible functions. The system is built upon the premise that active sites, coding 
mutations, and post-translational modifications within proteins may co-localize and share 
common functional mechanisms. 
 Availability and Implementation: AMASS DB is implemented with Biopython 
and Apache as a freely-available web server at www.amass-db.org. 





 Due to the rapid evolution of genome sequencing techniques, the understanding of 
the molecular basis of life has experienced a great revolution. Our ability to read the 
“source code” of life has produced large databases of biological sequences, and the 
bioinformatics field has emerged to find patterns in the code. Bioinformatics has 
originated as a sequence focused enterprise, and these techniques have yielded much 
insight into how genes and proteins work. Sequence conservation, at the nucleotide or 
residue level, provides tantalizing hints into where the underlying molecular mechanisms 
of a gene or protein reside. Thus, just from sequence data, the field has deciphered many 
biological puzzles. The result is a growing collection of functional site annotations in 
genes and proteins. Active sites in enzymes have been elucidated, conserved binding 
motifs have been found, and specific cancer mutations have been detected that are 
abundant in tumors. 
 Complementing the advances in genomic sequencing, new technologies have 
ushered in the era of proteomics. Mass spectrometry has enabled the routine and rapid 
“sequencing” of thousands of proteins found within a given biological sample. This 
technique enables the high-throughput discovery of protein post-translational 
modifications (PTMs) such as phosphorylation and acetylation, which can dramatically 
alter biological function in ways not described by the genome sequence. These post-
translational modifications provide another layer of complexity that describes molecular 
mechanisms at single sites within protein sequences. These residue-specific annotations 
will only continue to grow in a variety of bioinformatics databases. 
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 Structural proteomics has also experienced rapid growth with projects such as the 
Protein Structure Initiative[140] aiming to determine the atomic structure of every human 
protein. Bioinformatics must adapt to this change, and transition from its one-
dimensional (1D) sequence-oriented origins to a unified three-dimensional (3D) 
sequence/structure level of understanding. Connecting sequence annotations to protein 
structures may enable the discovery of co-localized functional sites of interest, and may 
allow investigators to find novel mechanisms of regulation. 
 As the number of crystallized proteins has increased, multiple projects and web 
portals have been designed and published that offer various analysis and visualization 
capabilities. Most of these projects focus on the analysis of single-nucleotide-
polymorphisms (SNPs) that are studied in genome wide association studies. The primary 
objective of most of these portals is to offer automated predictions of functional effects of 
SNPs based on either sequence analysis or predicted biophysical changes to protein 
structure. Some of these resources permit interactive visualization of mutated sites, but 
with limited support for exploration of other annotated functional sites. Furthermore, 
most of these resources only permit query of single sites, or do not permit any kind of 
queries as they index fixed SNP databases such as dbSNP. 
 SNPs3D[141] provides a pipeline that performs analysis of SNPs within protein 
structures, and assesses the biophysical consequences of SNPs based on changes such as 
surface accessibility and electrostatic interactions. Upon these predicted effects, a support 
vector machine classifier is used to predict whether or not a given SNP will have 
deleterious consequences. The location of each SNP can be visualized using Jmol on 
separate pages within the web interface. The SNPeffect[142] website offers a similar 
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analysis pipeline for predicting the effects of SNPs, and focuses on binding/aggregation 
predictions and backbone stability analysis. 
 The PolyPhen[143] server offers a sophisticated analysis service wherein users 
can query arbitrary SNPs of a given protein. The site uses eight sequence-based and 3 
structure-based algorithms to guess the potential functional consequences of an amino 
acid substitution. Among the structural features the authors investigated, they scrutinized 
the crystallographic B-factor of the residue, the hydrophobicity, and the accessible 
surface area. The authors constructed a probabilistic classifier to predict whether a given 
SNP will have a benign or damaging effect on protein function. The authors reported 
favorable prediction performance when compared with other SNP prediction platforms. 
 MSV3D[144] offers similar features for analyzing SNPs, and provides a similar 
resource, and has mapped SNPs for 20199 human proteins by offering either direct 
mappings or homology models. The resource offers detailed tabular descriptions of many 
physical and chemical aspects of residue substitutions, however only offers limited 
visualization capabilities with Jmol. 
 MutDB[145-147] offers a platform whereby variants from dbSNP and SwissProt 
are unified to protein structures. For visualization capabilities the site relies on embedded 
Jmol applets, but also offers plugins for UCSF Chimera and PyMOL for even more 
advanced display options. The interface allows the locations of variants to be easily 
displayed. 
 While these tools are excellent resources for molecular biologists studying novel 
SNPs, these portals focus primarily on automated classification and not interactive 
exploration and visualization. Some of these tools offer Jmol visualizations of the 
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location of SNPs, but rarely provide other annotated sites that are mapped to the 
structure. This makes the visualizations of limited utility to end-users who may wish to 
see the big picture of how a protein functions. Finally, these tools focus on SNPs, and 
thus provide no direct facility to investigate post-translational modifications from mass 
spectrometry data. 
 Recently, a handful of sites have emerged to focus on post-translational 
modifications. Phospho3D curates phosphosites from the Phospho.ELM[148] database 
and permits interactive visualization of these sites in separate Jmol pages. Additionally, 
Phospho3D mines 3D structures to determine zones surrounding each phosphosite, 
defined as the neighborhood of residues within a 12 Angstrom distance. Phospho3D 
additionally computes several structural properties for each site, including secondary 
structure, solvent accessibility, B-factors, depth and protrusion indices, and disorder 
probabilities. While Phospho3D is a comprehensive resource, its visualization 
capabilities are of limited utility as they do not associate textual sequence annotations to 
protein structures. Furthermore, the site offers no ability to query arbitrary sites on 
proteins or upload peptide modification datasets for analysis. Instead a service is offered 
whereby users can upload PDB structure files to find similar 3D zones surrounding 
phosphosites. 
 Another recent project focusing on post-translational modifications is 
ptmfunc.[149] This system and website is a comprehensive analysis pipeline that 
extracted nearly 200,000 phosphorylation, acetylation, and ubiquitinylation sites from 
several data sources. The authors developed algorithms to prioritize the functional 
importance of modifications to determine interesting sites for future study. Their analysis 
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methods included determining phosphorylation hotspots within domain families and 
finding modifications that occur at interfaces between two bound proteins in structures. 
This mass analysis effort was conducted and the results were assembled into an online 
website. Despite the impressive analysis, the website only provides minimal information 
on the scrutinized sites in a tabular format. No capabilities are provided to visualize the 
proteins and modifications. Furthermore, no capability exists whereby users can submit 
datasets for analysis. 
 While there is clearly a plethora of structure mapping web resources, they offer a 
heterogeneous set of features. Most focus has been on analyzing variants, yet more 
attention needs to be placed on the growing wealth of modification data. Even more 
importantly, unification of variants, modifications, and functional annotated sites may 
lead to additional insights into protein function. Finally, we feel that less focus on 
automated analysis/classification and greater emphasis on exploration/visualization will 
allow researchers to better complement their research. 
 We have developed AMASS, a web-accessible system that brings together 
multiple bioinformatics databases, associates 1D sequence features to 3D coordinates in 
protein structures, and then enables the discovery and visualization of co-localized 
protein features. AMASS aims to bridge the gap between the wealth of 1D sequence 
feature annotations and the rapidly growing collection of 3D protein structures. Our 
system aggregates sequence-level annotations from multiple databases: The Uniprot 
KnowledgeBase (UniprotKB)[11], the Catalogue of Somatic Mutations in Cancer 
(COSMIC)[12], and the PhosphoSite database[14] of post-translational modifications. 
Alongside this aggregation of sequence level annotations, our system matches searched 
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proteins with structures from the Protein Databank (PDB). Structures that have a similar 
sequence are automatically aligned to the query sequence, and sequence-level annotations 
are subsequently mapped to the 3D structure. Structures are visualized with the Jmol[15] 
browser based PDB viewer, and sequence annotations can be interactively explored by 
clicking links within the interface. 
 With this system, users can explore co-localized functional residues, which may 
include important cancer mutations, post-translational modifications, or annotated 
sequence features such as binding motifs and active sites. The system also permits 
queries of arbitrary residues within proteins, and upload of sequence data (such as mass 
spectrometry data) to find possible functional roles of thousands of queried sites. The 
inspiration for the AMASS system is rooted in mass-spectrometry based discovery of 
protein modifications that correlate with metabolic disorder. The system is also designed 
from the ground up to bring together multiple bioinformatics databases to provide a 
coherent picture of how a protein works. To this end, we have named our resource 
“AMASS”, and it can be accessed at amass-db.org. 
System and Methods:  
 The AMASS server allows visitors to both 1) browse for their favorite proteins to 
investigate sequence-structure relationships, and 2) to analyze peptide sequences and 
modification data derived from mass-spectrometry based experiments. Both usage modes 
provide very similar interfaces. When browsing for proteins by accession or symbol, a 
table of possible protein matches is presented. Alternatively when a user uploads a 
dataset for analysis, the input is a list of peptide or protein sequences with queried sites 
denoted as lower-case letters. This set of sequences is matched against sequences from 
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the Uniprot database. Matching proteins are presented in a similar table, with added 
columns indicating features in the protein structure that are proximal to the queried 
modification sites. These features include ligands in the structure and functional sequence 
elements mapped to the structure. 
 For each protein viewed on the site, we present a table of residue-level textual 
annotations derived from Uniprot and PhosphoSite. The system preferentially focuses on 
any annotation records that indicate active sites, clinically relevant variants, ligand 
binding residues, or sites that have been studied in prior mutagenesis experiments. 
Additionally, we present an interactive bar chart which displays single-residue count data 
derived from several sources. Somatic mutation frequencies in tumor samples are 
displayed from the COSMIC database. Additionally, we present post-translational 
modification count data derived from the PhosphoSite database, which aggregates 
modification count data based on prior mass-spec datasets and literature publications. By 
presenting such count data from multiple sources, users can visualize the functional 
importance of various residues. This count data serves to complement the textual 
annotations that we aggregate and present in tabular form. The counts plot and sequence 
annotations table are both linked, so that exploration of either with the mouse causes 
automatic highlighting to occur in the other. This feature gives users the ability to explore 




Figure 25 : Sequence counts and annotations display 
 
 
The 1D counts plot in the top panel shows modifications from the PhosphoSite database 
(yellow) and cancer mutations (red) from the COSMIC database. The table in the bottom 




 A major advantage of AMASS is that it has a mechanism for unifying this 
sequence annotation data with protein structures from the protein databank (PDB). If a 
queried protein has PDB structures, or is at least 50% similar to homologous proteins 
with structures, then these structures are presented in a table sorted by sequence 
similarity. Users can select structures to visualize with an embedded Jmol Java applet. 
Once a structure is loaded, users can interactively explore the structure by clicking on 
textual annotation records or on peaks in the counts plot. These actions also highlight the 
sequence alignment, which shows the user how the mappings are made between the 
queried protein and loaded structure. The alignments themselves can be clicked, allowing 
zoom-in of any residue on any specific chain. The structure viewing panel also contains 
several tools to change the color and transparency options of the model, as well as a 
contacts widget which uses Jmol to automatically find and highlight neighboring ligands 
which form Van-Der-Waals contacts with the most recently selected residue. 
 As an example, we use AMASS to search for human KRAS, a well-studied 
GTPase mutated in human cancers. Figure 25 illustrates how AMASS represents 1D 
sequence annotations, and Figure 26 shows a paired protein structure, complete with a 
visualization using Jmol and a displayed sequence alignment. A prominent somatic 
mutation (G12) and commonly-observed phosphotyrosine (Y32) are observed near the 









To attain structural insights into the mutations, modifications, and sequence features of 
human KRAS, a structure from the protein databank (4dsu) is loaded and aligned to the 
KRAS sequence. Residues of interest in the counts plot (from Figure 25) were clicked to 
highlight them in the structure. The prominent mutation peak at G12 is associated to a 
mutated aspartic acid in the structure and alignment (red stick model, left). The 
prominent phosphorylation peak at Y32 corresponds to a tyrosine residue (Blue stick 
model, top) that is near the GDP binding site. 
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 Development of AMASS required substantial database preparation and alignment 
computations. Most of this effort was performed ahead of time to allow rapid query and 
analysis for end-users. The development of the full pipeline involved writing a collection 
of Python scripts. On a modern server, downloading the relevant flat-file databases and 
populating our unified database takes approximately one week. 
 We used the Uniprot database as the core foundation of our platform. Given the 
comprehensive coverage of this database across many proteins and species, as well as its 
central role in mapping to many other external databases, we selected Uniprot to serve as 
the primary indexed identifier for each protein in our platform. Uniprot is composed of 
Trembl, a large collection of protein sequences prepared by translating genome 
sequences, and SwissProt, a much smaller but manually validated set of protein 
sequences. Swissprot is also commonly used as the primary sequence database for protein 
identification in mass-spectrometry experiments. Our pipeline downloads the compressed 
flat-file releases of these databases and parses them with the Biopython library, which 
enables efficient handling of the sequence data and feature annotations that Uniprot 
collects from many sources. 
 Our primary goal with AMASS is to enable the investigation of sequence-
structure relationships. The protein data bank has seen exponential growth over the last 
decade, but despite this growth there has been little concerted effort to correlate deposited 
structures with protein sequence identifiers. Several projects, such as PDBSWS [150] 
have been published over the last several years to close this divide by extracting protein 
sequences from PDB files and performing blast searches against protein sequence 
databases such as Uniprot. This strategy requires great care to ensure that the proper 
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pairings are performed between sequences and structures. Fortunately, the SIFTS 
consortium [151] has recently established a unified database of Uniprot sequence 
mappings to individual chains within PDB files. While this dataset does not provide 
alignments, it provided a reliable source of sequence identities to which we could 
perform our own alignments. 
 We mirrored the entire contents of the World Wide Protein DataBank (wwPDB) 
to our server, and used the Prody [152] PDB library to parse and analyze each PDB file in 
a large-scale effort. Header information, such as the title and crystallized ligands were 
stored in a relational datastore. We then used Prody to enumerate each chain parsed in the 
PDB structures. For polypeptide chains, a sequence of residue names and residue IDs was 
extracted. Single-letter amino acid sequences were interpreted from the 3-letter residue 
names, and these chain sequences were associated to Uniprot sequences with the SIFTS 
database. Each chain sequence was then individually aligned using Clustal Omega [153] 
to its associated Uniprot sequence to determine the residue-level mappings. These 
independent alignments were merged together into single “chain alignment” FASTA files 
which contain a parent Uniprot sequence and all associated chain sequences for that 
given PDB structure. We have observed that the vast majority of alignments between 
sequences and structures are identical as described by the SIFTS database. Minor 
discrepancies exist however, such as the presence of affinity tags within crystallized 
proteins or occasional site-directed mutants at relevant functional sites. 
 Aside from the chain sequence alignments, the residue IDs for each PDB chain 
were stored into a Python array and serialized to an object-oriented database for rapid 
retrieval. Given the computed “chain alignments” and these residue ID mappings, we 
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were then able to associate any Uniprot residue to residues within PDB chains, and 
subsequently to the atomic coordinates of particular residue IDs within a PDB file. This 
process formulates the core of our system, and allows mapping of 1D sequence 
annotations to 3D locations within protein structures. 
 In addition to extracting and aligning sequences from every PDB, we also 
extracted topological data from each structure. For every non-water residue, the Prody 
selection engine was used to find other non-water residues within a 7 angstrom distance. 
These searches were performed on every residue in every PDB file. These protein zones 
were stored in an indexed object-oriented database to allow rapid lookup for later 
analysis efforts. This approach was largely inspired by the approach taken by Phospho3D 
in which 3D zones were calculated for all phosphosites. Our system performs this 
analysis for all residues, modified or not. 
 Despite the large number of structures deposited in the Protein DataBank, its 
coverage of the proteome for any organism is far from complete. Many human proteins 
have not been crystallized. Usually however, highly similar homologous proteins can be 
found in the PDB, either as human paralogues or orthologues in other species. To expand 
the exploratory horizon of our platform, we designed it from the start to enable pairing of 
queried proteins with homologous proteins in the protein databank. Similar web resources 
that have been developed, such as MSV3D, instead produce homology models of 
uncrystallized proteins, which is more computationally demanding. Our approach is to 
simply find similar structures and present sequence alignments to end users. This is far 
simpler, and also more transparent, as it allows users to directly inspect the similarity 
between their queried protein and the paired structure. Inferences made at the single 
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residue level can be sanity checked if the paired structure is not conserved in other 
species. 
 To accomplish this sequence-structure pairing, we used all structure sequences 
documented in the SIFTS database as a query in an all-vs-all BLAST [154] search against 
the SwissProt database. Sequences that had at minimum of a 50% match were stored in a 
relational database. Subsequently, we pre-computed all sequence alignments between the 
SIFTS sequences and matched SwissProt sequences using Clustal Omega. [153] These 
“homology alignments” were separately stored as independent files to disk. These 
alignments are later merged with the PDB specific chain alignments to permit the 
mapping of sequence feature annotations from any protein sequence to 3D structures of 
homologous proteins. This alignment merging, and subsequent residue mapping, is the 
core methodology employed by the AMASS server. 
Algorithm: 
 During either live exploration of proteins on the web interface or analysis of 
uploaded datasets, the AMASS server pairs each protein sequence of interest with 
relevant structures from the protein databank. To find structures in the PDB with similar 
sequences, the system first consults a MySQL database which stores precomputed 
BLAST search result. In search mode, these structures are presented to the user, whereas 
in analysis mode these structures are each systematically investigated. 
 For each structure, the system loads the pre-computed “homology alignment” 
between the queried protein sequence and the Uniprot sequence assigned to that given 
structure. The system then loads the separate “chain alignment” files that map the Uniprot 
sequence to individual peptide chains within the PDB. The system merges these two 
137 
alignments based on the common PDB Uniprot sequence defined by the SIFTS database. 
This alignment merging is implemented in Python. Sequences in both alignments are first 
converted to linked-list data structures for efficient manipulation, and then gaps are 
inserted into each alignment while scanning the joined Uniprot sequence in each. After 
this, the sequences are converted back to strings and then packed back into a Biopython 
compatible sequence alignment object. 
 Once this merged alignment is produced between a queried protein and a 
homologous protein structure, we can map sequence positions on the query protein to the 
protein sequence in the PDB structure, and then onto single residues in each chain. To 
perform this mapping rapidly, we implemented a simple data structure in Python that 
represents the alignment as a series of Python integer arrays for efficient random access. 
Each protein and chain sequence within the alignment has an associated “forward map”, 
which is an integer array with length equal to the sequence. The integer values within the 
array map the sequence index to the position within the alignment. Each sequence also 
has an associated “reverse map”, which is an integer array with length equal to the 
sequence alignment. The integer values within this array map the alignment positions 
back to indexes within the sequences. Thus, to map any position within the query 
sequence, the forward map is used to find the column in the merged alignment. Then, to 
map to a single residue within a chain, this chain's reverse map is used to find the 
corresponding position in the chain sequence. Given this sequence position, we can 
finally determine the residue ID within the PDB file by consulting the residue ID 
mapping arrays that were stored to disk during the database creation. This sidesteps the 
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fact that many PDB files use residue numbering schemes that do not agree with sequence 
indexes in the native protein. 
 While our site allows visualization of any protein of interest, AMASS also 
provides an analysis backend to systematically scrutinize in “batch” mode single 
modifications on many peptide sequences, e.g., derived from mass-spectrometry 
experiments. The input format follows a standard in the mass-spectrometry field, in 
which peptide sequences are capitalized, while detected modifications are denoted with 
lower-case letters. The user provides an email address for notification when the job has 
completed, and indicates the species that the sample is derived from. After submitting the 
data, the system checks for common errors such as non-amino acid characters, and then 
de-duplicates non-unique peptide sequences while keeping an internal count of coverage 
and modifications. We encourage users to upload raw peptide data, wherein the same 
peptide sequence is listed many times. This “spectral count” data is reported back to the 
user for each and every residue in unmodified and modified counts. 
 Given the list of unique peptide sequences, our system first discovers the set of 
Uniprot sequences that potentially match the sample, given the species of origin that the 
user indicated during submission. This search is efficiently implemented with the UNIX 
fgrep program. After this set of target proteins is found, peptide sequences are assigned to 
whole protein sequences using the string containment algorithm implemented in Python. 
Site coverage and modification count data is accumulated in integer arrays, and then later 
stored to a MySQL database for long-term aggregation of the most commonly occurring 
protein modifications. 
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 After submission and validation, the job enters a queue. When executed, the 
backend analysis pipeline finds similar PDB structures and merges alignments as 
previously described. Modifications are then mapped to 3D coordinates, and a 
neighborhood of structural features within 7 Angstroms is found. Within the 
neighborhood residue set, our algorithm tests membership of residues that have important 
sequence features such as active sites, mutagenesis sites, or binding residues as annotated 
within the Uniprot or PhosphoSite databases. Additionally, our system determines if the 
site is located at the binding interface between two distinct proteins in a complex. Finally, 
the system checks nearby to look for interesting ligands bound to the protein, which can 
include enzymatic metabolites or drug compounds that bind the active sites of kinases. 
Implementation: 
 The AMASS database is hosted on a dedicated server with dual Xeon Westmere 
processors, 32GB of RAM, and 8TB of RAID storage. The server runs the Ubuntu 
GNU/Linux Operating System. The backend analysis engine and web frontend are both 
implemented entirely in the Python [17] programming language, utilizing the Biopython 
[155] bioinformatics library for sequence processing and the Prody PDB parser for 
structural analysis. 
 MySQL [156] is used as a relational database to store several datasets, including 
Uniprot protein accessions, IDs, description fields, and identifier mappings to external 
databases. Additionally, metadata extracted from PDB files was stored in relevant tables. 
MySQL enabled quick development of search interfaces on our web frontend with its full 
text search indexes. 
140 
 In addition to a conventional SQL datastore, we also made extensive use of 
object-oriented storage of Python objects in serialized binary files with the cPickle and 
Shelve modules. For certain datatypes, this allowed for increased performance of the 
backend analysis engine and web frontend. Python objects describing PDB chain 
alignments, structural neighborhood mappings, and Biopython Uniprot records were all 
stored as binary Python objects directly to disk. This strategy improved analysis speeds 
and simplified implementation as no object to relational mapping was required. This 
strategy also enabled easy portability of the database and distributed computation to be 
performed with shared network filesystems. 
 All PDB file parsing and analysis was performed using the excellent Prody 
library. At the beginning of our efforts, we surveyed several PDB parsing libraries and 
found Prody to be the fastest, and also had the most convenient object-oriented interface. 
Python scripts were written to pre-process all PDB files. This extensive process involved 
chain sequence enumeration and extraction using Prody, followed by sequence 
alignments with Biopython. Additionally, Prody was used to calculate structural 
neighborhoods for all non-water residues in each structure. By building this large 
database ahead of time, we greatly improved performance of our analysis engine when 
presented with novel datasets. 
 For the web frontend, the Apache2 [157] suite is used to serve the content. 
Dynamic pages are implemented as Python CGI scripts. The Jquery JavaScript library 
was used extensively to create interactive content on the pages. The DataTables [158] 
Jquery plugin was used to allow client-side searching and sorting in several HTML 
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tables. The Flot [159] plotting library was used to create interactive plots of site-specific 
count data. 
 Protein structure visualizations are powered by the open source Jmol [15] PDB 
viewer. The Jmol javascript API was used to implement several interactive interfaces 
which allow end-users to explore sequence features and analysis results. 
Case Studies: 
 To illustrate the utility of AMASS for uncovering and exploring interesting post-
translational modifications, we have analyzed a prior mass spectrometry dataset collected 
on isolated mitochondria from human skeletal muscle. [107] Within this data, AMASS 
found several proteins with potentially interesting modifications near active sites. 
Pyruvate Dehydrogenase (PDH): 
 The pyruvate dehydrogenase complex is a central metabolic enzyme that connects 
glycolysis with the citric acid cycle by converting pyruvate to acetyl-coa. Our mass-
spectrometry data from human muscle demonstrates that serines 293 and 295 of E1 
subunit alpha (Uniprot: ODPA_HUMAN) are phosphorylated in vivo. Both of these 
serines are documented in the PhosphoSite database, with S293 in particular having 625 
references to external mass-spectrometric datasets. Furthermore, S293 is the most studied 
mutagenesis site, with 13 references documented in PhosphoSite. Most interestingly, 
these two phosphorylations are located in a cluster of 6 phosphosites present in a short 
span of the protein sequence. (Figure 27) Two of these sites (S293 and S300) are 
annotated in Uniprot as targets of pyruvate dehydrogenase kinase (PDK4), which is a 












Figure 28: Phosphosites in PDH structure 
 
A serine and phosphoserine residue (orange) are located on a loop region in the crystal 
structure. This loop is proximal to TPP, a cofactor of PDH. 
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 The protein has 7 crystal structures in the PDB, and in one of these structures 
(3exh) AMASS found that S293 is proximal to an interesting ligand. Upon loading the 
structure and visualizing the alignments, we note that the crystal structure was prepared 
from the mature enzyme that has a 29-residue mitochondrial transit peptide removed. The 
phosphosite S293, identified in the full-length Uniprot sequence, aligns with S264 in the 
mature enzyme. Despite this discrepancy, the sequence alignment procedure of AMASS  
ensured that the correct full-length phosphosites were correctly associated to the chains in 
the structure. The crystal structure has four chains of this protein, and this residue is 
actually found phosphorylated in one of these chains. This structure was prepared by 
phosphorylating PDH with PDK4, and the heterogenous phosphorylation of the 4 chains 
permits comparison of secondary structure. 
 AMASS found that in chain C in particular, this phosphoserine is located very 
close to the ligand Thiamine PyroPhosphate (TPP), a derivative of Thiamine (Vitamin 
B1), and a required cofactor of PDH. Furthermore, we readily observe that the other 
phosphorylated serine S295 (S266 in the mature form) is also repositioned in the chains 
where S264 is phosporylated. It is discussed in the corresponding publication of this 
crystal model [160] that phosphorylation of the S293 residue (via PDK4) causes 
derangements of this phosphorylation loop region and prevents substrate channeling to 
the TPP cofactor, thus inactivating the entire PDH complex. In this case, S293 is well 
studied, yet the annotations within Uniprot only discuss PDK4 as the responsible kinase 
but do not assign a strong functional role of S293 in regulating metabolic activity. 
Nonetheless, AMASS found the proximity to TPP, which enabled us to uncover the 
literature citation associated with this PDB structure and ultimately provided us with 
144 
insight to our data. This emphasizes the potential of AMASS to serve as a tool to 
integrate data and help the research community improve functional annotations of sites. 
ATP Synthase Beta (ATPB): 
 In human skeletal muscle, peptides from human ATP synthase are particularly 
abundant. On the beta subunit of this complex, AMASS found a phosphothreonine 
modification (T213) that is located near interesting ligands in several structures in the 
protein databank. Human ATP synthase beta has not been crystallized, but several models 
exist of the bovine protein (97% sequence identity) and the yeast protein (78% identity). 
In many of these structures, AMASS finds that phosphorylated T213 is located nearby 
magnesium ions and either ATP or ADP molecules. This site was previously investigated 
in relation to insulin resistant skeletal muscle, and deduced to likely be located near the 
ATP binding domain based on sequence analysis. [161] 
 Using AMASS to directly visualize the ATP synthase beta protein (PDB 4asu), we 
observe that three beta subunits and three alpha subunits complex to form the F1 subunit. 
Each of the three beta subunits has an ADP molecule present at the active site. 
Additionally, magnesium cofactor ions are seen bound to the terminal phosphates of the 
ADP molecules. The T213 sidechain is positioned such that direct contact is made with 
the magnesium ions (Figure 29). This finding is interesting, as this phosphorylation of 
T213 could thus be an autocatalytic mechanism due to the proximity of the ADP 
phosphates, or perhaps an unknown reaction intermediate. We postulate that 
phosphorylation of this threonine may effect catalytic function by inhibiting binding of 







ADP and T213 (orange) which binds the magnesium cofactor (green). Below: Multiple 
sequence alignment showing mass spec coverage (purple) and alignment between human 
and bovine ATPB, and alignments to chains in PDB. 
Figure 29: Bovine ATP synthase and sequence alignment 
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Enolase Beta (ENOB): 
 Our muscle dataset identifies the three isozyme subunits of enolase. Alpha (24 
unique peptides), beta (27 unique peptides), and gamma (5 unique peptides). Two 
phosphorylations (S37 and T41) were detected that map to all three sequence forms, 
whereas a third phosphorylation (S176) only maps to the beta sequence. The beta form is 
characteristic of striated muscle, and so we focus our analysis solely on this isozyme 
subunit (ENOB_HUMAN). All three phosphorylations are documented in the 
PhosphoSite database. S37 and S176 only have a few mass-spectrometric counts in prior 
datasets, whereas T41 has 44 documented ocurrances in human samples. Investigating the 
PhosphoSite count data  in AMASS shows that S37 and T41 are proximal to Y44, which 








Figure 30: Phosphorylation counts of Beta Enolase 
 
 
Two serines that are phosphorylated in our dataset (orange) are proximal to the bound substrate 
(2-PG) at the active site of the enzyme. An additional serine S40 (not depicted yet) serves as a 
direct binding site of 2-PG. A tyrosine (blue) is located on the same loop but distal to the active 
site, and is highly phosphorylated in many datasets documented by the PhosphoSite database, but 
unobserved in our data. The active site residue of the enzyme is depicted in red. 
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 Only a single structure for ENOB_HUMAN exists in the PDB, however AMASS 
failed to find any interesting proximal features to these three sites. The gamma isozyme 
(ENOG_HUMAN) however has nine crystal structures in the PDB, and several of these 
structures were prepared with 2-phosphoglyceric acid and phosphoenolpyruvate, the 
substrates of this enzyme. Given that gamma enolase has 84% sequence identity with the 
beta form, AMASS aligned the queried modifications to those structures for similar 
analysis. S37 and T41 are both found proximal to the substrate binding sites. 
 We chose the structure 3ucd for visualization as it contained two polypeptide 
chains, one with 2-phosphoglyceric acid (2-PG) and the other with phosphoenolpyruvate 
(PEP) occupying the active site. In either chain, we find that S37 and T41 sit on a loop 
that overlaps the substrate binding pocket. Both serines are within a nanometer of either 
2-PG or PEP. The heavily-phopshorylated tyrosine Y44 is located on the same loop, but 
further from the binding pocket. Interestingly Y44 forms a salt bridge with a nearby 
D298, and might stabilize this loop region. Given that these phosphosites all cluster on 
this loop which contacts the bound substrate, we postulate that phosphorylations may 
effect catalytic function through electrostatic interactions with bound substrates. 
Argininosuccinate Synthase:  
 In human liver, we identify argininosuccinate synthase (ASSY_HUMAN) with a 
serine phosphorylation at S180 and lysine acetylations at K228 and K355. The enzyme 
catalyzes the formation of argininosuccinate from ATP, citrulline, and aspartate, and is 
involved in the hepatic urea cycle. Mutations to this protein can cause citrullinemia, a 
disease characterized by elevated citrulline levels in serum and urine as well as ammonia 
intoxication in infants.[162]  
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 A single structure in the PDB exists for human argininosuccinate synthase (2nz2), 
and is co-crystallized with citrulline. AMASS found that the S180 residue is proximal to 
the citrulline ligand in the structure, and also reported that S180 is an annotated citrullin 
binding residue in the Uniprot database. Interestingly, the sequence annotations table 
from Uniprot also describes S180 as a mutation site. In a patient suffering from neonatal 
citrullinemia, S180 was found mutated to an asparagine.[163] This is compelling as 
asparagine has only a marginally larger sidechain, yet its substitution was sufficient to 
clearly lead to enzyme deactivation in this particular case. This hints at the functional 
importance of S180. 
 A homologous structure (1j1z) from thermus thermophilus is also present in the 
PDB. The sequence is only 53% identical, however the structure appears similar, and 
more importantly the model was prepared with citrulline, aspartate, and ATP all bound at 
the active site. When aligned, human S180 corresponds to S173 in this organism. When 
the location of this serine is visualized using the AMASS contacts widget, we observe 
that it forms Van-Der-Waals contacts with citrulline and the gamma phosphate of ATP. It 
is inferred from this arrangement that the introduction of a negative charge at this serine 
through phosphorylation may inhibit binding of negatively-charged ATP. Serine 
phosphorylation may be an auto-catalytic property of this enzyme or an external 
regulatory mechanism that requires further investigation. Phosphorylation of S180 in 









Figure 31 : Active site of argininosuccinate synthase 
 
S180 (top, orange) shown interacting via VDW contacts with citrulline (left) and 
the gamma phosphate of ATP (right). Aspartate is depicted bottom-left. 
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Fructose Bisphosphate Aldolase: 
 Fructose bisphosphate aldolase is an important enzyme in glycolysis, and is found 
in three isoforms (A,B and C). Isoform A (ALDOA_HUMAN) is most prevalent in 
muscle, and we thus observe the most unique peptides for this form. For this protein, we 
detect 5 distinct phosphosites and one lysine acetylation. Intriguingly, three phosphosites 
are clustered in the sequence (S36, T37, and S39), and previously documented in a 
handful of samples in PhosphoSite. 
This protein is crystallized in 7 structures in the PDB, and one of these structures 
(4ald) has the fructose bisphosphate (2FP) ligand present. We observe that these three 
clustered phosphosites are located proximal to a terminal phosphate on the 2FP molecule. 
The two serines make direct VDW contact with the 2FP phosphate, whereas the threonine 
sidechain is oriented in an opposing direction. By using the contact widget, we 
additionally observed that the sidechain of K180 also binds this phosphate, and appears to 
be a primary electrostatic interactor with the ligand. We hypothesize that phosphorylation 
of serines 36 and 39 may effect 2FP binding through electrostatic repulsion of the 
terminal phopshate of 2FP. These serines could be phosphorylated by the bound ligand 





(Top) the structure of ALDOA_HUMAN showing three clustered phopshosites. Two of 
these sites are serines, and are forming direct VDW contact with a phosphate group of 
fructose bisphosphate. To the left is K108 (blue), a lysine which electrostatically binds 
this phosphate. (Bottom) Sequence alignments showing coverage of peptides mapped to 
all possible proteins determined from the dataset. Mass spectrometer coverage is 
indicated with blue highlighting, and modifications are shown in purple in the sequence. 
Orange highlighting indicates chain residues with interesting findings. 
 
 
Figure 32 : Structure and alignment of Aldolase A 
153 
Tubulin: 
 In human liver, we detect many peptides that are assigned to a variety of tubulin 
isoforms. Altogether, 11 isoforms and tubulin-like proteins from SwissProt are identified 
with peptides from liver. The isoform with the most representation and coverage is 
Tubulin beta-2A (TBB2A_HUMAN) with 27 unique peptides. Tubulin proteins are the 
constituents of microtubules, and polymerize by forming heterodimers between alpha and 
beta subunits. A GTP molecule is bound at the dimerization interface between chain A 
and chain B. An acetylaton is detected at K252, which corresponds to the same sequence 
position in the other tubulin isoforms. PhosphoSite reports that for Tubulin beta-2A, this 
lysine is acetylated in 75 distinct samples. 
AMASS mapped this modification to many distinct structures in the PDB of 
tubulin proteins from cow, sheep, and pig. In several of these structures, GTP is detected 
as a proximal ligand to this lysine. In visualizing a pig structure (2wbe) we note that 
K252 is present on the B chain and directly binds the alpha phosphate of GTP located at 
the binding pocket of tubulin chain A. Given that lysine acetylation results in a loss of 
positive charge, we postulate that acetylation of this crucial residue may inhibit GTP 
phosphate binding and thus regulate tubulin polymerization. Excitingly, tubulin 


































Figure 33: Sequence alignment (top) and modification mapping table (bottom) 
from the AMASS web interface showing how detected modifications map to the 
various possible isoforms of proteins. The peptides that mass spectrometers 
identify can be associated with several protein isoforms. Tubulin is an excellent 







Figure 34 : Tubulin dimer interface 
 
 
Tubulin chains A (blue) and B (green) are shown co-crystallized with a bound GTP ligand located at 
the tubulin A GTP binding pocket. Lysine 252 (blue, center) is shown binding the alpha phosphate of 
GTP. 
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Isocitrate Dehydrogenase (IDH): 
 In proteomics experiments conducted on human muscle tissue, we identify several 
peptides that match the cytosolic (IDHC_HUMAN) and mitochondrial (IDHP_HUMAN) 
forms of isocitrate dehydrogenase. In muscle tissue, we detect two lysine acetylations 
which can be attributed to the mitochondrial isoform: K48 and K180. K48 is not a 
reported modification in the Phosphosite database, however PhosphoSite reports that 
K180 is modified in human IDH in 28 datasets. The COSMIC database reports that two 
residues are frequent cancer mutation hostpots: R140 and R172. We display the sequence 
coverage of IDHP from our experimental data, with the two acetylated lysines 
highlighted in purple. Also shown is a plot of PhosphoSite modification count data 
(yellow) and COSMIC mutation frequencies (red). 
 Human mitochondrial IDH has not been crystallized, however AMASS associated 
it with the sequence from pigs which has 97% sequence identity. Pig mitochondrial IDH 
has a single structure in the PDB (1lwd), which was crystallized with a bound isocitrate 
ligand at the active site.[] AMASS determined that K180 acetylation may have a 
functional effect to the activity of this enzyme. When aligned with the pig sequence, 
K180 (human) corresponds to K149 (pig), which is a single residue from Y148 (Y179 in 
humans). The Uniprot record for IDHP_PIG has two sequence annotations for Y148. It is 
documented as a binding residue for isocitrate, and was also shown in a prior 
mutagenesis study[] to be critical for catalysis. Mutations to phenylalanine (F) lead to a 
significant decrease in Vmax. Alongside these annotations, Uniprot also refers to the two 






Figure 35 : IDH sequence coverage, phospho and mutation counts  
 
(A) IDH mass spectral sequence coverage in blue with modified residues highlighted in purple. (B) 
Count data showing cancer mutation frequencies from the COSMIC database (red) and post-
translational modification count data from PhosphoSite (yellow). K180, which is acetylated in human 
muscle, is abundantly acetylated in datasets aggregated in PhosphoSite. 
158 
 By interacting with the page, we are able to easily determine the structural 
locations of these critical residues. As we depict in Figure 36, Y148 is indeed a binding 
residue of isocitrate, as are the two arginine residues commonly mutated in cancers. The 
acetylated lysine, K180 (K149 in pig) is a single residue away from the binding tyrosine 
Y148, however the sidechain oriented in an orthogonal direction. The lysine appears to be 
positioned at the top of a cleft in the protein formed between two seperate halves of the 
active site. By using the contact finder widget on the page, we find that this lysine 
contacts a nearby asparagine residue located on the opposing wall of this cleft. From this 
visualization, we hypothesize that acetylation of this lysine may affect the structural 
stability of the binding pocket. K149 acetylation may also effect the orientation of Y148, 
thereby effecting catalysis. Mutagenesis studies and/or computational modeling is 
required to investigate this hypothesis further, however AMASS has proven useful to find 



















Figure 36 : IDH structure 
 
Acetylated lysine (top blue) is positioned directly above the critical binding residue Y148 
(left green), and interacts with negatively charged asparagine (top red). 
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Discussion: 
 We hope that AMASS will grow into a valuable resource for the biomedical 
research community, and we thus have a substantial roadmap of desired features planned 
for future releases. We plan to integrate many more biological databases to bring together 
as many functional annotations as possible. For example, the COSMIC database has 
given us an excellent jumpstart in providing mutational frequencies of single amino 
acids, however the recent release of full tumor sequencing data from The Cancer Genome 
Atlas (TCGA) project [165] hints that much more cancer mutation data can be integrated 
in the coming years as sequencing becomes cheaper. 
 Our analysis system is incredibly simplistic, as it only considers proximity of co-
localized features to infer significance. Our primary focus for this system was to create an 
interactive user-friendly interface. We feel that visualization and appropriate aggregation 
of data will allow users to generate their own hypotheses about functional sites. 
Nonetheless, several other tools available perform far more sophisticated analysis of the 
structural consequences of modified sites, typically for SNP databases. For example, 
PolyPhen and SNPs3D both offer computerized classification of whether or not amino 
acid changes may affect function based on changing biophysical properties such as 
sidechain hydrophobicity, charge, or packing. Adding this deeper level of analysis in the 
future may improve the utility of our tool. The challenge for post-translational 
modifications will be to find appropriate algorithms to assess functional consequences of 
these novel sidechains. 
 We have observed that many proteins in the Uniprot database lack comprehensive 
functional annotations, especially when proteins from less-studied species are queried. 
161 
Furthermore, highly-valuable feature records such as mutagenesis sites are species-
specific, since those annotations arise from academic publications that focused in a single 
model organism. We plan to improve this discrepancy in the future by integrating a 
homology clustering system into AMASS, whereby all homologous proteins (and their 
associated site annotations) can be visualized in alignments and simultaneously projected 
onto 3D structures. This improvement poses considerable user interface design 
challenges, but may vastly increase the exploratory horizon of our system. 
 Many protein structures within the PDB have multiple proteins in complex, 
however several distinct structures can be structurally aligned on common shared protein 
sequences to elucidate other possible complexes that may exist in vivo. For example, a 
structure containing proteins A and B can be structurally aligned with a separate structure 
consisting of proteins B and C. Such an alignment may hint how proteins A and C can 
interact in vivo. Performing such alignments across all structures may expand the set of 
possible neighboring features that can be discovered. Furthermore, adopting a technique 
similar to ptmfunc [149], whereby conserved domains amongst many distinct proteins are 
aligned, may allow greater generalization to be made for the functions of single sites. 
 With the development of AMASS, we have a system that is capable of quickly 
finding possible functional explanations of any queried modifications. This analysis 
however is only performed upon user submission of data, or when the user interactively 
explores a structure through the web interface.  
 In the future, we plan to perform a massive automated screen which will find co-
localized features in all protein structures. Aggregating these findings and clustering 
relevant functional sites, cancer mutations, and high-abundance modifications remains a 
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challenge, as does presenting the results in a medium that permits the ranking of 
identified clusters. To enable such ranking, one could devise simple heuristics based on 
the number and density of functional sites within the neighborhood of active site residues 
or ligand binding pockets. Additionally, representation of clusters in 3D, using the Jmol 
applet, would allow for the easy visualization of functionally relevant surfaces of 
proteins. We will additionally investigate the idea of rendering colored heat-maps onto 
3D structures that can represent variant statistics amongst haplotypes, cancer mutation 
rates, or modification count data for each residue. 
 Given our developed system and planned features, we envision that AMASS will 
serve as a valuable tool to the research community at large, by both enabling the 
understanding of datasets, as well as the discovery and annotation of unrecognized 









THE MISSION AHEAD 
Metabolic syndrome is a complex phenomenon, and is thusfar documented to 
have many associated causes and pathological associations with no clear direct cures in 
sight. Despite the simplistic explanation that metabolic syndrome can be avoided by 
affecting energy balance between dietary caloric intake and energy expenditure, the 
obesity epidemic continues to grow. Furthermore, the few individuals who are successful 
in combating the disease rarely maintain their achievements over the long term. 
In this dissertation, I have investigated molecular mechanisms of this condition at 
multiple levels of complexity. I have simulated the atomic biophysical properties of a 
single residue in a key protein at the center of mitochondrial metabolism, attempted to 
reverse engineer the central developmental pathways that regulate metabolism of energy 
in muscle and fat cells, and even attempted to understand the whole-body systemic 
regulation of energy utilization during times of fast and feast. These studies have taught 
me the true depth and breadth of how metabolic disorder manifests. It is fundamentally a 
condition that is influenced both “top down” and “bottom up”. 
 Analysis of the transcriptome of human skeletal muscle yielded profound insights 
into the nature of skeletal muscle insulin resistance. I developed a novel methodology of 
analyzing gene expression data, wherein expression values are directly correlated with 
metabolic phenotypes. This analysis revealed several pathways that have coherent 
underlying themes. In particular, genes correlating positively with glucose uptake are 
associated with the wnt signaling pathway. This pathway is now demonstrated to 
centrally regulate lipogenesis and glucose homeostasis in the cell. Genetic evidence from 
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type 2 diabetes GWAS studies confirm this association with insulin resistance, as core 
signaling elements in the wnt pathway are susceptibility loci. 
 In insulin resistance, several genes from the muscle atrophy pathway were found 
as strong correlates. In conditions of muscle atrophy, enhanced proteolysis from the 
ubiquitin proteosome system tears down cellular proteins. In the case of starvation, this 
mechanism provides amino acids which can be used for hepatic gluconeogenesis in times 
of restricted dietary glucose. During starvation, it is thus beneficial to induce a state of 
insulin resistance in peripheral tissues, as in these conditions glucose is scarce and must 
be reserved for the brain. When starving, the muscle must simultaneously stop taking in 
glucose, and it must start exporting amino acids. Thus, proteolysis and insulin resistance 
may be directly mechanistically connected. I propose that the primary insulin resistance 
off switch is the degradation of an unidentified central protein involved in glucose 
transporter trafficking. A clue to this is that the top correlating gene GOPC binds to 
proteins using the same PDZ motif which is targeted by Atrogin-1 for proteolysis. This 
could indicate that either GOPC, or an interacting partner of GOPC, is the target. Frizzled 
receptors share the common PDZ motif, and have been shown to be trafficked to the cell 
membrane by GOPC. Thus, Atrogin-mediated proteolysis of frizzled receptors may 
induce insulin resistance by eliminating wnt signaling. 
 During muscle atrophy, protein synthesis is also dramatically inhibited. This is 
partially mediated via targeted ubiquitination of a key translation initiation factor by the 
atrophy-inducing gene atrogin-1. This implies that protein turnover is dramatically 
reduced in insulin resistant subjects, and I propose that this phenomenon may explain the 
changes in acetylation that we observed in mitochondrial proteomes after exercise. 
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Insulin resistant individuals can less efficiently replace acetylated and defective enzymes 
with newly-synthesized proteins. This hypothesis can be tested in human subjects by 
unifying proteomic and transcriptomic data to ascertain whether or not the reductions in 
mitochondrial acetylation are associated with the expression levels of atrophy related 
genes. 
 The wnt pathway appears to be the primary activating signal for insulin stimulated 
glucose uptake in the cell, and this pathway also suppresses fat accumulation. The muscle 
atrophy pathway is activated during fasting, and appears to be the primary instigator of 
insulin resistance. This connection makes sense at the level of the whole organism. The 
atrophy pathway can be activated by other confounding factors however, namely 
inflammation of the tissue. Exposure to free fatty acids and residence of proinflammatory 
macrophages can lead to activation of the NFKB pathway via TNFa signaling, and this 
directly activates muscle proteolysis. Thus, in the diabetic muscle, enhanced proteolysis 
may be due to inflammation as opposed to starvation as the primary causal factor. The 
downstream effector proteins are the same, however. Thus if a mechanistic insulin off 
switch can be found that is mediated via proteolysis, then the state of insulin resistance 
can be inadvertently activated by inflammation. 
 The importance of proinflammatory macrophages in inducing skeletal muscle 
insulin resistance is hinted by a strong increase of the TRAP gene with exercise. Insulin 
sensitive subjects express TRAP to a larger degree after exercise. Prior literature indicates 
that TRAP has a role in modulating inflammation. TRAP dephosphorylates osteopontin, 
which is a critical adhesion molecule that attracts and polarizes macrophages into an M1 
pro-inflammatory state. Thus, it could be that the increased expression of TRAP in 
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insulin sensitive subjects reduces macrophage-induced inflammation, and that this 
reduces NFKB signaling and subsequent activation of muscle proteolysis pathways. This 
connection could be a direct “top down” pathway whereby inflammation is viewed as the 
upstream cause of the molecular mechanisms of insulin resistance. The work ahead 
involves coming to a deeper understanding of why macrophage recruitment and 
activation is higher in insulin resistant muscle. Why does the inflammation start? 
During this journey, I have also built new tools and skills. I designed and 
developed a web-available informatics resource that attempts to “Amass” sequence 
annotations from multiple sources and map it onto 3D protein structures. This system will 
enable researchers to discover and visualize connections between genetic variants, post-
translational modifications, and annotated functional sites in proteins and complexes. 
This resource is developed around the common theme of this dissertation: unifying 
biological evidence from all available sources to find unexpected connections. 
With the studies I have performed, it is now clear to me more than ever that 
metabolic syndrome is a complicated condition with many distinct causes. Thinking in a 
systemic fashion, and learning everything I can about the relevant signaling and 
metabolic pathways, I have formulated ideas of how metabolic syndrome can slowly 
develop. Although this short list of findings only inches us closer to a cure, the overall 
theme of systemic thinking will guide my future research career. I will continue to find 
connections, both by manual investigation of the literature and by developing new 
software and databases to aggregate data and “connect the dots”. Overall, my goal is to 
find the underlying causes of these metabolic conditions. 
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 With personalized medicine rapidly approaching on the horizon, different 
interventions will be needed for each individual, as I believe it is likely that everyone 
develops these illnesses for uniquely distinct reasons. No longer can we expect to help 
people by treating the symptoms. We must find each distinct cause of the disease. With 
this systemic knowledge, we can more effectively drop the weight of the obesity 
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